Revealing crystallographic protein minor states via multiconformer modeling and PanDDA background subtraction by Biel, Justin T
UCSF
UC San Francisco Electronic Theses and Dissertations
Title
Revealing crystallographic protein minor states via multiconformer modeling and PanDDA 
background subtraction
Permalink
https://escholarship.org/uc/item/28q8h5f7
Author
Biel, Justin T
Publication Date
2019
 
Peer reviewed|Thesis/dissertation
eScholarship.org Powered by the California Digital Library
University of California
 
 
 
 
 
 
 
 
by 
 
 
 
 
Submitted in partial satisfaction of the requirements for degree of 
 
 
in 
 
 
 
in the 
 
GRADUATE DIVISION 
of the 
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 
 
 
 
 
 
 
 
 
 
 
 
 
Approved: 
 
______________________________________________________________________________ 
       Chair 
 
 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
Committee Members 
)'(#!
	
	
$%+''



*!#&+'(!!$&%%&$(#"#$&'(('*")!($#$&"&"$!##
# &$)#')(&($#
"'&'&
#$&(""
$&((&$)
 
 
ii 
 
 
 
 
 
  
 
 
iii 
Acknowledgements 
 
 I’d like to thank everyone who has helped me along the way to getting my PhD. First, I’d 
like to thank parents, for raising me and supporting me in more ways than I can list. Your love 
and support mean everything. To my wonderful significant other, Pooja, whom I met in graduate 
school, I love you dearly, and I cherish the time we spent together during this process. I’d also 
like to especially thank my PhD supervisor, Jaime Fraser. You have been a superlative mentor, 
and I look forward to continuing to learn from you and work with you as we continue to 
investigate what we can learn with fragment screening. I’d like to thank my classmates, my 
current, and past lab members; the journey wouldn’t have been the same without you. And last 
but not least, I’d like to thank my many mentors and friends from my undergraduate studies, you 
enabled me to be where I am today. 
  
 
 
iv 
Revealing crystallographic protein minor states via multiconformer modeling and PanDDA 
background subtraction 
By 
Justin Thomas Biel 
 
Abstract 
Proteins are fascinating machines, and the investigation of their structures has led to many 
insights in biology and drug discovery. Proteins are not static, and their dynamics and their sub-
populated states are often relevant to their natural function or regulation. During my PhD, I 
worked on several projects revolving around the concept that by modeling multiple 
conformations from structural data, and therefore capturing the flexibility of protein structure, 
that enhanced insight could be gained from the structural data. First, I was involved in a review 
that described the state of the field in what was known about the extent of protein dynamics and 
the state of the art for measuring and modeling the states sampled by the protein. From there, I 
solved the structure of several ubiquitin mutants that undergone design and selection to alter their 
function. By collecting high resolution room temperature crystal structures, we revealed the 
extent of change in conformational heterogeneity across the directed evolution of these mutants. 
Finally, due to advances in technology and algorithms, we moved on to modeling minor states 
that were the result of a ligand binding event at less than full occupancy. I was involved in the 
fragment screening experiment for the protein PTP1B, where we assessed the ligandability of the 
protein via both cryo and room-temperature data collection. 
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Preface 
The bulk of this chapter appears as Bhabha G. et al. published in Accounts of Chemical Research 
(2015).  
When I first joined the Fraser lab, I had the great opportunity to work on a review with 
Gira Bhabha, who was a post-doc in the lab of Ron Vale. The experience of working on a review 
helped in getting intimately acquainted with the literature prior to the work on the main projects 
of my thesis. This review serves as a scientific introduction into the state of the field of 
conformational dynamics with a focus on enzymes the importance of understanding the many 
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states that are relevant for protein function. This chapter serves as an introduction to the rest of 
the thesis.  
 
Conspectus 
Because living organisms are in constant motion, the word “dynamics” can hold many 
meanings to biologists. Here we focus specifically on the conformational changes that occur in 
proteins and how studying these protein dynamics may provide insights into enzymatic catalysis. 
Advances in integrating techniques such as X-ray crystallography, nuclear magnetic 
resonance, and electron cryomicroscopy (cryo EM) allow us to model the dominant structures 
and exchange rates for many proteins and protein complexes. For proteins amenable to atomic 
resolution techniques, the major questions shift from simply describing the motions to 
discovering their role in function. Concurrently, there is an increasing need for using 
perturbations to test predictive models of dynamics–function relationships. Examples are the 
catalytic cycles of dihydrofolate reductase (DHFR) and cyclophilin A (CypA). 
In DHFR, mutations that alter the ability of the active site to sample productive higher 
energy states on the millisecond time scale reduce the rate of hydride transfer significantly. 
Recently identified rescue mutations restore function, but the mechanism by which they do so 
remains unclear. The exact role of any changes in the dynamics remains an open question. For 
CypA, a network of side chains that exchange between two conformations is critical for 
catalysis. Mutations that lock the network in one state also reduce catalytic activity. 
A further understanding of enzyme dynamics of well-studied enzymes such as 
dihydrofolate reductase and cyclophilin A will lead to improvement in ability to modulate the 
functions of computationally designed enzymes and large macromolecular machines. In designed 
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enzymes, directed evolution experiments increase catalytic rates. Detailed X-ray studies suggest 
that these mutations likely limit the conformational space explored by residues in the active site. 
For proteins where atomic resolution information is currently inaccessible, other techniques such 
as cryo-EM and high-resolution single molecule microscopy continue to advance. Understanding 
the conformational dynamics of larger systems such as protein machines will likely become 
more accessible and provide new opportunities to rationally modulate protein function. 
 
Introduction 
Even simple enzymes must bind a substrate, catalyze a reaction, and release a product. It 
is difficult to imagine an enzyme performing all of these actions from a single conformational 
state. The chemical changes after the substrate has converted to product elicit changes in the 
conformational ensemble populated by the enzyme (Figure 1.1). While advances in 
computational simulations are expanding our ability to see these changes at longer time scales, 
(Dror et al., 2012) here we focus on determining the conformational ensembles that enzymes 
populate and how these ensembles change during functional catalytic cycles. 
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Figure 1.1 Protein dynamics occur at different time scales. 
(a) Motions on the picosecond to nanosecond scale involve small changes in backbone or side 
chain torsion angles (Mittermaier and Kay, 2006). Calcium bound calmodulin (1exr, upper) 
exhibits conformational heterogeneity on the interface of the peptide binding site. The residual 
conformational entropy of binding (Marlow et al., 2010; Frederick et al., 2007) depends on side 
chains sampling alternative conformations as exemplified by Met36 and Leu39 (lower). Electron 
density contoured to 2.5 e–/Å3 in a dark blue mesh and 0.8 e–/Å3 in cyan volume representation. 
The lessons from calmodulin likely apply to enzymes where the loss of conformational entropy 
associated with the rigidification of active-site loops or side chains can specifically weaken 
binding to substrate or product complexes (Alber et al., 1983) and promote flux through the 
catalytic cycle. (b) A model of ubiquitin (2k39) derived from RDC data reporting on motions up 
to microseconds is shown as cartoon, with the other models in the ensemble shown as transparent 
ribbons (upper). The dynamic β1β2 loop moves between alternative loop conformations, 
represented as sticks (upper and lower). The population of the up (cyan), mid (blue), and down 
(purple) β1β2 conformations can be a critical determinant of binding preferences for protein–
protein interactions (Lange et al., 2008). The rates of transition between these states discriminate 
between induced fit and conformational selection mechanisms, (Hammes et al., 2009; Vogt et al., 
2012) which can influence catalytic mechanisms and inhibitor discovery (Fischer et al., 
2014). (c) For enzymes, loop motions on the millisecond time scale are often rate limiting for 
catalytic cycles, with essential roles for governing ligand flux (Boehr et al, 2008) and 
repositioning key catalytic residues for catalysis (Whittier et al., 2013). The WPD loop of protein 
tyrosine phosphatase 1B (PTP1B) moves between the “closed” (1sug, orange) and “open” (1t49, 
cyan) form on the millisecond time scale, forming the catalytically competent closed active site 
conformation (Whittier et al, 2013). Further molecular detail of the two conformations are shown 
in the lower panel with electron density contoured to 0.3 e–/Å3. (d) The archaeal proteasome, a ∼700-kDa complex, controls active site access through the dynamic exchange of the N-terminus 
to block or reveal the central pore on the time scale of seconds (Latham et al., 2014). The 
structure of the proteasome is shown as a homoheptamer with each subunit in a different color 
(upper). In the lower panel, the ensemble of structures of the N-terminus of one of the seven 
subunits is shown in blue (2ku1). I Many enzymes enter long-lived states, with distinct catalytic 
activities, through stochastic fluctuations (Xie et al., 2008). Quaternary structure reconstruction 
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of two RAS molecules (yellow) and son of sevenless (SOS, gray surface) complex. The Cdc25, 
REM, DH, histone, and PH domains of SOS are colored blue, green, orange, brown, and red, 
respectively (1xd2 (RAS) and 3ksy (SOS)). This complex exchanges between long-lived states 
with distinct catalytic rates. The structural basis of this exchange is currently unknown but likely 
involves rearrangements of protein–protein interfaces shown schematically in equilibrium 
(Iversen et al., 2014). (f) The folded crystal structure (1ssx) of α-lytic protease (upper) is a 
kinetically trapped structure. After folding catalyzed by a proline domain, the kinetic barrier to 
unfolding makes this protein stable on the scale of years. The benzoyl moiety of Phe228 deviates 
by 6° from planarity. Removing this distortion can change the unfolding barrier from over a year 
to less than 2 weeks (Kelch et al., 2012). Electron density contoured to 4.75 e–/Å3 (dark blue 
mesh, lower) and 0.5 e–/Å3 (cyan volume representation). 
 
X-ray crystallography and NMR spectroscopy can often be used in concert to answer a 
question that could not be answered by any single technique (Henzler-Wildeman and Kern, 
2007; Ward et al., 2013) High-resolution (<1.4 Å) X-ray crystallography, ideally at room 
temperature, and NMR experiments, including measuring J-coupling constants, (Tuttle et al., 
2013) can be combined to determine the structural basis of excited states critical for transit 
through catalytic cycles (as in the case of dihydrofolate reductase (DHFR) and cyclophilin A 
(CypA) discussed below) (Fenwick et al., 2014; van den Bedem et al., 2013). However, not all 
enzymes are amenable to these techniques, and many of the central functional questions of 
protein dynamics at the domain and complex level can be answered using relatively low-
resolution structural data paired with kinetic analyses. 
For enzymes amenable to high-resolution techniques, such as DHFR and CypA, these 
technical advances are catalyzing a shift from asking “can we describe protein dynamics” to 
“what is the role of protein dynamics in function”. Gaining a deeper understanding of these 
protein dynamics can be extremely challenging; especially important is resisting the urge to 
ascribe a function to all motions observed by a specific experimental or computational approach. 
Structural models of enzyme motions are key to understanding whether sampling of specific 
conformations is essential for properly orienting the substrate during catalysis, (Nazel and 
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Klinman, 2009) directly addressing the controversy of whether protein motions are coupled to 
catalytic function (Kamerlin and Warshel, 2010). 
Making the link between dynamics and function requires making some perturbation to 
the system and assessing the effect of this perturbation. These perturbations could include 
mutations, changes in the environment of the enzyme, or in more complicated systems, changes 
in other components interacting with the enzyme. It is critical when making mutations to 
consider all possible effects of the mutation in addition to the effect on protein dynamics, in 
order to truly understand the role of the mutated residue (Herschlag and Natarajan, 2013). This 
includes understanding the role the mutated residue plays in the structural integrity of the protein 
and the function of the protein. It is important to note that rigidity and flexibility are simply two 
extremes of the “protein dynamics” spectrum. Functionally important changes to protein 
dynamics can act by enhancing rigidity, enhancing flexibility, or altering the correlated motions 
of residues. For larger and more complicated systems, including protein machines, our level of 
understanding is often not as detailed compared with that for simple, single-domain, small 
enzymes. Therefore, the major questions for these machines may still be focused on defining the 
conformational changes that occur and the relative repositioning of subunits within the folded 
complex. 
 
The Role of Dynamics in Dihydrofolate Reductase 
Dihydrofolate reductase (DHFR) catalyzes the stereospecific reduction of dihydrofolate 
(DHF) to tetrahydrofolate (THF) (Figure 1.2 panel a). Five stable intermediates are observed in 
the catalytic cycle of Escherichia coli DHFR (ecDHFR): the holoenzyme, ecE:NADPH; the 
Michaelis complex, ecE:NADPH:DHF; and the three product ternary complexes 
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ecE:NADP+:THF, ecE:THF, and ecE:NADPH:THF (Schnell et al., 2004; Benkovic et al., 1988; 
Fierke and Benkovic, 1989; Fierke et al., 1987). Crystal structures of several complexes were 
solved by Kraut and co-workers, yielding insights into the structural mechanism of ecDHFR 
(Sawaya and Kraut, 1997; Bystroff and Kraut, 1991; Bystroff et al., 1990; Reyes et al., 
1995). For crystallographic work, E:NADP+:FOL was used as a model for the Michaelis 
complex (E:NADPH:DHF), and 5,10-dideazatetrahydrofolic acid (ddTHF) was used as a stable 
analog of THF, due to the instability of THF. The crystal structures revealed that ecDHFR 
undergoes a conformational change in the active site loop (Met20 loop, residues 9–24) that 
depends on the ligands bound. The conformational change in ecDHFR is therefore coincident 
with the different stages of the catalytic cycle. The Met20 loop was observed in three dominant 
conformations: “closed”, “occluded”, and “open”. In the “closed” conformation, the Met20 loop 
packs tightly against the nicotinamide ring of the cofactor, while in the “occluded” conformation, 
it projects into the active site and sterically blocks (“occludes”) the nicotinamide-binding pocket, 
which is compatible with the diffusion of the nicotinamide ring out of the active site (Figure 1.2 
panel a). 
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Figure 1.2 Dynamics in DHFR.  
(a) Crystal structures of E. coli DHFR show the Met20 loop in the occluded (1rx4, blue) and 
closed (1rx2, red) conformations. During the catalytic cycle of DHFR, this loop fluctuates 
between these conformations on the millisecond time scale. The ligands NADPH (left ligand) 
and folate (right ligand) are shown in orange and yellow, respectively. (b) Mutation of Asn23 to 
two proline residues (N23PP) shown as sticks in red and Ser148 to alanine (S148A) shown in 
pink reduce activity of ecDHFR. Mutation of Gly51 to the sequence PEKN (shown in blue) 
partially recovers the catalytic activity. The activity is increased further by the Leu28Phe (L28F, 
green) mutation. The structure of N23PP/PEKN (4gh8) is shown with NADPH shown in orange, 
with substrate mimic methotrexate in tan. (c) pH independent hydride transfer rates of different 
mutants show the quantitative effects of mutations that alter the dynamics of the Met20 loop and 
packing around the substrate. 
 
X-ray structures within the same space group of the holoenzyme (E:NADPH) and the 
model Michaelis complex (E:NADP+:FOL) show that these complexes adopt the closed 
conformation, whereas the three product complexes (E:NADP+:THF, E:THF, and 
E:NADPH:THF) adopt the occluded conformation. The occluded conformation is stabilized by 
hydrogen bonds between Asn23 and the backbone and side chain of Ser148. For binary substrate 
complexes, the M20 loop conformation was dependent on space-group, being “occluded”, 
“open”, or even disordered, with no clear electron density for the majority of the loop. While 
crystallographic analysis in a variety of space groups showed the Met20 loop to be in three 
dominant conformations, NMR data including chemical shift analyses and NOEs showed that in 
solution the enzyme is predominantly either in the “closed” conformation or in the “occluded” 
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conformation and never stably in the “open” conformation (Osborne et al., 2003; 
Venkitakrishnan et al., 2004). 
NMR relaxation dispersion experiments on the five stable intermediates of the catalytic 
cycle showed that each intermediate samples higher energy “excited states”, whose structural 
features resemble the preceding or following intermediates (Boehr et al., 2006). Substrate and 
cofactor exchange likely depends on these excited states, suggesting that the ligand-dependent 
modulation of these protein conformational dynamics is important as the enzyme proceeds 
through its catalytic cycle. A mutation in the Met20 loop of ecDHFR (N23PP or N23PP/S148A) 
inhibits the closed-to-occluded transition and also inhibits the sampling of productive higher-
energy states on the millisecond time scale, as assayed by NMR relaxation dispersion (Bhabha et 
al., 2011) (Figure 1.2 panel b). Remarkably, enzyme kinetic experiments revealed that hydride 
transfer, the chemical step of the enzyme reaction, was severely impaired in this mutant. Further 
analysis using high-resolution room temperature crystallography coupled with multiconformer 
model building using qFit (van den Bedem et al., 2009) and automated “pathway analysis” using 
CONTACT (van den Bedem et al., 2013) suggested that the mutation results in an increase of 
nonproductive, frustrated motions, while the concerted dynamics in the Met20 loop are inhibited. 
These results led to our current view: the mutation alters millisecond time scale conformational 
fluctuations, affecting the probability of populating conformations that are conducive to the 
optimal transition state configuration. As expected, the N23PP and N23PP/S148A mutations also 
affect ligand flux. 
Guided by comparisons to the homologous human DHFR, (Bhabha et al., 2013) “rescue” 
mutations in the N23PP background have been identified (Francis et al., 2013; Liu et al., 
2013) (Figure 1.2 panels b,c). These mutations increase the hydrophobic packing around the 
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substrate molecule. It is currently an open question how these mutations affect conformational 
dynamics of the protein, if at all, and the mechanism by which they rescue hydride transfer rates 
remains to be determined. Many computational and experimental studies have also examined 
flexibility changes introduced by the G121V mutation (Gekko et al., 1993; Mauldin et al., 
2012). While simulations have provided initial explanations of these effects, a current challenge 
for computational approaches is to rationalize both the local and long-range effects across the 
large activity ranges spanned by these mutations and to make predictions of how other mutations 
that tune these parameters will manifest experimentally (Adamcyzk et al., 2011; Agarwal et al., 
2002; Dametto et al., 2012; Ramanathan et al., 2014). 
 
The Role of Dynamics in Cyclophilin A 
 Human cyclophilin A (CypA) belongs to the proline isomerase family of enzymes, which 
play critical roles in protein folding, signaling, and the immune response (Lu et al., 2007; 
Sokolskaja et al., 2006). The reaction catalyzed by CypA, cis–trans proline isomerization, does 
not make or break new chemical bonds, making it possible to detect conformational exchange of 
both the substrate and the saturated enzyme during catalysis by NMR. Both backbone and side 
chain NMR dynamics experiments have been performed at various time scales revealing a 
network of residues that undergo two-state conformational exchange, which are thought to 
represent the enzyme’s conformation when bound to cis- or trans-proline substrates (Figure 1.3 
panel a) (Eisenmesser et al., 2005; Eisenmesser et al., 2002). Interestingly, NMR relaxation 
dispersion experiments show that similar conformational switching is observed in the free 
enzyme. These rates correspond closely to the sum of the rate constants of cis-to-trans and trans-
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to-cis isomerization (kex = 2500 s–1) suggesting that the rate of the catalytic cycle is governed by 
the intrinsic protein dynamics. 
 
 
Figure 1.3. Dynamics in CypA. 
(a) Exchanging residues detected by CPMG experiments show two groups with exchange 
rate kex = 1140 ± 200 s–1 (red) and kex = 2260 ± 200 s–1 (blue) in the absence of substrate. All 
residues with detectable dynamic exchange can be fit to one rate (∼2400 s–1) when the protein is 
saturated with substrate, which interconverts from cis to trans on the enzyme (1rmh). (b) Wild-
type CypA (3k0n) shows two sets of conformations at room temperature. The network of side 
chains of residues S99, F113, M61, and R55 are shown with surface representations around 
sticks, with the major conformation in red and the minor conformation in orange. These residues 
lie across the central β strands shown in panel a. (c) The network of these four residues for the 
S99T mutant at room temperature only occupies the minor-like conformation, shown in green 
(3k0o). 
 
 While NMR studies provided numerous insights and hinted that the minor conformation 
sampled in the free enzyme was relevant to catalysis, a detailed structural picture of the minor 
conformation was not decipherable from NMR experiments alone. The chemical shift differences 
between the excited and ground state provided few hints about the structural nature of the 
“excited” state. Examination of low levels of electron density, derived from new high resolution 
X-ray data collected at room temperature, uncovered a network of minor side-chain 
conformations for the residues exhibiting NMR dispersion (Figure 1.3 panel b). It is worth noting 
that both visual and automated examination, using Ringer (Lang et al., 2010), of the electron 
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density on data collected under cryogenic conditions did not uncover the full subset of minor 
conformations. These results point to several complications for deriving a structural basis for 
conformational dynamics. First, even though the CPMG experiments conducted here probed 
changes in the backbone environment, the conformational changes are mostly at the side chain 
level. Changes in side chain dihedral angles and the proximity of aromatic groups, in particular 
Phe113, create these changes with little change in backbone torsions. Second, the small energy 
differences (∼1–2 kcal/mol) separating these states render them very susceptible to perturbations 
like cryocooling or lattice contacts and can have unforeseen consequences, including eliminate 
evidence for the “excited state” even in high resolution X-ray data. 
To further link X-ray and NMR measurements, a mutation (Ser99Thr) was designed to 
stabilize the network of side-chain rotamers associated with the minor conformation in solution 
as well as in the crystal (Figure 1.3 panel c). Like the DHFR N23PP mutant, this mutation 
ablated detectable exchange on the microsecond to millisecond time scale. Furthermore, enzyme 
assays showed that shifting the equilibrium toward the side-chain rotamers populated by the 
minor conformation results in slower enzyme catalysis. Simulations have provided further 
evidence of a coupling between enzyme and substrate conformations during the catalytic cycle 
(McGowan and Hamelberg, 2013). Recent studies incorporating new NMR measurements and 
simulations point to the importance of considering a conformational ensemble in creating the 
environment compatible with catalysis and binding both the cis and trans forms of the substrate 
(Camilloni et al., 2014). 
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Dynamics in Designed Enzymes 
 One of the most exciting recent developments in enzymology is the application of protein 
design methodologies to create enzymes that catalyze reactions not found in nature (Kiss et al., 
2013). Several simple reactions have now been created based on the designs that place catalytic 
groups in specific orientations relative to a computational model of the transition state (Bolon 
and Mayo, 2001; Rothlisberger et al,. 2008; Jiang et al., 2008). These initial designs are 
generally weak catalysts, and directed evolution strategies have been implemented to improve 
them by several orders of magnitude (Khersonsky et al., 2010; Khersonsky et al., 2011; 
Khersonsky et al., 2012). While these evolved enzymes have greatly increased catalytic rates, 
structural and enzymological studies have revealed that some of the principles implemented in 
the designs are subverted over the course of multiple rounds of selection. For example, a detailed 
study of a designed retroaldolase revealed only a modest shift in the reactivity of the lysine and 
no role for a designed water-mediated interaction in catalysis (Lassila et al., 2010). The design 
was successful in creating strong hydrophobic binding interactions with the substrate (Lassila et 
al., 2010), which parallels lessons from simple micelle systems (Schmidt et al., 2013). A separate 
study on a distinct designed retroaldolase revealed that a second lysine residue acquired during 
directed evolution was responsible for greater rate enhancement than the original “catalytic” 
lysine and that the substrate occupied an entirely new position in the catalytic cavity (Giger et al., 
2013). Similarly, positioning of the substrate changed dramatically during the course of directed 
evolution studies of a designed Kemp eliminase (Figure 1.4 panels a,b) (Privett et al., 2012; 
Blomberg et al., 2013). Many rounds of selection resulted in catalysis with efficiency 
approaching that of natural enzymes and an intricate series of interactions in the active site 
(Figure 1.4 panel c) (Blomberg et al., 2013). However, examination of low levels of electron 
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density in this high-resolution data set suggests there are still interactions available for 
optimization (Figure 1.4 panels d,e). Therefore, even in the most proficient synthetic catalysts, an 
abundance of highly flexible residues in the active site may be limiting the formation of precise 
and stable interactions required for catalysis. 
 
 
Figure 1.4. Designed enzymes. 
(a) The Kemp eliminase reaction scheme. (b) Structure of designed Kemp eliminase prior to 
directed evolution (3nyd) with two alternative ligand conformations (cyan and purple). Electron 
density contoured to 1.5 e–/Å3 as a dark blue mesh, with a lower contour shown as a cyan volume 
representation at 0.3 e–/Å3. (c) Structure of final designed Kemp eliminase (4BS0) highlighting 
the hydrogen bond network. Disordered water replaces the acetate of the previous structure. 
Electron density contoured to 2.65 e–/Å3 as a dark blue mesh, with a lower contour shown as a 
cyan volume representation at 0.3 e–/Å3. Difference density contoured to 0.3 e–/Å3, colored green 
for positive and red for negative. Hydrogen bonds in hydrogen bond network drawn as dashed 
black lines. (d) Disorder of tryptophan residue 44 in final Kemp eliminase. The modeled 
alternative conformation deposited in the PDB is shown in dark green. Electron density 
contoured as in panel b. I Possible alternative conformation of catalytic Asp127 as detected by 
two positive difference peaks indicating alternative positions of the carboxylic oxygens that 
stabilize interactions with alternative water conformations. Electron density contoured as in 
panel c. 
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 A current focus of computational studies on designed enzymes is to use molecular 
dynamics simulations to screen for candidates with overly flexible active sites (Kiss et al., 
2013) or excess solvent penetration (Kiss et al., 2010). However, collectively these studies 
suggest that increased active-site conformational flexibility, while detrimental to the chemical 
step, are likely key to the evolvability of these enzymes (Tokuriki and Tawfik, 2009): the 
imprecision of the design process and of nonspecific hydrophobic interactions allows for the 
eventual tuning of catalytic residues during the course of directed evolution procedures. As the 
reactions performed by designed enzymes become more demanding, the role of directed 
evolution in rigidifying the active site will become more important (Korendovych and Degrado, 
2014); however, it is important to note that flexibility of second shell residues may still be 
desirable to ensure efficient transit through the catalytic cycle (Ruscio et al., 2009). 
Characterizing the energy landscapes of designed enzymes and using this information to improve 
the design process will be key to realizing the dream of designing synthetic catalysts for many 
important, yet currently difficult, reactions (Preiswerk et al., 2014). 
 
Extending Protein Dynamics to Large “Protein Machines” 
For larger enzymes that often undergo large-scale conformational changes, NMR 
spectroscopy and high-resolution X-ray crystallography may not be feasible (Figure 1.5). In 
these cases, electron cryomicroscopy (cryo-EM) and single-molecule Förster resonance energy 
transfer (smFRET) or single molecule two-color localization experiments can yield important 
insights into protein dynamics. For example, smFRET experiments have revealed excited states 
of the ribosome (Kim et al., 2014). Our understanding of protein dynamics using these methods 
is less atomically detailed and tends to focus on reorientation of large subdomains. However, 
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these experiments will provide key information in guiding future studies on macromolecular 
machines and complexes. Advances such as recently developed direct electron detectors (Li et 
al., 2013) and sophisticated methods of 3D classification (Scheres, 2012) have catapulted cryo-
EM to the forefront of understanding protein conformational landscapes in larger systems, at 
resolutions overlapping with the low end of those achieved by X-ray crystallography. While the 
resolutions achievable are still lower than what is required to understand enzyme catalysis at as 
detailed a level as available for DHFR or CypA, a fairly thorough picture of larger scale 
conformational changes can be developed through comparison of density maps and de 
novo models. Using these tools to probe the conformational landscape of larger protein machines 
will provide exciting new insights into their function. 
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Figure 1.5. The challenge of larger protein machines.  
The motor domain of dynein, a microtubule-based motor protein belonging to the AAA family of 
enzymes, is shown, colored by domain (3VKH). The entire dynein heavy chain is considerably 
larger and is difficult to produce in quantities required for structural biology studies. For 
comparison, DHFR (1RX2) and CypA (2CPL) are shown to scale. 
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Preface 
The bulk of this chapter appears as Biel J.T. et al. published in Structure (2017). 
 This chapter encompasses the work of my first project in the Fraser lab, which began 
originally as my project during my initial rotation in the lab. Here I solved the high-resolution 
crystal structures of two mutants of the protein ubiquitin, that had been created through a 
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combination of design and selection to enhance their affinity specifically for one of the natural 
ubiquitin binding partners, USP7. This work demonstrates how modeling multiple conformations 
can lead to enhanced understanding of a protein system as enabled by room temperature 
crystallography. 
 
Summary 
Although protein design has been used to introduce new functions, designed variants 
generally only function as well as natural proteins after rounds of laboratory evolution. One 
possibility for this pattern is that designed mutants frequently sample nonfunctional 
conformations. To test this idea, we exploited advances in multiconformer modeling of room 
temperature X-ray data collection on redesigned ubiquitin variants selected for increasing 
binding affinity to the deubiquitinase USP7. Initial core mutations disrupt natural packing and 
lead to increased flexibility. Additional, experimentally selected mutations quenched 
conformational heterogeneity through new stabilizing interactions. Stabilizing interactions, such 
as cation-pi stacking and ordered waters, which are not included in standard protein design 
energy functions, can create specific interactions that have long range effects on flexibility across 
the protein. Our results suggest that increasing flexibility may be a useful strategy to escape local 
minima during initial directed evolution and protein design steps when creating new functions. 
 
Introduction 
One of the major aims of both protein engineering and computational design is to create 
proteins with new or enhanced functions (Butterfoss and Kuhlman, 2006). Proteins can be 
redesigned to promote new catalytic reactions or, in the simpler case, for binding to new 
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partners. Recent years have seen successes including the design of new enzymes (Kiss et al., 
2013), new small molecule binders (Tinberg et al., 2013), and new protein-protein interfaces 
(Karanicolas et al., 2011). However, these redesigned proteins are generally optimized with 
many rounds of laboratory evolution to achieve functions approaching those of natural systems 
(Blomberg et al., 2013; Khersonsky et al., 2010). There are several ways that the engineering or 
design process can fall short of optimal function: the protein may not fold in the conformation 
predicted; the intended structure may not imbue the desired function; or the protein may 
dominantly populate nonfunctional conformations. We (Bhabha et al., 2015), and others 
(Korendovych and DeGrado, 2014; Osuna et al., 2015), have speculated that the third 
explanation is a major reason why redesigned proteins are only marginally functional initially. 
The hypothesis is that initial mutations introduced during redesign disrupt the native packing of 
the parental wild-type (WT) protein, resulting in increased flexibility and sampling of 
nonfunctional conformations. 
To improve function, subsequent directed evolution experiments fix mutations that act to 
stabilize the functionally important conformations found in the broadened ensemble of the 
redesigned protein (Frushicheva et al., 2014). This pattern of design and selection has been 
performed for functions including small molecule binding (Tinberg et al., 2013) and protein-
protein interaction (Karanicolas et al., 2011), the most developed examples of directed evolution 
changing dynamics and function emerged from enzyme design. Molecular dynamics simulations 
of designed enzymes indicate that initial designs suffer from poor preorganization (Frushicheva 
et al., 2010) and that mutations acquired during further selections reduce conformational 
dynamics near the active site (Osuna et al., 2015). Molecular dynamics simulations have also 
been used as a computational filter to screen out designs that suffer from conformational 
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instability (Wijma et al., 2015). In principle, NMR methods could be used to assess whether 
local dynamics are altered from WT by redesign and subsequent evolution (Johnson and Handel, 
1999; Walsh et al., 2001). However, it has remained difficult to track changes in conformational 
heterogeneity during these processes because of the inability to resolve the relevant 
conformations in atomic detail for proteins that select for new binding or catalytic activities. 
To overcome these limitations, X-ray crystallographic techniques to resolve alternative 
conformations with atomic resolution have recently been developed (Burnley et al., 2012; Keedy 
et al., 2015). The key insight enabling these techniques is the recognition that weak signals 
present in electron density maps represent alternative conformations (Lang et al., 2014, 2010). 
These signals can be interpreted with a multiconformer model where individual residues are built 
as a parsimonious set of alternative conformations with differing coordinates, occupancies and 
B-factors (Woldeyes et al., 2014). These features are often more noticeable in X-ray data 
collected at room temperature. Interpreting these signals in systems such as CypA (Fraser et al., 
2009), Ras (Fraser et al., 2011), and DHFR (van den Bedem et al., 2013), has delivered new 
insights into the structural basis of correlated protein dynamics and their relationship to function. 
By monitoring differences in multiconformer models, it should be possible to observe how 
conformational heterogeneity changes as a function of redesign and laboratory evolution for 
novel enzymatic or binding activities. Here we investigated the changes to conformational 
heterogeneity of ubiquitin variants selected to bind tightly and specifically to the deubiquitinase, 
ubiquitin specific protease 7, USP7, also known as HAUSP in humans (Zhang et al., 2013). 
Ubiquitin is a hub protein that binds partners with several different interfaces (Husnjak 
and Dikic, 2012). Previous studies have linked the conformational flexibility of ubiquitin, 
particularly in the β1β2 loop, to its ability to bind these diverse binding partners (Lange et al., 
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2008). Unlike the enzyme design examples discussed above, USP7 is already a natural, albeit 
weak, binder of WT ubiquitin. Zhang et al (Zhang et al., 2013) subjected ubiquitin to a 
combination of Rosetta design and phage display to encode additional affinity and specificity for 
USP7. The premise of the project was to mutate the core of ubiquitin to stabilize the “down” 
conformation of the β1β2 loop. An initial mutant was selected from a phage display library of 7 
sites selected based on Rosetta Design calculations. Originally referred to as u7ub25, this mutant 
is referred to herein as the “core” mutant. The final “affinity matured” mutant, originally called 
u7ub25_2540, contains an additional 3 surface mutations that were selected by additional phage 
display experiments (Figure 2.1). While structures of the variants bound to USP7 have not been 
possible to obtain, we reasoned that the structural and dynamic features of the unbound variants 
could provide new insights into the forces that stabilize binding. Here, we determined the 
structures of both the core and affinity matured variants to high resolution using room 
temperature X-ray diffraction. The structure of the affinity matured variant showed that the β1β2 
loop adopted the same “up” conformation as WT ubiquitin (Zhang et al., 2013), and as the minor 
conformer of the core mutant. Thus, the mechanism by which these mutations lead to increased 
specificity remains unclear. We found that the heterogeneity of these mutants follow a trend 
where the initial mutations lead to increased flexibility when compared to previously determined 
WT ubiquitin crystal structures in different crystal forms and that the final mutations then 
stabilize a dominant conformation. Our results show how characterizing the conformational 
landscapes of redesigned proteins could improve protein engineering and computational protein 
design. 
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Figure 2.1. Locations and Identities of Mutations Made across Directed Evolution Trajectory of 
Ubiquitin  
(A) Chart showing amino acid identities of mutation sites for the wild-type (WT), core, and 
affinity-matured mutants. Blue coloring represents residue identities first introduced in the core 
mutant. Green shows new residue identities for the affinity-matured mutations. 
(B) WT ubiquitin (PDB: 1ubq) model shown in gray with spheres representing locations of 
mutation sites, colored as in (A) and labeled by residue number. 
 
Results 
Conformational heterogeneity of the β1β2 loop 
 During initial refinement and model building (Tables 2.1 and 2.2), we noticed electron 
density clearly motivating the need for multiconformer models (Figure 2.2 panel a). For 
example, the β1β2 loop displays many large difference density features that cannot all be 
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accounted for by a single conformer model with isotropic B-factors (Figure 2.2 panel a), or even 
with anisotropic B-factors. In fact, if added first, the anisotropic B-factors can spread into the 
difference signal for alternative conformations making the density much more difficult to 
interpret. Therefore, we chose to model alternate conformations first, then add anisotropic B-
factors if necessary. In an initial attempt to build a multiconformer model, we used the 
automated program qFit (Keedy et al., 2015; van den Bedem et al., 2009), which builds 
multiconformer models via a “sample-and-select” procedure. While qFit has been recently 
updated to accommodate more backbone flexibility (Keedy et al., 2015), it was not intended to 
model large displacements with separated backbone density peaks. Consequently, qFit is not able 
to model highly flexible areas, such as this β1β2 loop (Figure 2.2 panel b). For some residues, 
such as Phe7 in the core mutant, side chains are even moved by qFit into density that is unlikely 
to arise from that residue. Clearly the complex backbone shifts in this region are not well 
captured by these automated techniques. 
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Table 2.1. Data statistics at different resolution cutoffs 
A) Table of values for core mutant structures at different maximal resolutions. Completeness, 
CC1/2 and I/σ are shown for the high resolution bin at each resolution cutoff choice. Both Rwork 
and Rfree percent values up to resolution cutoff shown for each row corresponding to the structure 
built using data to resolution cutoff shown for each column. Each column represents different 
structures built using data with different resolution cutoffs, however, structures can only be 
compared when the same reflections are compared, i.e. values in the same row. 
B) Statistics for affinity matured structures at different resolution cutoffs. As above, 
completeness, CC1/2 and I/σ are shown for the highest resolution bin, and R/Rfree statistics are 
shown for all reflections within the designated resolution cutoff (Rows). 
 
A – Core Mutant 
Completeness 
(%) 
CC1/2 
(%) 
Rmerge 
(%) I/σ 
Refinement Resolution 
R-factor calculation 
Resolution (Å) 
1.16 Å 1.12 Å 1.08 Å 1.04 Å 
100 96.8 17.9 8.46 1.16 Å 14.4/ 16.3 
14.2/ 
16.0 
15.1/ 
16.2 
15.0/ 
16.1 
100 95.3 22.4 6.89 1.12 Å  14.2/ 16.1 
15.1/ 
16.3 
15.0/ 
16.4 
97.2 89.4 29.9 4.47 1.08 Å   15.1/ 16.5 
15.1/ 
16.5 
91.1 74.7 41.8 2.41 1.04 Å    15.2/ 16.7 
B – Affinity Matured Mutant 
Completeness 
(%) 
CC1/2 
(%) 
Rmerge 
(%) I/σ 
Refinement 
Resolution 
R-factor 
calculation 
Resolution 
(Å) 
1.16 Å 1.12 Å 1.08 Å 1.04 Å 1.00 Å 0.96 Å 
100 98.1 24.8 9.24 1.16 Å 11.0/ 12.5 
11.1/ 
12.4 
11.1/ 
12.3 
11.3/ 
12.4 
11.4/ 
12.4 
11.6/ 
12.6 
100 96.9 32.5 7.01 1.12 Å  11.0/ 12.5 
11.1/ 
12.4 
11.2/ 
12.5 
11.3/ 
12.6 
11.5/ 
12.6 
96.8 90.9 47.9 4.22 1.08 Å   11.2/ 12.5 
11.3/ 
12.5 
11.3/ 
12.6 
11.5/ 
12.7 
87.8 76.7 66.6 2.28 1.04 Å    11.5/ 12.8 
11.5/ 
12.8 
11.7/ 
12.9 
68.7 41.3 118.3 1.00 1.00 Å     11.8/ 13.1 
12.0/ 
13.3 
34.3 7.7 233.1 0.38 0.96 Å      12.2/ 13.5 
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Table 2.2. Data Collection and Refinement Statistics. 
 
 Core (u7ub25) Affinity Matured (u7ub25_2540) 
Wavelength (Å) 0.9537 0.9537 
Resolution range (Å) 22.04–1.12 (1.16–1.12) 38.04–1.08 (1.119–1.08) 
Space group P 31 2 1 P 31 2 1 
Unit cell dimensions   
    a, b, c (Å) 42.72, 42.72, 54.88 43.92, 43.92, 55.44 
    a, b, g (º) 90, 90, 120 90, 90, 120 
Total reflections 130,992 (13,152) 311,084 (26,130) 
Unique reflections 22,427 (2,242) 27,011 (2,620) 
Multiplicity 5.8 (5.9) 11.5 (9.9) 
Completeness (%) 98 (100) 100 (98) 
Mean I/s (I) 18.25 (7.13) 28.21 (4.70) 
Wilson B factor (Å2) 9.91 8.95 
Rmerge 0.0540 (0.224) 0.0469 (0.454) 
Rmeas 0.05949 (0.2458) 0.0492 (0.4788) 
CC1/2 0.998 (0.955) 1 (0.929) 
CC* 1 (0.988) 1 (0.982) 
Reflections used in refinement 22,426 (2,242) 27,011 (2,622) 
Reflections used for Rfree 1,371 (137) 1,574 (155) 
Rwork 0.154 (0.148) 0.103 (0.118) 
Rfree 0.175 (0.204) 0.121 (0.158) 
CC (work) 0.943 (0.946) 0.976 (0.973) 
CC (free) 0.914 (0.892) 0.981 (0.953) 
No. of nonhydrogen atoms   
Total 1,135 1,358 
    Macromolecules 1,093 1,247 
    Ligands 5 10 
    Solvent 37 101 
Protein residues 73 75 
Root-mean-square deviation   
    Bonds (Å) 0.016 0.009 
    Angles (º) 1.57 1.05 
Ramachandran favored (%) 99 100 
Ramachandran allowed (%) 1.4 0 
Ramachandran outliers (%) 0 0 
Rotamer outliers (%) 1.7 0 
Clashscore 2.71 1.18 
B factor (Å2)   
Average 12.62 10.95 
    Macromolecules 12.27 10.02 
    Ligands 21.76 15.89 
    Solvent 21.56 21.92 
Statistics for the highest-resolution shell are shown in parentheses. 
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Figure 2.2. β1β2 Loop of the Core Mutant Showing Residues 5–13, Models, and Maps at 
Different Points in the Refinement Procedure 
(A) Best single conformer model and corresponding 2mFo-DFc map shown in volume 
representation at three contour levels: 0.65 eÅ−3, 1.5 eÅ−3, and 3.5 eÅ−3 from lightest to darkest. 
mFo-DFc map shown in green and red mesh at 3 or −3 eÅ−3, respectively. (B) Output model from 
qFit 2.0 built from single conformer model. While qFit is able to accurately model the side-chain 
heterogeneity at the more ordered base of chain for residue 5 valine, qFit was unable to capture 
the backbone heterogeneity in this loop, and in fact may be misled by the complex density as can 
be seen for the clearly misplaced Phe7 side chains. (C) Final, manually built multiconformer 
model with final 2mFo-DFc map, and single conformer difference map (mFo-DFc). This shows 
how the newly built heterogeneity corresponds to the major difference peaks in the original map. 
(D) The final manually built model with corresponding maps. While some difference features 
still exist, the difference signal in this region has largely been reduced in comparison with the 
original single conformer structure. 
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Due to the limitations of automated model building for this region, we undertook 
extensive manual interpretation of these regions with alternative conformations. To ensure that 
the resultant manually built models were consistent with the data, we performed two independent 
interpretations of the electron density maps (by JTB and MCT, blinded from each other). The 
approach of comparing independent refinements has been previously used to assess accuracy of 
structure determination under different purifications (Daopin et al., 1994), with different 
refinement software (Fields et al., 1994), and with the same data (Terwilliger et al., 2007). 
Although modeling alternative conformations at low signal levels is necessary to successfully 
interpret and minimize the local difference density, care must be taken not to interpret signal 
unless there is a stereochemically reasonable model that can be built (Richardson et al., 2013). 
The independent refinement procedure allowed us to check for consistent interpretation in 
regions of high disorder, such as the β1β2 loop, where relevant signals for alternative 
conformations frequently appear only at low electron density contour levels. The resulting 
models were almost identical essentially varying only in the interpretation of rotamers for 
flexible side chains. For residues that had different rotamers or varied in number of 
conformations modeled (Figure 2.8), we evaluated the two models based on rotameric positions, 
steric clashes, plausible tertiary interactions (e.g. hydrogen bonds to nearby side chain 
heteroatoms), consistency with the 2Fo-Fc map, and the extent to which local Fo-Fc difference 
density was explained. After making a consensus model based on these comparisons, we added 
anisotropic B-factors to protein atoms and finalized the solvent placement. These additions 
improved the map quality, allowing extra signal for other features to be interpreted in the final 
model (Figure 2.2 panel d). In the area of the β1β2 loop, the signal at the high and low contour 
levels clearly defines the molecular envelope, and the difference density in this region is largely 
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reduced (Figure 2.2 panel d). When the final structure is overlaid with the difference density 
from the single conformer structure (Figure 2.2 panel c), the new additional conformations 
clearly explain the previous difference peaks. 
The heterogeneity of the β1β2 loop consists of large shifts of the Cα atoms, separating 
alternative states by as much as 4.5 Å. Alternative conformations of backbone carbonyls are 
observed pointing in different orientations and the backbone takes two distinct paths for residues 
9–11. These loop conformations differ from the expected conformations contained in NMR 
models of the WT protein (Figure 2.3 panel c), in which the β1β2 loop moves in a hinge like 
manner, with residues 8–10 moving in unison between “up” and “down” conformations (Lange 
et al., 2008). 
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Figure 2.3. Conformations of the β1β2 Loop 
(A) Final multiconformer model of the β1β2 loop for the core mutant. Backbone atoms in the 
loop are rendered in sticks, while the side chains are left as lines. (B) Final model of β1β2 loop 
for the affinity-matured mutant. Panel shown with electron density in Figure 2.9. (C) Backbone 
conformational ensemble from NMR relaxation dispersion experiments (PDB: 2k39). The 
majority of conformations exhibit a simple backbone shift, producing a hinge-like motion 
as observed in previous molecular dynamics simulations. (D) β1β2 loop conformations from 
different ubiquitin structures. WT ubiquitin apo structure (PDB: 1ubq) in gray, and bound to 
USP7 in orange (PDB: 1nbf). The core mutant is shown in dark blue, and the affinity matured in 
green. See also Figure 2.9. 
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In contrast to the core mutant (Figure 2.3 panel a), the electron density for the affinity 
matured mutant is consistent with a much less heterogeneous conformational ensemble (Figure 
2.3 panel b, Figure 2.9). Although the affinity matured conformation is closer to the WT “up” 
conformation of previous crystal structures than the USP7-bound “down” conformation (Figure 
2.3 panel d), it is a more potent and selective binder than either the core mutant or WT (Zhang et 
al., 2013). Because the crystallization conditions and other considerations such as crystal lattice 
contacts and data collection temperature are equivalent between these two datasets, our results 
indicate that the addition of the final three surface mutations in the affinity matured mutant are 
responsible for quenching this heterogeneity. Below we outline how specific mutations have 
acted to increase conformational heterogeneity from the WT to the core mutant and to decrease 
heterogeneity from the core to affinity matured mutants. 
 
Structural changes of mutations in and near the β1β2 loop 
 The core variant has 6 mutations that were introduced with the goal of increasing the 
affinity to USP7, by changing the packing of the protein core to favor the “down” conformation 
of the β1β2 loop. Two of the mutations are on the β1β2 loop, T7F and L8R, which both mutate 
the side chains adjacent to the USP7 binding interface. Three of the other mutations are located 
in the core of the protein (I13Y, E34L and L69G) and the final mutation, L71R, is on the edge of 
the hydrophobic core on the C-terminus. 
Many of the mutations made in the core variant are adjacent to each other, leading to 
compensatory effects on packing. At the base of β1β2 loop the WT Thr7 is replaced by a bulkier 
Phe residue, which is then compensated by a large-to-small mutation (L69G) on the adjacent β5 
strand (Figure 2.4 panels a,b). While steric packing is conserved, T7F can no longer make 
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hydrogen bonds to the backbone carbonyl of Lys11 or to the side chain of Thr9. Both residues 
that previously participated in hydrogen bonds in the WT background show enhanced 
heterogeneity in the core mutant, as seen for the Lys11-carbonyl (Figure 2.4 panel b). For residue 
Thr9, the lack of a hydrogen bond allows the threonine side chain to flip out relative to the WT 
conformation (Figure 2.4 panels a,b). In the absence of the WT leucine side chain for residue 69 
(L69G) for which the newly introduced residue 7 phenylalanine (T7F) to pack against, we 
observed dramatically shifted conformations of Phe7 in the electron density. Collectively, these 
features likely stabilize the β1β2 loop in WT ubiquitin, and their absence correlates with the 
increased heterogeneity of the core mutant. 
 
 
Figure 2.4. Structural Changes upon Mutation near the β1β2 Loop 
(A) Key packing and hydrogen bond interactions around mutation sites T7F and L69G. WT 
ubiquitin (1ubq) is shown in gray. Gray dashed lines show hydrogen bonds existent in WT 
ubiquitin between residues 7, 9, and 11. Sticks are shown for the side chains of residues 7 and 9, 
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as well as for the backbone of residue 11. (B) Both conformations of the residues shown in (A) 
are shown for the core mutant. Mutated residues are colored in a lighter blue. The Cα of Gly69 is 
shown as a small sphere for clarity. (C–E) Interactions between residue 6 of β-strand 1 and 
residue 68 of strand 5 for the WT ubiquitin (gray, C), the core mutant (blue, D), and the affinity-
matured mutant (green, E). A modeled water appears linking the backbone of residue 6 with the 
histidine 68 side chain in both the core mutant and WT (PDB: 3ons). This interaction is directly 
replaced in the affinity-matured mutant by a hydrogen bond between the new arginine side chain 
and the backbone carbonyl of residue 6. See also Figure 2.10. 
 
The affinity matured mutant has three additional mutations (R42W, Q49R, H68R). H68R 
sits on the final β-strand directly adjacent to the β1β2 loop. A bridging water molecule links the 
carbonyl oxygen of Lys6 and the histidine side chain of residue 68 in the core mutant. This 
bridging water molecule is modeled in multiple previously determined WT ubiquitin crystal 
structures (3ons and 1yiw) and there is a corresponding unmodeled electron density peak in the 
original WT ubiquitin dataset (1ubq) (Figure 2.10). In the final affinity matured mutant this 
water-mediated interaction is replaced by a direct hydrogen bond between the introduced 
arginine side chain and the Lys6 carbonyl directly, stabilizing the loop in one conformation 
(Figure 2.4 panels c,d,e). 
 
Conformational heterogeneity is reduced in affinity matured α1β3 loop and C-terminus 
Two regions adjacent to the β1β2 loop also follow the same trend as the loop itself, 
displaying increased heterogeneity from the WT to the core mutant and decreased heterogeneity 
from the core to affinity matured mutants. The first of these areas that display heterogeneity in 
the core mutant is the C-terminal tail (residues 73–76), which is disordered in the electron 
density map of the core mutant. The density for L71R, one of the core mutations located just 
before the C-terminus, is not observable for the side chain beyond Cβ, but is ordered in the 
affinity matured structure. In the affinity matured mutant, two of the three new mutations are 
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involved in a new interaction with the C-terminus. The R42W and Q49R mutations create a 
cation-pi-cation stacking interaction with R72 (Figure 2.5 panels a,b,c). This interaction further 
links the C-terminus to the other β-strands of the protein, ordering residue 72 near the C-
terminus. 
 
Figure 2.5. Reduced Conformational Heterogeneity from Core Mutant to Affinity-Matured 
Mutant (A–C) The packing of residues 42, 49, and 72 is shown. Panels and colors show the WT, 
core, and affinity-matured mutants in gray, blue, and green, respectively. Once mutated, residues 
are shown in a lighter shade of the same color. Residue Arg72 could not be fully built in the core 
mutant model and thus is truncated at the Cβ. Residues mutated in the affinity-matured protein 
now show new cation-pi interactions, both between residues 72 and 42 and between residues 42 
and 49. (D) Residues 36–39 are shown, highlighting heterogeneity in the affinity-matured mutant 
that spans residues 32–41. There is signal for two conformations that differ in this region by a 
shift of as much as 2.2 Å. 2Fo-Fcmap shown as a volume contoured to 3.5, 1.5, and 0.65 
eÅ−3 (light blue, blue, and black), with the difference Fo-Fc map contoured to 3 eÅ−3. (E) The 
heterogeneity seen in the core mutant in (D) is not seen for the affinity-matured structure at the 
same residues. Maps are contoured as in (D). See also Figure 2.11. 
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A second area that displays significant conformational heterogeneity in the core mutant, 
but not in the affinity matured mutant is the loop region between the α1 helix and the β3 strand 
(residues 32–41). In this loop the backbone displays heterogeneity where alternative 
conformations are shifted by a 1.0–2.2 Å, resulting from a subtle hinging at the ends of the loop 
(Figure 2.5 panel d). In the most shifted region in the loop, the Asp39 backbone carbonyl, the 
density has two discrete peaks corresponding to two states, rather than a smooth continuum that 
could be modeled by a single conformation with an anisotropic B-factor. Within the α1β3 loop, 
we observe another pair of compensatory mutations for residues 13 (I13Y) and 34 (E34L) in the 
core mutant. Specifically, Tyr13 buries Leu34 (Figure 2.11), maintaining the interaction between 
aliphatic groups at these sidechain positions. The hydrophilic hydroxyl group in Tyr13 is also 
retained in a nearly equivalent position to the carboxyl group of Glu34 in the WT protein. 
Although sidechain interactions appear to be maintained, this new interaction coincides with 
increased mobility of the α1β3 loop. Subtle differences in packing that result from these amino 
acid substitutions, and concomitant changes to adjacent residues, may introduce flexibility in this 
region. In contrast to the core mutant, the α1β3 loop in the affinity matured mutant does not 
display significant heterogeneity (Figure 2.5 panel e). Although none of the affinity matured 
mutations are in this exact region, it is likely that the additional stabilization of the C-terminus 
gained from the new cation-pi-cation interaction between residues W42, R49, and R71 in the 
affinity matured mutant propagates to the α1β3 loop via backbone interactions. Notably, a 
network of hydrogen bonds connects residues 40 and 41 of the α1β3 loop with residues 70 and 
72 of the C-terminus. We therefore hypothesize that the new interactions observed in the affinity 
matured mutant cooperate with native hydrogen bonding motifs to quench the dynamics of the 
α1β3 loop. 
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Both states of residue Asp52-Gly53 peptide flip occur in core and affinity matured structures 
Residues Asp52 and Gly53 have been previously identified as a structural switch in 
ubiquitin that undergoes a discrete peptide flip (Huang et al., 2011) that exchanges on the 
microsecond timescale (Sidhu et al., 2011; Smith et al., 2016). The original crystal structure of 
wild-type ubiquitin (1ubq), a standard in computational benchmarking studies, shows the peptide 
in the “NH-out” state with the Asp52 carbonyl making a hydrogen bond to the backbone of the 
α1-helix starting residue Glu24. In the crystal structure (3ons) from conditions similar used for 
solid state NMR the “NH-in” state is seen, where the Glu24 side chain is swung down relative to 
the NH-out conformation to make a hydrogen bond with the Glu24 backbone and the G53 NH 
group. This observation has provided a structural rationale for slow NMR dynamics 
measurements in solution (Majumdar and Ghose, 2004; Massi et al., 2005) and in solid state 
(Tollinger et al., 2012): the chemical shifts of backbone amides surrounding residue 24 are 
perturbed as the sidechain transitions to a new rotamer. Moreover, this flip is thought to be a key 
structural switch between different states of ubiquitin. The flip state of the peptide can be 
predicted from the backbone coordinates of other residues clear across the protein (Smith et al., 
2016). 
The major conformation in both of our structures corresponds to the NH-in conformation 
found in the 3ons structure. When modeling this region as a single conformer, we observed 
signals in the Fo-Fc map supporting an alternative conformation corresponding to the NH-out 
state (Figure 2.6 panel a). In our final model, the peptide flip is modeled in both states (Figure 
2.6 panel b) for both structures at occupancies of 60–70% for the major NH-in and 30–40% for 
the NH-out. Interestingly, the NH-in state has been implicated in the binding mode of ubiquitin 
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to the USP class of deubiquitinases which includes the target, USP7 (Smith et al., 2016). While 
the population of the NH-in state may have been increased relative to WT, it remains surprising 
that both peptide flip states are observed in our structures given the strong association of this 
peptide flip with the binding of USP7. These structures indicate that it is possible for both of 
these states to exist within the same crystal form, and provide an additional example of how 
multiconformer X-ray models can be used to provide a structural basis for dynamics observed by 
NMR. 
 
 
Figure 2.6. Asp52-Gly53 Peptide Flip is Seen in Both States (A) Model and maps from the 
affinity-matured mutation prior to modeling a peptide flip in this region. 2Fo-Fc map shown as a 
volume contoured to 3.5, 1.5, and 0.65 eÅ−3 (light blue, blue, and black), with the difference Fo-
Fc map contoured to 3 eÅ−3. There are clear difference features both positive (green) and 
negative (red), highlighted by black arrows. (B) Modeled peptide flip in final structure of the 
core mutant. Maps are contoured as in (A). The difference features are now gone. 
 
Discussion 
 We have structurally characterized two ubiquitin variants created via a combination of 
computational protein design calculations and phage display. These variants are poorly modeled 
by traditional single conformer models, or even with existing automated model building tools for 
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regions of high heterogeneity. Enabled by room temperature X-ray data collection, and 
manually-built multiconfomer models, we have described the emergence and quenching of 
conformational heterogeneity along a protein design and engineering trajectory. From these 
multiconformer models, we observed the interplay of computational protein design and 
laboratory evolution, describing both the core and affinity matured mutants that were developed 
to bind tightly to USP7. Notably, the intermediate core mutant displayed significant 
conformational heterogeneity across the majority of the protein, varying in magnitude. The large-
scale backbone motions of the β1β2 loop are in direct contrast to the original goal of stabilizing a 
single pro-USP7 binding conformation. Instead, the core mutations enhance the flexibility of the 
protein, creating β1β2 loop conformations that are distinct from states in the hinge-like motion 
predicted by NMR analyses of the WT protein (Lange et al., 2008). In contrast, additional 
surface mutations introduced in the final affinity matured mutant cooperate to reduce flexibility 
and the β1β2 loop can be modeled in a single conformation. 
 Our observations suggest that the process of rational protein design followed by directed 
evolution resembles simulated annealing procedures used to escape local conformational minima 
in X-ray refinement (Brünger et al., 1997; Korostelev et al., 2002). For these ubiquitin variants, 
the core mutations, selected based on Rosetta calculations and phage display, act like the heating 
step. These mutations disrupt the natural dynamics and packing of the WT protein, creating a 
large and diverse ensemble of states. Relative to the initial WT conformation, these dynamics 
likely increase sampling of states that have the desired function; however, many undesirable 
conformations are also sampled. Further affinity maturation acts like the cooling step in 
simulated annealing, selectively stabilizing the functional states. This final pattern of flexibility 
changes is similar to what has been hypothesized for designed enzymes subjected to directed 
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evolution (Bhabha et al., 2015; Kiss et al., 2013) and observed in antibody maturation (Adhikary 
et al., 2015; Jimenez et al., 2004). The discordant mapping between the conformational 
landscape, which is most heterogeneous in the “core” mutant, and functional landscape, which 
shows the largest functional gain from the initial “core” phage display, demonstrates the complex 
interplay between conformational dynamics and function. Although our observations are in the 
context of the evolution of new binding specificity, they can likely be translated to the more 
complicated challenge of evolving new catalytic activities (Campbell et al., 2016) 
 The ability for proteins to evolve new functions in this way relies on the fact that the 
hydrophobic cores of most proteins can accommodate many alternative sequences without 
compromising stability (Lim and Sauer, 1989). This permissiveness can be exploited to alter 
functional specificity (Koulechova et al., 2015). Here, we observed how changes in side chain 
packing between mutations in direct contact can lead to dramatic changes in backbone flexibility. 
Therefore, core mutations, even with multiple compensatory mutations, can disrupt the natural 
dynamic packing and may increase backbone flexibility. These changes lead to altered dynamics, 
which can be exploited for evolving new functions. The nearly global quenching of backbone 
heterogeneity in the affinity matured mutant, both in regions directly adjacent to mutations and 
across the protein, point to the importance of the cooperativity in these dynamic packing 
interactions. 
 Surprisingly, the reduced dynamics in the affinity matured variant are enabled by 
introduction of new surface interactions, including a cation-pi-cation interaction observed 
between residues Arg72, Trp42, and Arg49. These new side chains apparently cooperate to 
“freeze” motion on the backbone behind these new interactions. The importance of this cation-
pi-cation motif in this structure suggests possibilities to improve rational design of new or altered 
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protein function by incorporating rarer interactions in the design process. Despite efforts to 
develop potentials for cation-pi interactions in Rosetta (Misura et al., 2004), they are not 
currently modeled in the standard Rosetta energy function and thus would be completely missed 
in the design process. Cation-pi interactions have recently been used to stabilize a miniature 
designed protein (Craven et al., 2016) and are common in naturally occurring proteins 
(Dougherty, 2013). In addition, ordered waters, which are not directly accounted for by Rosetta 
(Jiang et al., 2005), play a key role in the stabilization of hydrogen bond networks such as 
between the WT His68 and the β1β2 loop. These overlooked features of protein structure play 
key roles in conformational stabilization and could be incorporated to improve the protein design 
process. 
 Interestingly, despite the dramatic increase in affinity for the binding partner USP7, the 
β1β2 loop in our apo-crystal structures does not adopt the “down” conformation seen in the WT 
ubiquitin USP7 complex. Instead, the affinity matured loop state resembles the WT apo “up” 
state (Figure 2.3 panel d). It is unclear whether the “down” conformation is stabilized by these 
mutations, albeit still as a minor conformation that cannot be detected crystallographically. 
Rather than disrupting the dynamics of the β1β2 loop in such a way that the “down” state is the 
only state accessed, one explanation for the enhanced affinity to USP7 may be that the mutations 
introduced key interfacial residues that produce a more complementary surface to the large 
binding cleft of USP7. Alternatively, the mutations may reduce the energetic penalty for 
reorganizing into the bound conformation in an induced fit mechanism. Repeated attempts to co-
crystallize mutant ubiquitins with USP7 have not been successful. However, when our model is 
docked into holo-USP7 crystal structures, it has significant clashes, similar to docking a WT apo-
ubiquitin crystal structure into this pocket (Figure 2.7). Interestingly, the pattern of clashes 
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changes, with new clashes appearing near the β1β2 loop (residues Tyr13 and Thr14), and for 
residues Lys33, 47–49, and Gln62. Also, the residues involved in the newly introduced cation-pi 
interaction also show clashes when docked into USP7. The pattern of clashes also changes when 
docked into an apo crystal structure of USP7 without a ubiquitin in the binding site. Most 
notably there is a shift of clashes in the region of the β1and β2 strands, shifting from residues 
Tyr13 and Thr14 to Thr12, Phe4, and the side chain of Glu64 (Figure 2.7), which is likely a 
result of the clam-shell shift of USP7 when binding to its partner. Collectively, these clashes 
argue against the ubiquitin mutants targeting the apo-like state of USP7. We speculate that the 
affinity matured mutant also undergoes rearrangement with USP7 upon binding, similar to what 
is seen based on WT crystal structures. Zhang et al, showed that while the specificity for the 
affinity matured mutant was mostly specific to just USP7, the additional deletion of the two C-
terminal glycine residues was necessary to obtain specificity over USP5. The C-terminus makes 
extensive contacts with both USP7 and USP5, suggesting that the specificity is reliant on folded 
part of the domain where new contacts enhance affinity for USP7 over USP5. 
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Figure 2.7. Wild-Type and Affinity-Matured Ubiquitin Have Distinct Patterns of Contacts to Apo 
and Holo USP7 (A) Unbound WT Ub (gray, 1ubq) shown in ribbon overlaid with the bound Ub 
from the holo USP7 structure (orange, 1nbf). Ub-bound USP7 is shown in cartoon and surface 
(tan, 1nbf). Clashing atoms between the unbound WT Ub and USP7 are mainly concentrated at 
the β1β2 loop (top) and shown as spheres, with the remainder of the residue shown as sticks. (B) 
Affinity-enhanced mutant (green) shown overlaid with bound Ub from the holo USP7 structure. 
Although contacts are changed at the β1β2 loop (top), additional clashes, indicative of an altered 
binding mode or receptor accommodation, are spread throughout the protein. An asterisk marks 
notable changes in clashes between apo and holo USP7 structures. (C) Unbound WT Ub 
(gray, 1ubq) shown overlaid with the unbound apo-USP7 structure (lighter brown, PDB: 5j7t). 
Overlay was constructed by alignment of domains to the bound USP7 (1nbf). Increased clashes 
throughout the protein show the accommodation of the receptor in the holo form. (D) Affinity-
matured mutant (green) shown overlaid with the unbound apo-USP7 structure (5j7t). Although 
clashes are increased in some regions, they are reduced in others, which suggests that the 
conformational flexibility of the receptor may be exploited by the affinity-matured mutant in 
the final binding pose. An asterisk marks notable changes in clashes between apo and holo USP7 
structures. 
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Future studies of the core and affinity matured mutants bound to USP7 are needed to 
further answer these questions regarding the mechanism whereby these ubiquitin mutants 
obtained such high affinity for USP7. The relationship between protein function and 
heterogeneity and dynamics is complex; the creation of new alternative conformations does not 
necessarily imply reduced affinity or performance. A protein’s WT sequence is presumably 
nearly-optimized for fitness and its conformational landscape is sufficiently tuned for function. 
Mutations can therefore introduce extra conformers which might have a negative impact on 
fitness; however, these extra conformations can, in rare instances, provide the raw material for 
functional innovation or specialization. Directed evolution can stabilize the extra states 
introduced by the mutations selected through protein design, quenching heterogeneity. Given the 
recent interest in using ubiquitin variants for structural biology chaperones as in vitro modulators 
of the ubiquitin proteasome system (Canny et al., 2016; Ernst et al., 2013; Gorelik et al., 
2016; Phillips et al., 2013; Zhang et al., 2016), there may be additional opportunities to use these 
proteins to test these hypotheses and learn about the importance of conformational dynamics in 
protein function (Phillips et al., 2013). Experimentally characterizing nearly iso-energetic states 
will improve our ability to evaluate the success of the design of protein ensembles. As design 
challenges move from stabilizing a single state to creating functional cycles, finding sequences 
with that predictably modulate flexibility or rigidity will become increasingly important. 
 
Method Details 
Protein purification 
 Protocol adapted from Zhang et al ((Canny et al., 2016; Ernst et al., 2013; Gorelik et al., 
2016; Phillips et al., 2013; Zhang et al., 2016)) and references therein. Each of the ubiquitin 
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mutants were expressed from a pET derivative vector containing the protein gene with a TEV 
cleavable N-terminal His6 tag in E. coli BL21(DE3) cells. Cells were grown in LB media to an 
OD600 of 0.6–0.8, and were then induced with 1mM IPTG at 37 °C for 4 hours. Cell pellets 
were resuspended into 25 mM Tris pH 8.0, 300 mM NaCl and protease inhibitors. The 
resuspended pellet was then lysed by EmusiFlex. Lysate was cleared by centrifugation at 15,000 
rpm. Supernatant was flowed over a 5 mL Ni-NTA column. Ni-NTA column was washed with 
20 mM Tris pH 7.0, 300 mM NaCl, 20 mM imidazole and eluted with 20 mM Tris pH 7.0, 
300mM NaCl, 500 mM imidazole. Elution was dialyzed into 20 mM Tris pH 8.0, 150 mM NaCl 
and then cleaved with TEV overnight at 4 °C. The sample was then loaded back onto a Ni-NTA 
column, and the flow through was collected. Sample was then concentrated to less than 10 mL 
and loaded onto a S75 column equilibrated with the previous buffer (20 mM Tris pH 8.0, 150 
mM NaCl). Protein concentration of the pooled fractions was assessed after concentration down 
to 1–2 ml via a BSA assay and monitored during further concentration via absorption. Protein 
was stored only overnight at 4 °C before concentration and use for crystallization. 
 
Crystallization and data collection 
 Protein solution from was concentrated to 20 mg/ml for the core mutant and 10 mg/ml for 
the affinity matured mutant. Then 1ul of protein solution was mixed with 1ul of precipitation 
solution in hanging drop trays. Precipitation solution for core mutant contained 0.1 M citric acid 
pH 4.6, and 2.6 M ammonium sulfate. For the affinity matured mutant, the precipitation solution 
contained 0.1 M citric acid pH 4.2, and 2.2 M ammonium sulfate. Crystals formed overnight and 
grew to full size over the course of several days. Diffraction data were collected at the Advanced 
Light Source (ALS, Berkeley, CA), beamline 8.3.1. 
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Optimizing the diffraction resolution cutoff 
 After optimizing crystals for the room temperature collection of high resolution datasets 
for the initial core and the final affinity matured mutants, we had to select an appropriate 
resolution cutoff for our data. Because the ability to detect and faithfully model conformational 
heterogeneity is resolution dependent, we aimed to push the resolution of our dataset as far as 
possible. High resolution reflections, despite their lower signal-to-noise, can contain meaningful 
information that can improve the map and model, even past more traditional methods of picking 
a resolution cutoff. Instead of simply using CC1/2, completeness and I/σ, we used the Karplus and 
Diederichs approach of monitoring Rfree in parallel refinements to determine the optimal 
resolution cutoff for our datasets (Karplus and Diederichs, 2012). When using parallel 
refinements to determine the optimal resolution cutoff, additional higher resolution reflections 
are judged to contain meaningful signals only if model agreement increases in lower resolution 
bins after refinement. 
 A molecular replacement solution was found with the 1ubq WT ubiquitin model. While, 
a previous lower resolution structure of the affinity enhanced mutant exists (PDB ID: 4hk2) this 
model was solved with a much larger unit cell containing extra non-crystallographic symmetry 
copies that were not justified by the diffraction images in our datasets. Due to these 
complications, we have not focused on comparisons with 4hk2 and restricted our analysis to the 
(high resolution) room temperature dataset. 
 For an initial conservative resolution cutoff, we chose 1.16 Å as a cutoff to begin our 
parallel refinement tests, and created additional bins of reflections to be added in 0.04 Å 
increments up to a high resolution cutoff of 0.96 Å. While a 0.04 Å resolution change may seem 
small, ~2000 unique reflections are added in each bin. The values for CC1/2 in the high resolution 
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bins remained over 50% up to 1.04 Å resolution, while completeness began to drop at resolutions 
better than 1.12 Å (Table 2.1). To begin the resolution test, first we built a single conformer 
model using the reflections up to the first cutoff (1.16 Å). We then built alternative 
conformations into strong difference density signals corresponding to clear alternative 
conformations. At this point, we added reflections from each additional resolution bin ranging 
from 1.16 Å to 0.96 Å, and re-refined the model to convergence in parallel refinements. Based 
on the R-values from these parallel refinements, the determined optimal resolution cutoffs were 
1.12 Å for the core mutant and 1.08 Å for the affinity matured mutant (Tables 2.1 and 2.2, Figure 
2.12). 
 
Quantification and statistical analysis 
 Statistical parameters are reported in Figure Legends and in Method Details. 
 
Data and software availability 
 XDS was used to process the raw diffraction data and different software found in the 
phenix suite was then used to determine, refine, and build the structural model. All software used 
are reported in Method Details. The accession number for the coordinates and structure factors 
for the core mutant (u7ub25) is PDB: 5t0f, and for the affinity matures mutant (u7ub25_2540) is 
PDB: 5t0g. 
 
Acknowledgments 
JTB is supported by a NSF GRFP. M.C.T. is supported by NIH F32 HL129989. J.S.F. is 
supported by a Searle Scholar Award from the Kinship Foundation, a Pew Scholar Award from 
 
 
56 
the Pew Charitable Trusts, a Packard Fellowship from the David and Lucile Packard Foundation, 
NIH DP5 OD009180, NIH R21 GM110580, and NSF STC-1231306. Data collection at BL831 
at the Advanced Light Source is supported by the Director, Office of Science, Office of Basic 
Energy Sciences, of the U.S. Department of Energy under Contract No. DE-AC02-05CH11231, 
UC Office of the President, Multi-campus Research Programs and Initiatives grant MR-15-
32859, and the Program Breakthrough Biomedical Research, which is partially funded by the 
Sandler Foundation. We acknowledge helpful conversations with H. van den Bedem, T. 
Kortemme, N. Betheil and the Fraser lab, especially D. Keedy. 
 
Author Contributions 
Performed experiments JTB 
Performed refinements JTB, MCT 
Designed experiments JTB, CNC, JEC, JSF 
Wrote manuscript JTB, JSF 
Edited manuscript JTB, MCT, CNC, JEC, JSF 
 
  
 
 
57 
Supplemental Information 
 
Figure 2.8 Regions of interpretative difference between MCT and JTB blinded-models.  
This figure is a supplement related to Figure 2.2. Models built by JTB (blue) and MCT (orange) 
are both shown overlayed. The 2Fo-Fc density map is contoured to 0.65 eÅ-3, 1.5 eÅ-3 and 3.5 
eÅ-3 (lightest to darkest); JTB maps are shown as volume, and MCT maps shown as mesh. A) 
Residue Ser20 shown, where MCT has built a third conformer of the serine side-chain that is not 
strongly supported by the density, and was deleted in the final model (not shown here). B) 
Residue Arg25 where MCT built one extra conformation of asparagine side-chain supported by 
the density. This conformer was incorporated into final model. C) Here, model built by JTB has 
an extra Leu43 conformer that sticks out of the density. D) An extra Leu67 side-chain was built 
by MCT that was later interpreted as a conformer model into signal that became more clear after 
further refinement. 
 
 
Supplemental Information: 
 
Figure S1, related to Figure 2. Regions of interpretative difference between MCT and JTB 
blinded-models. 
Models built by JTB (blue) and MCT (orange) are both shown overlayed. The 2Fo-Fc density map 
is contoured to 0.65 eÅ-3, 1.5 eÅ-3 and 3.5 eÅ-3 (lightest to darkest); JTB maps are shown as 
volume, and MCT maps shown as mesh. 
A) Residue Ser20 shown, where MCT has build a third conformer of the serine side-chain that is 
not strongly upported by the density, and wa  deleted in the final model (not shown here). 
B) Residue Arg25 where MCT built one extra conformation of asparagine side-chain supported by 
the density. This conformer was incorporated into final model. 
C) Here, model built by JTB has an extra Leu43 conformer that sticks out of the density.  
D) An extra Leu67 side-chain was built by MCT that was later interpreted as a different two-
conformer model into signal that became more clear after further refinement. 
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Figure 2.9. Affinity matured β1β2 loop with density.  
This figure is a supplement related to Figure 2.3. Residues 5-13 shown as sticks, with 2Fo-Fc 
density map contoured to 0.65 eÅ-3, 1.5 eÅ-3 and 3.5 eÅ-3 from lightest to darkest. Fo-Fc 
difference map contoured at 3 eÅ-3.  
 
 
 
Figure S2, related to Figure 3. Affinity matured β1β2 loop with density. 
R idues 5-13 shown as sticks, with 2Fo-Fc density map contoured to 0.65 eÅ-3, 1.5 eÅ-3 and 3.5 
eÅ-3 from lightest to darkest. Fo-Fc difference map contoured at 3 eÅ-3. 
 
 
Figure S3, related to Figure 4. Unmodeled water bridging His68 and Lys6. 
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Figure 2.10 Unmodeled water bridging His68 and Lys6. 
This figure is a supplement related to Figure 2.4. 
 
 
 
 
Figure 2.11. Compensatory mutation at residues E34L and I13Y D) Packing interaction between 
the β2-strand’s I13 with the helix cap residue Glu34. 
This figure is a supplement related to Figure 2.5. Altered packing interaction of residues 13 and 
34 in the core mutant. Both conformations of the residues are shown, and the mutant side-chains 
are shown in a lighter blue. WT ubiquitin from crystal structure 1ubq, showing positive 
 
Figure S2, related to Figure 3. Affinity matured β1β2 loop with density. 
Residues 5-13 shown as sticks, with 2Fo-Fc density map contoured to 0.65 eÅ-3, 1.5 eÅ-3 and 3.5 
eÅ-3 from lightest to darkest. Fo-Fc difference map contoured at 3 eÅ-3. 
 
Figure S3, related to Figure 4. Unmodeled water bridging His68 and Lys6. 
 
i S4, related to Figure 5. C mpensatory mutation at residues E34L and I13Y 
D) Packing i teraction between the β2-stran ’s I13 with the helix cap residue Glu34. 
E) Altered packing interaction of residues 13 and 34 in the core mutant. Both conformations of the 
residues are shown, and the mutant side-chains are shown in a lighter blue. 
WT ubiquitin from crystal structure 1ubq, showing positive difference density for a water (built 
here) bridging the His68 side-chain and the Lys6 carbonyl. Hydrogen bonds linking atoms to built 
water are shown as dashed lines. Residues 5-7 and 67-69 are shown as sticks. The 2Fo-Fc map 
is contoured at 0.65 eÅ-3, 1.2 eÅ-3, from light to dark blue. The Fo-Fc map is contoured at 0.25 
eÅ-3. 
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difference density for a water (built here) bridging the His68 side-chain and the Lys6 carbonyl. 
Hydrogen bonds linking atoms to build water are shown as dashed lines. Residues 5-7 and 67-69 
are shown as sticks. The 2Fo-Fc map is contoured at 0.65 eÅ-3, 1.2 eÅ-3, from light to dark blue. 
The Fo-Fc map is contoured at 0.25 eÅ-3.  
 
 
 
Figure 2.12. Chart illustrating strategy for selecting a resolution cutoff and refining a final 
model. 
This figure is a supplement related to Table 2.1. After processing raw images using the 
diffraction data processing program XDS (Kabsch, 2010) at the highest resolution (0.96 Å), data 
was truncated to several lower resolution thresholds. Reflections selected for the Rfree set were 
created for the highest resolution data are consistent across all resolution cutoffs. The lowest 
resolution truncation was fed into molecular replacement with WT ubiquitin (PDB ID: 1ubq) 
used as a search model. After a single conformer model was built, the additional alternative 
conformations were identified by both JTB and MCT authors independently. After comparing 
JTB and MCT models, a final model (at 1.16 Å) was fed into parallel refinements against the 
higher resolution data for each resolution cutoff. Rwork and Rfree were compared to select best 
resolution for which to move forward. This final resolution was used to feed the single 
conformer model into automated model building by qFit. The final model determined using the 
reflections up to 1.16 Å was further interpreted by making additional solvent changes, resolving 
clashes and inspecting signal resolved by the higher resolution data.  
 
  
 
 
 
Figure S5, related to Table 1. Chart illustrating strategy for selecting a resolution cutoff and 
refining a final model. 
After processing raw images using the diffraction data processing program XDS (Kabsch, 2010) 
at the highest resolution (0.96 Å), data was truncated to several lower resolution thresholds. 
Reflections selected for the Rfree s t were created for the high st resolution data are consistent 
across all resolution cutoffs. The lowest resolution truncation was fed into molecular replacement 
with WT biquitin (PDB ID: 1ubq) used as  search model. After a single conformer model was 
built, the additional alternative conformations ere identified by both JTB and MCT authors 
independently. After comparing JTB and MCT models, a final model (at 1.16 Å) was fed into 
parallel refinements gainst the igher r olution data for each resolution cutoff. Rwork and Rfree 
were compared to select best resolution for which to move forward. This final resolution was used 
to feed the single conformer model into automated model building by qFit. The final model 
determined using the reflections up to 1.16 Å was further interpreted by making additional solvent 
changes, resolving clashes and inspecting signal resolved by the higher resolution data. 
 !
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Chapter III 
Group Deposition of Fragment Bound PanDDA Crystal Structures to the P.D.B. 
 
Introduction 
Recently we submitted 110 structures to the PDB containing the hits of a fragment screen 
conducted on protein tyrosine phosphatase 1B (PTP1B) (Chapter IV). In this chapter I will start 
by outlining a bit more background on the PanDDA algorithm that was central to the fragment 
screening efforts outlined in the following chapter. Next because the output of PanDDA analysis 
results in the modeling of two distinct populations in the data, both apo and holo requires a new 
layering of information into multiconformer models, I will discuss the possibilities for how to 
store this kind of information in coordinate files, and where we hope this will improve and/or 
change in the future. Finally, I will discuss the process of depositing such a large grouping of 
unique datasets to the Protein Data Bank (PDB). 
 
A background on PanDDA 
I’ll start with an overview of the PanDDA software’s functionality. The goal of a 
fragment soaking experiment is to both identify potential binding sites for which to develop high 
affinity ligands, and to discover initial hits from which to chemically expand to increase binding 
affinity. However, the analysis of ligand density can be a challenging because initial fragment 
hits almost never bind with fill occupancy. In short, to improve the power to identify weak hits, 
PanDDA leverages the collection of many datasets; critically, several measurements of the apo-
condition. From this, PanDDA is able to generate statistics on the variation in the signal of apo 
datasets. These apo datasets can be datasets collected separately without soaking, or they can 
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simply be soaked crystals where the screened ligand does not bind. From the distribution of the 
signal, statistically significant deviations (events) from the apo-state density are detected in real 
space. This highlights which datasets have ligand binding events and also where (in real-space) 
the ligand may be binding. These structural changes can come from the intended source (i.e. 
ligand binding), or additionally, as we have seen in multiple of our datasets for PTP1B, from 
other structural changes such as oxidation of a cysteine. The next goal for the PanDDA software 
is then to computationally decouple the density from the state that has ligand bound from the 
fraction that remains in the apo-state. Given that we have many examples of the apo-state density 
we can estimate the mean value of the apo-state density to come up with an averaged apo-state 
density. Then, if we can estimate the occupancy of the binding event, we can then subtract the 
apo-state density in real-space leaving us with an “event” map that describes only the fraction of 
the signal that describes the holo-state density. The following assumptions allows for estimation 
of the occupancy of the binding event: one, the density at the binding site (the place in real-space 
where the event was detected) has different density than the apo-state, and two, that the 
correlation of the rest of the density in the unit cell is highly correlated between apo and holo-
states. By scanning across different possible occupancies of the binding event, the value that 
maximizes the correlation of the density of the event map globally across the unit cell, while 
minimizing the similarity at the site of the event locally provides a first approximation of the 
occupancy. An initial event map is then created at that occupancy, from which a holo-state 
model is then built into the event map density. Then the holo-state model is merged with the apo-
state model at the relative occupancies of the event and apo-state respectfully. This merged 
model can be refined in phenix with additional restraints created by the PanDDA software. New 
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event maps can also be created that reflect improved estimation of the occupancy of the binding 
event, which can in turn be used to reinterpret the holo-state model.  
  
The multi-state multi-conformer PanDDA model-type 
Because analysis via PanDDA allows for the separation of signal from the holo-state from 
the fraction of the signal that remains in the apo-state, a new type of multi-conformer model 
needs to be created. A conceptually simple model would be to simply have two separate models 
(holo and apo) designated by separate single alternative conformation labels (alt-locs). Several 
factors complicate this approach. The first is that many residues the conformation may have the 
same conformation in both the holo and apo-state. Having alt-locs for each set of alternative 
conformations for each state increases the number of parameters used in the refinement, which 
creates potential for overfitting. This can be mitigated by merging some residues into a single 
conformation when the rmsd between the apo and holo-states is sufficiently small. By default, 
residues with a rmsd of less than 0.05 are merged. We chose a value of 0.2 instead of the default 
value to reduce the number of nearly duplicate alternative conformations. The second 
complication is that one or more states may not be well represented by only a single 
conformation per residue. This can be solved by allocating more alt-locs to each state (apo/holo) 
as necessary. However, this creates one more complication, that restraints between adjacent 
residues fall apart when there are different numbers of alternative conformations or differing 
labels for the alternative conformations. For example, let’s assume alt-locs A and B are assigned 
to the apo-state, and C and D are assigned to the holo-state. For a hypothetical residue “i” that is 
well fit by one conformer per state (apo/holo) and that the apo and holo conformations are 
different, the alt loc labels for this residue are thus assigned to alt locs A and C. Then lets 
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consider the hypothetical residue “i+1”,  which is best fit by two conformers per state and are 
thus assigned the alt locs A, B, C, and D. Current refinement packages will only apply restraints 
across the peptide bond for alt locs A and C. The refinement software does not know how to 
interpret which conformer A, or C of residue “i” connects with the conformers B and D of 
residue “i+1”. The one exception is when connecting multiple alternative conformations to an 
adjacent residue with only one conformation as it is clear that all alt-locs must connect to the 
single conformer. Therefore, the current strategy for PanDDA models is to, for each residue, 
either have a single conformation or have a preset number of alternative conformations for each 
residue so that there are no transitions from differing numbers of alternative conformations 
greater than 1. In our case, because some residues have two distinct conformations in either the 
holo or apo state, the preset number of alternative conformations is four (two hol-state alt-locs, 
and two apo-state alt-locs). 
 
Preparing the data for submission to the PDB group deposition system 
Normally, a new submission session is created for each PDB that is going to be deposited 
through ADIT. The user then deposits by filling out forms and editing metadata extracted from 
the PDB and MTZ using the submission GUI. There the reflection data and coordinate .cif files 
are finalized. However, for submissions of this size, we were able to use the PDB’s group 
deposition tool, which is still under active development and is made available from the PDB only 
upon request. For the PDB group deposition a single compressed tar formatted file (tarball) is 
uploaded containing all of the coordinate files, structure factor files, and a single index.txt file 
that lists and describes all other files in the tarball. The files are then interpreted by the PDB 
system. If there are no errors in interpreting the files, they undergo validation and validation 
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reports are made. If there is a single error in either the file interpretation or a validation issue that 
needs to be corrected, a new tarball must be created containing all of the files and all files must 
be reinterpreted by the system. There is currently no gui to edit information about the submission 
as a whole, or on a dataset by dataset basis. Everything must be done in batch are reuploaded. 
The maximum number of datasets that can be submitted with one group deposition is limited by 
the file size of the tarball at 1 GB.  
 
Preparing the models for submission 
While submission to the PDB now requires submitting coordinates and structure factors, 
there are several tools for converting or obtaining the final cif format. For converting the 
coordinates, we chose to use the pdb_extract software (version 3.22), for its ability to add the 
requisite information about the methods used during refinement, data processing, author info, 
etc. While we had issue getting the latest version, recommended for the group deposition, on 
some of our machines, the pdb_extract in the sbgrid software suite was able to get the majority of 
the data elements incorporated into the file. For the remainder we had to write our own simple 
text editing script to add the remaining elements required for the header of the cif for each 
dataset.  
 
Preparing the structure factors for deposition 
Preparing the structure factors files turned out to be a much larger challenge. In addition 
to depositing the relevant maps and data used in the PanDDA pipeline, the PDB requested that 
we provide structure factors describing the maps that come from the PanDDA software in order 
for other users to be able to download and see these critical pieces of data when interpreting our 
 
 
73 
structures. Because PanDDA leverages data across many datasets, these maps cannot be 
calculated from a single dataset’s structure factors alone and therefore need to be deposited as a 
separate element in the deposited structure factor cif file. The final uploaded structure factor files 
had 5 entries in this order: The reflections used in the final refinement, the original reflections, 
the calculated structure factors to recreate the event map describing the holo-state, the calculated 
structure factors to recreate the average map at that resolution that describes the apo state density 
used for subtraction to achieve the event map, and finally, the structure factors to recreate the z-
map (a difference map that describes the z-score deviation of the signal in this dataset away from 
the apo-state distribution). All of the PanDDA maps are calculated in real-space as maps, so to 
deposit this information, the maps were first converted into effective structure factors. To 
accomplish this, we attempted many different methods which we could not get to work, but 
finally settled on the following protocol. Each ccp4 style map’s header was edited using the 
python package mrcfile to appear to be from the space group P1. Then the 
phenix.map_to_structure_factors tool was run to convert the maps to structure factors in the mtz 
file format. Phenix.map_to_structure_factors can only run on P1 maps, which is why we had to 
edit the header to mimic a P1 map the size and shape of the asymmetric unit. Then the mtz files 
had to be converted to cif files using phenix.mtz_as_cif. The main problem with this approach, 
however, is that I was unable figure out a way to prevent the columns containing extra 
information from also being included into the .cif file with this tool. So, I wrote a script to read 
the created structure factor cif file and remove the unnecessary columns. Additionally, some 
mandatory items were still missing from the headers of the structure factor cifs so I also had to 
write a script to place this information as well. Looking back, I probably would have attempted 
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to edit the columns of the mtz file before converting it to the cif file format, rather than 
converting it and then having to edit the cif. 
 
Discussion 
 With the ability to deconvolve multiple states of protein structures from a single crystal 
dataset comes the challenge of creating a model that can represent the new level of complexity 
that this data brings. With two states of the protein each potentially containing conformational 
heterogeneity, the normal approach of taking different conformations and assigning alternative 
conformation labels does not fully capture the hierarchy of states contained in the crystal 
structure. While other options are available within the file formats that currently exist, such as 
for NMR structures where there are many different single conformer models, many software 
packages are not currently built to handle and read these types of files. In the future, both model 
type and software must change together to achieve the best representation of these data.  
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Chapter IV 
An expanded allosteric network in PTP1B by multitemperature crystallography, fragment 
screening, and covalent tethering. 
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 With the advent of the PanDDA algorithm enabling the detection of protein minor states 
with extreme sensitivity, we were excited to see how this new method would interplay with the 
approaches used by our group such as room temperature crystallography, multi-conformer 
modeling, etc. I worked on this project primarily in collaboration with Daniel Keedy, working on 
the fragment screening portion of the published work.  
  
Abstract 
Allostery is an inherent feature of proteins, but it remains challenging to reveal the 
mechanisms by which allosteric signals propagate. A clearer understanding of this intrinsic 
circuitry would afford new opportunities to modulate protein function. Here, we have identified 
allosteric sites in protein tyrosine phosphatase 1B (PTP1B) by combining multiple-temperature 
X-ray crystallography experiments and structure determination from hundreds of individual 
small-molecule fragment soaks. New modeling approaches reveal 'hidden' low-occupancy 
conformational states for protein and ligands. Our results converge on allosteric sites that are 
conformationally coupled to the active-site WPD loop and are hotspots for fragment binding. 
Targeting one of these sites with covalently tethered molecules or mutations allosterically 
inhibits enzyme activity. Overall, this work demonstrates how the ensemble nature of 
macromolecular structure, revealed here by multitemperature crystallography, can elucidate 
allosteric mechanisms and open new doors for long-range control of protein function. 
 
Introduction 
Proteins are collections of atoms that are mechanically coupled to one another, which 
gives rise to coordinated motions within the constraints of the folded structure. These motions 
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are critical for many processes in molecular biology, including small-molecule and 
protein:protein binding interactions, catalytic cycles in enzymes, and allosteric communication 
between active sites and distal regulatory sites. Allostery in particular is now recognized to occur 
not only in classical oligomeric proteins like hemoglobin but also in monomers -- and indeed 
may be inherent to nearly all protein structures (Motlagh et al., 2014; Gunasekaran et al., 2004). 
However, we do not yet understand at a fundamental level how mechanically coupled atoms 
underlie communication through protein structures, which prevents us from mapping their 
intrinsic allosteric ‘circuitry’. Moreover, because protein surfaces are large and intermolecular 
interactions are complex, it is difficult to predict which surface sites can bind an effector (such as 
a small molecule) that will allosterically communicate with the active site. These gaps severely 
limit our ability to elucidate natural allosteric regulatory mechanisms in biology, and to exploit 
allosteric circuitry in proteins for therapeutic intervention with perturbations such as small 
molecules. 
One system that would benefit immensely from an improved mechanistic understanding 
of allostery is the archetypal protein tyrosine phosphatase, PTP1B (also known as PTPN1). 
PTP1B is highly validated as a therapeutic target for diabetes (Elchebly et al., 1999) and cancer 
(Krishnan et al., 2014) and has also been linked to Rett syndrome (Krishnan et al., 2015). 
Extensive efforts have been made to develop active-site inhibitors for PTP1B. Unfortunately, 
active-site inhibitors in general often bind non-specifically to homologous proteins, leading to 
off-target cellular effects (DeDecker, 2000). Moreover, the active sites of many enzymes, 
including phosphatases, are highly polar, and the polar inhibitors which bind to them often suffer 
from poor bioavailability (Hardy and Wells, 2004; Zhang, 2001). Attempts have been made to 
circumvent these limitations and selectively target the active site of PTP1B -- for example, by 
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linking non-hydrolyzable phosphotyrosine (pTyr) analogs that bind the active site with small-
molecule fragments that bind in nearby, less conserved sites (Zhang, 2017). Nevertheless, no 
active-site inhibitors for PTP1B have reached clinical use, leading some to label PTP1B 
‘undruggable’. 
By contrast, an allosteric inhibitor that binds to a less-conserved and less-polar surface 
site could bypass the limitations of active-site inhibitors. Two classes of compounds have been 
identified that allosterically inhibit PTP1B, although each has limitations. The first class of 
compounds are based on a benzbromarone (BB) scaffold and inhibit allosterically by binding to 
the space normally occupied by the regulatory C-terminal α7 helix (Wiesmann et al., 2004). 
Recent work combining mutagenesis, X-ray crystallography, NMR spectroscopy, and molecular 
dynamics simulations revealed how rotations of the α3 helix and a discrete switch of the catalytic 
WPD loop are impacted by these BB allosteric inhibitors (Choy et al., 2017). Unfortunately, the 
BB molecules were not successfully translated to the clinic. The second class are natural 
products, including a molecule called MSI-1436, that bind to multiple sites that primarily involve 
the disordered C-terminus (Krishnan et al., 2014). However, the binding poses were not 
structurally resolved, limiting our ability to understand the molecules’ allosteric mechanism and 
rationally improve their potency. For example, a variant of MSI-1436 had improved inhibition 
but a different response to mutations at the putative binding sites, suggesting an unknown change 
in mechanism (Krishnan et al., 2018). MSI-1436 passed Phase I clinical trials but was not 
advanced to Phase II (Ghattas et al., 2016). A new approach to revealing the intrinsic allosteric 
circuitry of proteins would reveal different opportunities to develop allosteric inhibitors for 
PTP1B that could potentially overcome the limitations of these existing molecules. Such an 
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approach would additionally set the stage for efforts to dissect allosteric regulatory strategies in 
other biologically important phospho-signaling proteins. 
Here, we have addressed the challenge of discovering unique opportunities for allosteric 
inhibition of PTP1B by taking advantage of two new techniques in X-ray crystallography that 
reveal minor conformational states of protein and ligands. First, multitemperature 
crystallography (Keedy et al., 2015b) can reveal previously hidden alternative conformations that 
enable biological functions. Here, we use this approach in PTP1B to reveal alternative 
conformations that are coupled to each other, forming an allosteric network. Our findings 
provide support for the previously hypothesized allosteric network in PTP1B that responds to BB 
inhibitors (Choy et al., 2017). Moreover, they reveal extensions of this network, including 
additional allosteric binding sites that are distinct from the BB site (Figure 4.1). Similar regions 
of PTP1B have been implicated as allosteric sites based on mutagenesis coupled with traditional 
cryogenic X-ray crystallography, molecular dynamics simulations, and NMR spectroscopy 
(Choy et al., 2017; Cui et al., 2017); here, we complement those studies by using 
multitemperature crystallography to reveal in atomic detail the conformational heterogeneity that 
allosterically links these sites to the active site. Second, high-throughput small-molecule 
fragment soaking and structure determination (Collins et al., 2017) has enabled new algorithms 
for revealing low-occupancy ligands (Pearce et al., 2017). We use this approach to 
comprehensively canvas the PTP1B surface with 1627 small-molecule fragments, 110 of which 
were structurally resolved in complex with PTP1B. The fragments cluster into 11 fragment-
binding hotspots outside of the active site. To prioritize putative allosteric sites rather than 
benign binding sites, we focused on the subset of fragment-binding sites that were also 
conformationally coupled to the active site based on multitemperature crystallography of apo 
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PTP1B. Strikingly, the sites chosen in this way bound more fragments than did any other sites -- 
suggesting that conformational heterogeneity may be important for both allostery and ligand 
binding. Our work builds on previous studies of these sites in PTP1B (Choy et al., 2017; Cui et 
al., 2017), which did not report chemical matter that binds to them. Finally, we use covalently 
tethered small molecules (Erlanson et al., 2004) at one of these sites to confirm that it is 
functionally linked to enzyme activity, thereby supporting our predictions from multitemperature 
crystallography of the apo protein. 
 
Figure 4.1. Schematic of key structural components in PTP1B. 
(A) The ‘front side’ of PTP1B features the active site covered by the dynamic catalytic WPD 
loop, as well as several other structural elements relevant to substrate recognition and binding. 
The α6 helix next to the WPD loop leads into the α7 helix and disordered C-terminus, which are 
positioned near loop 11 (partially occluded in this view). (B) On the ‘back side’ of PTP1B, with 
the view rotated by roughly 180°, the α7 helix and disordered C-terminus sit atop the α3 helix, 
the α6 helix, and the edge of the central β sheet including loop 11. The pocket between the α3 
helix and the β sheet includes several sidechains which interact with each other, leading to the 
‘197 site’ (green). Elsewhere on the back side, a sidechain in loop 16 interacts with the α6-α7 
connection to form the ‘loop 16 site’ or ‘L16 site’ (blue). These two allosteric sites are distinct 
from the previously established ‘BB site’ (orange) (Wiesmann et al., 2004), which is underneath 
the α7 helix that is displaced by BB allosteric inhibitor binding. As PTP1B transitions between 
its global states, many of the key structural components illustrated here undergo coordinated 
conformational changes, which together define the protein’s intrinsic allosteric circuitry. 
 
 Overall, by highlighting promising allosteric sites and ligands that bind to them, our work 
may aid future development of potent non-covalent small-molecule allosteric inhibitors for 
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PTP1B. More broadly, we illustrate a generalizable approach to characterizing and exploiting 
coupled conformational heterogeneity to enable long-range control of protein function. 
 
Results 
Identifying allosterically coupled residues with multitemperature crystallography 
 To identify allosteric sites in PTP1B that can communicate with the active site, we 
searched for regions of the protein whose conformational heterogeneity is coupled to that of the 
active site. We began by examining the conformational heterogeneity of the active-site WPD 
loop. Transition of this loop from the open to the closed state is rate-limiting for catalysis 
(Whittier et al., 2013). In the only available apo crystal structure of PTP1B in which the WPD 
loop is free from crystal-lattice contacts (PDB ID 1sug) (Pedersen et al., 2004), the loop is 
modeled in the closed state. However, low-contour electron density can reveal hidden alternative 
conformations in protein crystal structures (Lang et al., 2010; Fraser et al., 2011). We therefore 
investigated the electron density near the WPD loop in the apo structure more closely (Figure 4.2 
panel B). 
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Figure 4.2. The conformational ensemble of the active-site WPD loop and allosterically coupled 
regions.  
(A) The active-site WPD loop in PTP1B adopts either a closed conformation (example from 
PDB ID 1sug) or an open conformation (example from PDB ID 1t49). View from the ‘front side’ 
of PTP1B. (B) In the previously published apo structure of PTP1B, solved at 100 K (PDB ID 
1sug), 0.8 σ 2Fo-Fc electron density (cyan) supports the modeled closed conformation, but 
substantial electron density remains unexplained (arrow). (C) Adding the open conformation of 
the WPD loop as a secondary conformation at partial occupancy accounts for this electron 
density. In structures solved at different elevated temperatures, electron density for the open 
conformation becomes more prominent as its occupancy (labeled) relative to the closed 
conformation increases. (D) The occupancy of the open conformation increases non-linearly with 
temperature. (E) Overall roadmap of allostery on the ‘back side’ of PTP1B, with the allosteric 
197 site and loop 16 (L16) site highlighted in the context of the larger allosteric network 
including the previously established BB site, a7 helix, and WPD loop. Sidechains are shown in 
stick representation for several key residues in the WPD loop and allosteric regions. For those 
residues with alternative conformations at 278 K, both open-state (darker hues) and closed-state 
(lighter hues) conformations are shown. The viewing orientation in (A–C) is as in Figure 4.1 
panel A (‘front side’ of PTP1B), except zoomed in on the active site (labeled in Figure 4.1 panel 
A). The viewing orientation in (E) is as in Figure 4.1 panel B (‘back side’ of PTP1B). 
 
 Surprisingly, upon closer inspection, the electron density strongly suggests a significant 
population for the open state as well (Figure 4.2 panel C, left). Our re-refined model with both 
open and closed states as alternative conformations visually accounts for the electron density 
around this loop much better than the original model (Figure 4.2 panel C, left). By contrast, when 
we re-refined 36 other available crystal structures of PTP1B complexed with active-site 
inhibitors using both open and closed loop states as putative alternative conformations, Fo-Fc 
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difference electron density and the bimodal distribution of refined occupancies indicated the 
single-state models were a better fit (Figure 4.10). These results suggest that, even in the crystal, 
apo PTP1B samples both WPD loop states and that active-site inhibitors then lock the loop either 
fully open or fully closed. 
 To better characterize the conformational heterogeneity of the WPD loop in apo PTP1B, 
we collected X-ray datasets at several elevated temperatures including 180 K, 240 K, and 278 K 
(‘room temperature’) in addition to the 100 K (‘cryogenic’) model from the PDB, all at better 
than 2 Å resolution (Table 4.1). Each complete dataset was obtained from a single crystal, and 
crystallographic statistics indicated that radiation damage was not a concern even at the elevated 
temperatures (Diederichs, 2006) (Figure 4.12). We built an initial multiconformer model for each 
temperature using the automated algorithm qFit (Keedy et al., 2015a). These models are 
parsimonious in that each atom has alternative positions only if justified by the experimental 
data, and a single position otherwise. Such models are equally good and usually better 
explanations of the experimental X-ray data (Keedy et al., 2015a; van den Bedem et al., 2009), 
and have been used to understand many biologically relevant phenomena at protein:water 
interfaces (Keedy et al., 2014), dynamic enzyme active sites (Keedy et al., 2015b; Fraser et al., 
2009), and allosteric networks perturbed by mutations (van den Bedem et al., 2013). We then 
manually refined alternative conformations for protein, buffer components, and solvent. In 
particular, we took advantage of the wealth of available structures of PTP1B in the PDB 
(Berman et al., 2000) to sample coordinates for putative alternative conformations; in many 
cases, these conformations explained missing regions with positive Fo-Fc electron density that 
would have otherwise been difficult to model. Removing the alternative conformations and re-
refining the resulting single-conformer models, either with or without automated solvent 
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placement, yields deteriorated statistics, which confirms that the multiconformer models are 
appropriate explanations of the experimental data at each temperature. 
Table 4.1. Crystallographic statistics for multitemperature and mutant X-ray datasets. 
Overall statistics given first (statistics for highest-resolution bin in parentheses). For WT apo, 
100 K: statistics are taken from our remodeled structure where appropriate, or from the original 
PDB ID 1sug when possible otherwise, or given as ‘---” where unavailable. 
 WT apo, 
100 K 
WT* apo, 
180 K 
WT* apo, 
240 K 
WT* apo, 
278 K 
WT* 
with BB3, 
278 K 
K197C 
apo, 100 
K 
K197C 
tethered 
to 2, 100 
K 
PDB ID 6B90 6B8E 6B8T 6B8X 6B8Z 6BAI 6B95 
Number of 
crystals used 
1 1 1 1 1 1 1 
Wavelength (Å) 0.8110 1.115869 1.115869 0.9795 1.11583 1.11583 1.11583 
Resolution range 
(Å) 
33.60–
1.95 
(2.02–
1.95) 
19.18–1.82 
(1.89–
1.82) 
62.54–1.85 
(1.89–
1.85) 
31.31–
1.74 
(1.92–
1.74) 
43.88–1.8 
(1.86–1.8) 
75.57–
1.95 
(2.02–
1.95) 
43.98–
1.95 
(2.02–
1.95) 
Space group P 31 2 1 P 31 2 1 P 31 2 1 P 31 2 1 P 31 2 1 P 31 2 1 P 31 2 1 
Unit cell (Å, º) 88.12 
88.12 
103.90 90 
90 120 
88.57 
88.57 
104.32 90 
90 120 
89.44 
89.44 
106.00  
90 90 120 
89.52 
89.52 
106.25 90 
90 120 
89.65 
89.65 
106.39 90 
90 120 
87.27 
87.27 
104.10 90 
90 120 
87.96 
87.96 
104.63 90 
90 120 
Total reflections --- 339461 
(33574) 
256701 
(25484) 
299041 
(30678) 
771858 
(76158) 
653798 
(63759) 
170094 
(16845) 
Unique reflections 34486 
(3371) 
42866 
(4223) 
42343 
(4156) 
50486 
(4960) 
46311 
(4561) 
33409 
(3296) 
34596 
(3387) 
Multiplicity 7.4 (---) 7.9 (7.9) 6.1 (6.1) 5.9 (6.2) 16.7 
(16.7) 
19.6 
(19.3) 
4.9 (5.0) 
Completeness (%) 99.9 
(100.0) 
99.9 
(100.0) 
100.0 
(100.0) 
99.0 
(98.3) 
100.0 
(100.0) 
98.06 
(98.51) 
99.81 
(99.88) 
Mean I/sigma(I) 26.4  
(4.4) 
21.40 
(1.46) 
15.89 
(1.46) 
17.15 
(1.49) 
11.69 
(0.75) 
25.06 
(0.94) 
12.04 
(0.81) 
Wilson B (Å2) 24.12 23.69 28.48 19.48 34.96 46.3 38.82 
Rmerge 0.073 
(0.515) 
0.089 
(1.483) 
0.079 
(1.215) 
0.098 
(1.209) 
0.148 
(2.664) 
0.076 
(3.056) 
0.088 
(1.852) 
Rmeas --- 0.096 
(1.585) 
0.086 
(1.329) 
0.108 
(1.318) 
0.153 
(2.748) 
0.078 
(3.138) 
0.098 
(2.071) 
Rpim --- 0.034 
(0.556) 
0.035 
(0.535) 
0.044 
(0.520) 
0.038 
(0.672) 
0.018 
(0.705) 
0.044 
(0.916) 
CC1/2 --- 0.999 
(0.520) 
0.999 
(0.560) 
0.999 
(0.496) 
0.997 
(0.366) 
1.000 
(0.438) 
0.999 
(0.292) 
CC* --- 1.000 
(0.827) 
1.000 
(0.847) 
1.000 
(0.814) 
0.999 
(0.732) 
1.000 
(0.781) 
1.000 
(0.672) 
Reflections used 
in refinement 
34486 
(3371) 
42862 
(4223) 
42343 
(4156) 
50486 
(4959) 
46309 
(4561) 
33302 
(3296) 
34576 
(3386) 
Reflections used 
for Rfree 
1356 
(128) 
1689 (165) 1669 (163) 1993 
(196) 
1820  
(176) 
1310  
(135) 
1362  
(135) 
Rwork 0.1580 
(0.1881) 
0.1708 
(0.2781) 
0.1674 
(0.2760) 
0.1752 
(0.3511) 
0.1675 
(0.3116) 
0.2061 
(0.3365) 
0.1858 
(0.3295) 
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 WT apo, 
100 K 
WT* apo, 
180 K 
WT* apo, 
240 K 
WT* apo, 
278 K 
WT* 
with BB3, 
278 K 
K197C 
apo, 100 
K 
K197C 
tethered 
to 2, 100 
K 
Rfree 0.1926 
(0.2090) 
0.1997 
(0.2911) 
0.2123 
(0.2869) 
0.2059 
(0.3888) 
0.1978 
(0.3017) 
0.2569 
(0.3292) 
0.2307 
(0.3686) 
CCwork --- 0.963 
(0.753) 
0.958 
(0.789) 
0.964 
(0.673) 
0.964 
(0.709) 
0.934 
(0.618) 
0.957 
(0.574) 
CCfree --- 0.948 
(0.744) 
0.908 
(0.677) 
0.948 
(0.739) 
0.961 
(0.757) 
0.994 
(0.484) 
0.938 
(0.294) 
Non-H atoms 2997 3021 3149 3260 2709 2502 2541 
Macromolecule 
atoms 
2657 2687 2875 3011 2460 2377 2370 
Ligand atoms 46 40 34 24 82 16 36 
Solvent atoms 294 294 240 225 167 109 135 
Protein residues 298 298 299 298 289 282 285 
RMS bonds (Å) 0.010 0.011 0.011 0.012 0.011 0.015 0.013 
RMS angles (°) 1.01 1.02 1.10 1.08 1.14 1.30 1.15 
Ramachandran 
favored (%) 
97.64 97.64 97.98 95.95 97.19 95.00 95.76 
Ramachandran 
allowed (%) 
2.03 2.03 1.68 3.72 2.11 4.64 2.83 
Ramachandran 
outliers (%) 
0.34 0.34 0.34 0.34 0.70 0.36 1.41 
Rotamer outliers 
(%) 
1.35 2.67 1.87 2.38 2.19 6.44 4.91 
Clashscore 2.79 3.31 3.62 2.98 2.79 6.06 3.36 
MolProbity score 1.24 1.52 1.36 1.65 1.47 2.29 1.95 
Average B (Å2) 29.35 30.22 36.50 28.06 43.58 55.81 49.66 
Average B, 
macromolecule 
(Å2) 
28.14 29.11 35.51 27.01 43.30 56.02 49.53 
Average B, 
ligands (Å2) 
47.43 48.08 60.29 67.33 41.13 45.41 53.91 
Average B, 
solvent (Å2) 
37.46 37.90 44.96 38.01 48.96 52.76 50.82 
 
 The WPD loop adopts both the open and closed conformations across this range (Figure 
4.2 panel C) and the population of the open vs. closed states was sensitive to temperature (Figure 
4.2 panel D). The loop is approximately 67% closed at 100 K, but 65% open at 278 K. These 
occupancies evolve non-linearly (Keedy et al., 2015b) at intermediate temperatures. 
 Overall, we also observed temperature-dependent conformational heterogeneity for 
several other regions of PTP1B, including the previously characterized BB allosteric site, plus 
additional sites we refer to as the ‘197 site’ and the ‘loop 16 (L16) site’. These regions are all 
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contiguous in the structure (Figure 4.2 panel E), suggesting that they together constitute an 
expanded collective allosteric network in PTP1B that is coupled to the WPD loop. The manner in 
which they are connected is described in detail in the following sections. 
 
Multitemperature crystallography of the BB allosteric site 
 To connect these multitemperature structures to known allosteric regulatory mechanisms, 
we first turned to a benzbromarone derivative compound (here referred to as BB2) that binds to 
an allosteric site >12 Å away from the active site and inhibits enzyme activity (Wiesmann et al., 
2004). The authors of the study reporting BB2 described a series of induced conformational 
changes that begins with BB2 directly displacing Trp291 to disorder the entire C-terminal α7 
helix, and ends with Phe191 χ2 dihedral-angle rotations clashing with the WPD loop anchor 
residue Trp179 to stabilize the open state. We tested the hypothesis that these allosterically 
inhibited conformations pre-exist in apo PTP1B by examining these regions in our 
multitemperature apo crystal structures. Indeed, in apo PTP1B the α7 helix is more ordered at 
lower temperatures but more disordered at higher temperatures (Figure 4.3 panel A). Also, 
Trp179 and Phe191 adopt dual conformations at higher temperatures (Figure 4.3 panel B) that 
coincide well with the apo and allosterically inhibited conformations (Figure 4.3 panel C). We 
also see alternative conformations at high temperatures for several residues within and directly 
flanking the WPD loop (Arg221, Pro185, Trp179, Phe269) which have been implicated as being 
important for a CH/π switch during WPD loop opening/closing (Choy et al., 2017) (Figure 4.13). 
Multiple conformations for Leu192 were more difficult to detect at higher temperatures in apo 
PTP1B. This is likely because Leu192 shifts more subtly between the 100 K apo and 
allosterically inhibited conformations, which is also consistent with a recent report that Leu192 is 
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a relatively static inter-helical ‘wedge’ (Choy et al., 2017). Taken together, these results suggest 
that BB2 stabilizes a subset of pre-existing conformations in apo PTP1B. 
 We additionally solved a high-resolution (1.80 Å, Table 1) structure of PTP1B in 
complex with BB3 (which differs from BB2 only by an extra terminal aminothiazole group) at 
273 K and found it to be very similar to the 100 K structures with BB3 (PDB ID 1t4j) and with 
BB2 (PDB ID 1t49) despite the difference in temperature (Figure 4.14). However, two 
interesting features are evident at 273 K. First, at 273 K but not at 100 K, modeling BB3 with a 
single conformer leads to Fo-Fc difference electron density peaks at both ends of the molecule 
(Figure 4.15 panel A). To account for these peaks in the map, it is necessary to add a second 
alternative conformer to the model, which includes a translation at one end and dihedral-angle 
changes at the other end (Figure 4.15 panel B). Chemical changes to BB3 designed to eliminate 
this remaining heterogeneity could potentially improve affinity and inhibition. 
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Figure 4.3. Multitemperature crystallography of apo PTP1B recapitulates an allosteric 
mechanism. (A) In apo PTP1B, the occupancy of the α7 helix decreases (i.e. the helix becomes 
more disordered) with temperature. The helix was modeled with one conformation and its 
occupancy was refined; the remaining occupancy corresponds to the disordered state of the helix. 
(B) Several residues that allosterically link α7 and the active-site WPD loop also undergo shifts 
with temperature. (C) These additional conformations match the state trapped by the allosteric 
inhibitor BB2 (PDB 1t49) (Wiesmann et al., 2004) which binds >12 Å away from the active site. 
The viewing orientation in (B–C) is as in Figure 4.1 panel A (‘front side’ of PTP1B), except 
slightly zoomed in. 
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 Second, at 273 K, we observe significant electron density just above BB3 (Figure 4.15 
panel C). Modeling a reordered, non-helical conformation of α7 explains this density well, and 
places Trp291 in good position for aromatic stacking interactions with BB3 and other 
interactions with nearby sidechains on the α3 helix (Figure 4.15 panel D). Trp291 is displaced by 
BB3 or BB2 binding in a striking example of molecular mimicry (Wiesmann et al., 2004) 
(Figure 4.3 panel C). Our 273 K data suggest that a subsequent reordering of the α7 polypeptide 
occurs, which may contribute to the affinity of BB3 for PTP1B. In contrast to our 273 K data, 
electron density in this region is weak in the 100 K structures with BB3 and BB2. However, in 
the 100 K structure with BB1, a different derivative of the BB scaffold, α7 also reorders -- but 
adopts a significantly different conformation than we observe at 273 K with BB3 (Figure 4.15 
panels E,G). Together, these results suggest that in addition to being a major allosteric hub when 
ordered (Choy et al., 2017), α7 is also quite malleable when disordered, and may interact in 
diverse ways with bound ligands -- behavior which is similar to the mechanism proposed for 
inhibitors that bind via the disordered C-terminus beyond α7 (Krishnan et al., 2014). 
 
Multitemperature crystallography of the allosteric loop 16 site 
 We also observed temperature-dependent ordering in a loop (loop 16, L16; residues 237–
243) that sits underneath the α6-α7 junction just beyond the BB binding site. By contrast to 
lower temperature (Figure 4.4 panel A), the electron density for L16 at higher temperature 
(Figure 4.4 panel B) clearly reveals an alternative conformation with its backbone shifted by >5 
Å from the primary conformation (Figure 4.4 panel D). Modeling this alternative loop 
conformation back into the lower-temperature models and refining its occupancy reveals a 
temperature dependence (Figure 4.4 panel E, Figure 4.16) that is qualitatively similar to the 
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temperature dependences of the WPD loop. Remarkably, this L16 alternative conformation 
sampled by apo PTP1B matches the L16 conformation when PTP1B is allosterically inhibited by 
BB2 (Figure 4.4 panel C). This rearrangement provides further evidence that BB2 selects pre-
existing, globally dispersed conformations rather than inducing new ones. 
 
Figure 4.4. Both an allosteric inhibitor and high temperature favor an alternative conformation 
for an α7-coupled loop 16. 
(A) At low temperature, loop 16 (residues 237–243, bottom right) is single-conformer, as 
evidenced by 2Fo-Fc electron density contoured at 1.0 σ (cyan volume) and at 1.0 σ (blue mesh). 
(B) At high temperature, when the protein is modeled as single-conformer, the electron density 
suggests the existence of an alternative conformation. (C) The structure with BB2 bound (>12 Å 
away) (PDB ID 1t49) perfectly explains the mysterious electron density. (D) The final 278 K 
dual-conformation model is a good explanation of the data. (E) The refined occupancy of the 
alternative conformation (state ‘B’) in apo PTP1B increases continuously but non-linearly with 
temperature. The viewing orientation in (A–D) is as in Figure 4.1 panel B (‘back side’ of 
PTP1B), except zoomed in on the loop 16 site (labeled in Figure 4.1 panel B). 
 
 The L16 site is seemingly coupled to the α6 helix: Lys239 from L16 H-bonds with Ile281 
from α6 in the global closed state, but not in the global open state in which L16 adopts its 
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alternative conformation. Because α6 is directly coupled to the α7 order-disorder transition, we 
therefore propose that the L16 site is a component of the collective allosteric network in PTP1B. 
 The L16 site was not identified as part of the allosteric network in PTP1B based on a 
study using mutagenesis, NMR, and MD (Choy et al., 2017). However, in a more recent study, 
several residues lining what we call the L16 site (including Met3, Lys237, and Ser242) were 
included in a region called ‘Cluster II’, which was suggested to be a previously unidentified 
allosteric site based on reciprocal NMR chemical shift perturbations upon mutation of this site or 
the WPD loop (Cui et al., 2017). Our work here using multitemperature crystallography 
complements these findings by independently identifying this allosteric site using a new 
methodology, and by revealing in atomic detail how multiple conformational states at the L16 
site may aid communication with the active site. Interestingly, a separate approach combining 
molecular dynamics and machine learning also recently pointed to this area as a potential 
‘cryptic’ binding site (Cimermancic et al., 2016a). Therefore, the L16 site may be not only 
energetically coupled to the active site, but also capable of forming an under-appreciated small-
molecule binding pocket via the conformational heterogeneity we observe. 
 
Multitemperature crystallography of the allosteric 197 site 
 In addition to the temperature-dependent conformational heterogeneity observed at the 
BB site and L16 site, we observed residues with temperature-sensitive conformational 
heterogeneity in the ‘197 site’ (Figure 4.5). Moreover, the alternative conformations of several 
residues in this region have a pattern of steric incompatibility with multiple states of the WPD 
loop and α7 helix, suggesting that the 197 site may be mechanistically linked to the active site in 
a similar way as the BB binding site. 
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Figure 4.5. Coupled conformational heterogeneity leads to the allosteric 197 site. (A) Several 
residues distinct from both the active site and a previously characterized allosteric network each 
have minor alternative conformations that become more populated with temperature. This is 
quantified by the sum of 2Fo-Fc electron density values for the centers of atoms that are unique 
to the minor state (defined as being at least 1.0 Å away from any atoms in the major state), 
normalized across temperatures from 0 to 1 for each residue. (B) These residues colocalize to a 
region of the protein surrounded by loop 11 (top-left), the quasi-ordered α7 helix (top-right), and 
the α3 helix (right), including the eponymous K197. 2Fo-Fc electron density contoured at 0.6 σ 
(cyan volume) and at 0.8 σ (blue mesh) justify multiple conformations for these residues in our 
278 K apo model, as quantified in (A). The alternative conformations of these residues appear to 
interact with one another and thus may be allosterically coupled. Ordered crystallization mother 
liquor or cryoprotectant molecules (glycerols in pink, from the PDB and our structures, or MPD 
molecules in green, from the PDB) can be present at the terminus of this allosteric pathway, 
suggesting it may be amenable to binding other small molecules. The viewing orientation in B) is 
as in Figure 4.1 panel B (‘back side’ of PTP1B), except zoomed in on the 197 site (labeled 
in Figure 4.1 panel B). 
 
 A major link between the WPD loop and the 197 site is Tyr152. When the WPD loop is 
closed and the α7 helix is ordered, Tyr152 adopts a ‘down rotamer’ (Figure 4.17, red). By 
contrast, when the WPD loop is open and the α7 helix is disordered, the 278 K electron density 
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suggests that Tyr152 adopts an ‘up rotamer’ (Figure 4.17 panel C, orange). However, difference 
electron density peaks remain (Figure 4.17 panel C) that indicate the presence of the down 
rotamer as an alternative conformation. Consistent with this interpretation, modeling just the 
additional down rotamer is insufficient to explain the density (Figure 4.17 panel D). These two 
rotamers are accommodated in the WPD-loop-open state by a shift of the L11 backbone (Figure 
4.17). The down rotamer is sterically incompatible with phosphorylation of Tyr152, which 
occurs in vivo (Bandyopadhyay et al., 1997; Rhee et al., 2001), suggesting that the up rotamer 
may have additional regulatory roles. Tyr152 in the L11 backbone conformation with just the 
down rotamer (red in Figure 4.17) is sterically incompatible with the open WPD loop 
conformation (Figure 4.17 panel E). Similarly, the Tyr152 up rotamer is sterically incompatible 
with the ordered α7 conformation (Figure 4.17 panel E). In turn, α7 is conformationally 
synchronized with the WPD loop (Figure 4.3 panel A and Figure 4.2 panel D) and is a key hub 
connecting loop 11 and the WPD loop (Choy et al., 2017). These results together suggest that the 
allosteric circuitry of PTP1B involving Tyr152 is complex and multibody. Tyr152 likely 
exemplifies a population shuffling mechanism whereby mixtures of microstates (rotameric state 
of Tyr152) exchange on a fast timescale as the protein transitions between macrostates (WPD 
loop state, α7 ordering, and L11 backbone shifting) on a slower timescale (Smith et al., 2015). 
Our findings thus shed additional light on the mechanism by which loop 11 allosterically 
communicates with the active site, thus complementing other recent studies using mutagenesis, 
MD, and NMR to map allostery in PTP1B (Choy et al., 2017; Cui et al., 2017). 
 In our datasets at temperatures above 100 K, the electron density suggests a complex 
interplay between alternative conformations for Asn193 on the α3 helix and Tyr152 on loop 11 
(L11) (Figure 4.17). Asn193 is part of the α3 helix (residues 187–202), which immediately 
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follows the WPD loop in sequence. The N-terminal region of this helix (through Phe196) rotates 
by 2–20°, resulting in shifts of 0.2–0.7 Å for some Cα atoms, based on 100 K crystal structures 
of apo (WPD-open) vs. active-site-inhibitor-bound (WPD-closed) PTP1B (Choy et al., 2017). 
Similarly, the multiconformer model for our 278 K apo dataset includes alternative backbone 
conformations for the WPD loop and the beginning of α3, through Asn193 plus Phe196-Lys197 
(this is a conservative interpretation of which residues in the helix have alternative backbone 
conformations). Our results suggest that α3 inherently shifts as the protein transitions betweens 
its global macrostates, even in the apo state. 
 Strikingly, several residues propagating down L11 from Tyr152, and down α3 from 
Asn193, also adopt multiple conformations at higher temperatures (Figure 4.5). These residues 
colocalize in a shallow pocket nestled between loop 11, the β4 and β5 strands, and the α3 and α7 
helices. We refer to this area here as the ‘197 site’ because the sidechain of Lys197 extends into 
the pocket. Our analysis indicates a complex, interconnected network involving multiple 
aromatic stacking, hydrogen-bonding, van der Waals, and electrostatic interactions. To 
complement this model-based assessment with a map-based approach, for several residues in the 
pocket we quantified electron density as a function of temperature for atom positions that are 
unique to the minor conformation (i.e. do not overlap with any atoms in the major conformation), 
reasoning that residues which respond to temperature similarly may be conformationally coupled 
(Keedy et al., 2015b). The population of each minor conformation increases non-linearly with 
temperature (Figure 4.5 panel A) in a similar fashion as the open state of the WPD loop (Figure 
4.2 panel D) and the disordered state of the α7 helix (Figure 4.3 panel A), in support of the idea 
that these various regions of the protein are mutually conformationally coupled. 
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 We next discuss several similarities and a few differences between what we refer to as 
the 197 site and similar regions implicated by other recent studies of allostery in PTP1B. First, in 
addition to predicting the L16 site (see above), reciprocal chemical shift changes upon mutation 
suggested that several residues at both ends of the 197 site (Tyr152, Tyr153, Lys150, Arg105) 
are part of a region referred to as ‘Cluster I’ that is allosterically linked to the active site (Cui et 
al., 2017). However, that study did not implicate additional key residues on the α3 helix, 
for example Asn193 and Lys197. Second, mutagenesis, NMR, and cryogenic crystallography 
implicated several elements of our 197 site as being part of the larger allosteric network in 
PTP1B: loop 11 (including Tyr152 and Tyr153), the α3 helix (especially Asn193), and the α7 
helix (Choy et al., 2017). Chemical-shift-restrained molecular dynamics simulations further 
suggested that Tyr152 on loop 11 and Asn193 on the α3 helix have mutually coupled alternative 
conformations (Choy et al., 2017). However, here we highlight additional residues (e.g. Asp148 
and Glu157 on the β strands on either end of loop 11) as being conformationally coupled to each 
other and to the rest of the allosteric network and the active site, and which may collectively 
form a binding pocket. Therefore, our work accomplishes two things with regard to these 
existing studies. First, we add support to their findings by reaching similar conclusions using 
orthogonal methods. Second, we complement the other studies by revealing additional amino 
acid residues that may play roles in binding and allosteric communication at the 197 site. 
 We also emphasize that the 197 site is structurally distinct from the two allosteric sites 
that have previously been targeted with small molecules to achieve inhibition (Krishnan et al., 
2014; Wiesmann et al., 2004), so any small molecules that bind to the 197 site would represent a 
distinct strategy for inhibiting PTP1B. Surprisingly, in all of our multitemperature apo structures, 
ordered glycerols are present not only in the active site as mentioned above but also in the 197 
 
 
96 
site (Figure 4.18), and MPD also binds here in another published structure (PDB ID 2cm2). 
These observations suggest that the 197 site may be bindable by other small molecules. We 
therefore hypothesized that binding of a small molecule to the 197 site could propagate changes 
in conformational heterogeneity to the WPD loop to interfere with catalysis. 
 To test whether more directed perturbations to the 197 site can allosterically modulate 
enzyme function, we introduced ‘dynamically destructive’ mutations (Y152G, Y153A, K197A) 
that were predicted to preserve the protein’s general structure, yet interfere with the 
conformational heterogeneity along the putative allosteric pathway lining the 197 site by 
removing interactions between alternative conformations. For Y152 we chose a mutation to 
glycine instead of alanine to more fully disengage residue 152 from the WPD loop, given that the 
Cβ and Hβ atoms of Y152 sterically engage with the WPD loop (Figure 4.17 panel E). All three 
mutations indeed reduce catalytic efficiency, to varying extents: the mutation nearest to the WPD 
loop (Y152G) reduced kcat/KM the most, and the mutation farthest from the WPD loop (K197A) 
reduced kcat/KM the least (Figure 4.19). Our results are generally in line with reported effects for 
the Y152A + Y153A (‘YAYA’) double mutation (Choy et al., 2017) and for the Y153A single 
mutation (Cui et al., 2017); small discrepancies may be due in part to differences in the length of 
the protein construct being used. Overall, our results illustrate that local perturbations in the 
vicinity of the allosteric 197 site can impact catalysis. 
 Overall, we describe a large, collectively coupled allosteric network on one contiguous 
face of the protein (Figure 4.2 panel E). This network is interconnected not only on the surface, 
but also within the hydrophobic core. For example, Tyr176 adopts alternative sidechain 
conformations at higher temperatures that differ by a small rotation of the relatively non-
rotameric χ2 dihedral angle (Lovell et al., 2000) (Figure 4.20). The two conformations of Tyr176 
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are structurally compatible with different conformations of the surface-exposed Tyr152 (Choy et 
al., 2017; Cui et al., 2017) in one direction, and of the buried Trp179 in the WPD loop and BB 
allosteric pathway (Wiesmann et al., 2004) in the other direction (Figure 4.20). Thus, surface 
residues such as Tyr152 may be conformationally coupled to the buried underside of the WPD 
loop via a similar mechanism as BB binding -- remotely modulating the Trp179 anchor via 
coordinated hydrophobic shifts -- but from a different angle of attack, via Tyr176. Overall, such 
coordinated local shifts within the hydrophobic core likely ‘lubricate’ the transition between 
discrete global states of PTP1B. 
 
Assessing the ligandability of the surface of PTP1B using automated crystallography 
 Although the results described above establish a conformationally coupled network 
within the structure of PTP1B, allosteric inhibition also requires binding sites for small 
molecules that can conformationally bias this network to modulate function. To identify potential 
allosteric ligand-binding sites in PTP1B, we mapped the small-molecule binding potential or 
‘ligandability’ of the entire protein surface. Specifically, we used small-molecule fragments, 
which by virtue of their small size provide a relatively large sampling of drug-like chemical 
space (Murray and Blundell, 2010). Astex Pharmaceuticals has previously explored fragment-
based drug design for PTP1B (Hartshorn et al., 2005); however, that screen used molecules pre-
selected to enrich for binders to phosphatase active sites, which contrasts with our goal of 
exploring the surface outside of the active site. To determine cocrystal structures of hundreds of 
fragments with PTP1B, we used the high-throughput fragment-soaking and crystallographic 
pipeline available at Diamond Light Source (Collins et al., 2017) to individually soak 1918 apo 
PTP1B crystals with small-molecule fragments in DMSO from several curated libraries, and 
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another 48 with just DMSO. We then used robotic sample handling to automatically collect 
complete X-ray datasets at 100 K (Figure 4.6). Of the 1966 total soaks, 1774 yielded diffraction 
data that could be successfully processed. The data were generally high-resolution: the average 
resolution was 2.1 Å, 65% of resolutions were better than 2.0 Å, and 87% were better than 2.5 Å 
(Figure 4.6 panel A). The large number of datasets enabled us to use the new Pan-Dataset 
Density Analysis (PanDDA) algorithm (Pearce et al., 2017) to reveal bound fragments. PanDDA 
performs weighted subtractions of the ‘background’ electron density (computed from apo and 
unbound datasets) from each electron density map (Figure 4. 6 panels B–C). The optimal 
subtraction, chosen by a heuristic, yields electron density corresponding to the ligand-bound 
fraction of unit cells in the crystal. 
 
Figure 4.6. Electron-density background subtraction reveals small-molecule fragments at 
allosteric sites in PTP1B. (A) Histogram of X-ray resolution for 1774 structures of PTP1B 
soaked with small-molecule fragments (gray) vs. the 110 structures from that set with small-
molecule fragments bound to PTP1B (green). (B) For one example fragment, a traditional 2Fo-
Fc map contoured at 1.25 σ (cyan volume) and at 3.5 σ (blue mesh) provides no clear evidence 
for a bound fragment. (C) By contrast, a background-subtracted PanDDA event map (85% 
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background subtraction in this case) contoured at the same levels clearly reveals the precise pose 
of the bound fragment, plus additional ordered water molecules that accompany it (red spheres). 
(D) PanDDA analysis and manual inspection reveal 110 fragment-bound structures of PTP1B, 
with bound fragments clustered into 12 non-overlapping binding sites. Some structures contain 
multiple bound copies of the same fragment. Several sites of interest are labeled. (E) Overview 
of bound fragments across the PTP1B surface. Left: front of protein, facing active site (WPD 
loop open and closed conformations in red). Right: back of protein, facing several fragment-
binding hotspots: the 197 site, BB site, and L16 site. The viewing orientation in E) (left) is as 
in Figure 4.1 panel A (‘front side’ of PTP1B). The viewing orientation in E) (right) is as 
in Figure 4.1 panel B (‘back side’ of PTP1B).  
 
 Our PanDDA analysis of 1774 datasets revealed 381 putative binding events. We 
manually inspected each putative binding event, and were able to confidently model the fragment 
in atomic detail for 110 hits (Figure 4.6 panel D). Overall, 12 different sites in PTP1B were 
observed to bind fragments (Figure 4.6 panel E). These sites are structurally distinct from one 
another -- that is, they share no residues in common, and fragments bound within different sites 
do not overlap with each other. They are also widely distributed across the protein surface. 
Twenty-five fragments bind to multiple sites, but promiscuous binding is not unexpected from 
such small fragments, and still provides valuable information about favorable binding poses in 
each site. 
 PanDDA initially identified >80 putative binding events in the active site. Many of these 
can be attributed to movements of the WPD loop (Figure 4.2), often induced by oxidation of the 
catalytic Cys215, which is a natural regulatory mechanism (van Montfort et al., 2003). Apart 
from these protein events and other false positives, we observe four fragments bound in the 
active site. This number is relatively low likely because our libraries were not customized to bind 
to the highly charged active site of PTP1B, as was the case in the Astex study (Hartshorn et al., 
2005). 
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 To identify allosteric binders, we examined sites outside of the active site. Strikingly, we 
observed 24 bound fragments in the BB allosteric site (Figure 4.7 panel A). The poses of many 
of these fragments overlap portions of the BB scaffold (Figure 4.7 panel A, Figure 4.21). 
However, many of them also contain chemical groups that suggestively protrude in new 
directions from the BB scaffold (Figure 4.21). This retrospective result validates the idea that 
fragment screening identifies binding sites, and specific fragment poses in those sites, that can be 
fruitfully exploited for allosteric inhibition. Interestingly, in one structure with a fragment bound 
in the BB site, the α7 helix adopts a reordered conformation that covers the binding site (Figure 
4.7 panel A), reminiscent of other examples in published structures and in our high-temperature 
datasets (Figure 4.15). These compounds could also inspire design of modified BB2 derivatives 
that may overcome the low affinity that limited the development of that series. 
 
Figure 4.7. Fragments cluster at three binding hotspots distal from the active site. (A) Twenty-
four fragments (green) bind to the same site and in similar poses as the BB2 inhibitor (orange, 
PDB ID 1t49), and similarly displace the α7 helix (foreground, transparent blue, PDB ID 1sug). 
BB2 is also shown in the following panels to emphasize that its binding site is distinct from the 
other fragment-binding hotspots. One structure with a fragment bound in this site features a 
reordered conformation of the α7 helix (pink). (B) Seventeen fragments bind to the L16 site, 
where they may modulate the conformations of loop 16, the α6 helix, and the protein’s N-
terminus on the α1 helix. (C) Thirty fragments bind to the 197 site in one primary subsite 
contacting K197, or a distinct secondary subsite nearby. The viewing orientation in (A) is as 
in Figure 4.1 panel B (‘back side’ of PTP1B), except zoomed in on the BB site (labeled in Figure 
4.1 panel B). The viewing orientation in (B) is also as in Figure 4.1 panel B, except looking left 
from the right of that image and zoomed in on the L16 and BB site site. The viewing orientation 
in A) is as also in Figure 4.1 panel B, except zoomed in on the 197 site and BB site (labeled 
in Figure 4.1 panel B). See also Figure 4.6 panel E (right) for orientation. 
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 We also examined fragments bound to the L16 site and the 197 site, which were 
suggested to be allosteric sites by our multitemperature analysis of apo PTP1B. Excitingly, both 
sites are fragment-binding hotspots: 17 fragments bind to the L16 site (Figure 4.7 panel B) and 
30 fragments bind to the 197 site (Figure 4.7 panel C). Thus, independent methods to assess 
allosteric coupling and ligandability converge on the same sites in PTP1B. Our results agree with 
previous studies, based on mutagenesis and NMR, which implicated several residues in the L16 
site (Cui et al., 2017) and in the 197 site (Choy et al., 2017; Cui et al., 2017) as participating in 
an active-site-linked allosteric network. We also add value to those studies in another way: by 
reporting the binding poses of a few dozen small-molecule ligands that bind to these sites in 
atomic detail. Because these two sites are both conformationally coupled to the active site and 
capable of binding a variety of small molecules, they may be promising sites to explore for 
small-molecule allosteric inhibition of PTP1B activity. 
 The L16 site is between loop 16 (L16), the beginning of α1, and the end of α6. Most of 
the 17 fragments that bind here appear to ‘pry apart’ these elements (Figure 4.7 panel B) to 
create a cryptic binding site (Cimermancic et al., 2016a). Because the end of α6 is coupled to the 
beginning of α7, which is perhaps the central allosteric hub of PTP1B (Choy et al., 2017), this 
site seems promising for allosteric inhibition. The fragments that bind here are diverse but have 
some common features: aromatic moieties sandwich between Pro239 (of L16) and Met282 (α6), 
and carboxyl groups hydrogen-bond to the backbone amide of Glu2 (α6). These fragments do not 
spatially overlap with any fragments in the nearby BB site, confirming that the L16 site is 
genuinely distinct from the previously explored allosteric site. 
 The 197 site is on the opposite side of the BB site, near α3 (including Lys197) and L11 
(including Tyr152). Thirty fragments bind in the 197 site, with 14 in the primary subsite near 
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Lys197, and 17 in a nearby but distinct subsite separated by a ‘ridge’ formed by the Gln157 and 
Glu170 sidechains (Figure 4.7 panel C) (one fragment binds in both the primary subsite and the 
secondary subsite). These fragments are characterized by packing of aromatic moieties above 
Leu172, with additional aromatic or polar extensions in various directions. As with the L16 site, 
fragments in this site do not overlap with any fragments in the nearby BB site. However, several 
of the fragments in the 197 site do overlap with the positions of ordered glycerols from our 
multitemperature structures (which were absent from all fragment-soaked structures to avoid 
competition for binding) (Figure 4.22). Similarly, glycerol in PDB ID 3qkp and β-octylglucoside 
in PDB ID 2cmc (among other examples) bind to sites that are occupied by fragments in our 
structures. These findings emphasize that fortuitous binding of buffer components and other 
miscellaneous compounds can in some cases provide useful information about binding sites 
(Mattos and Ringe, 1996). It may be possible to link fragments in the primary subsite and 
secondary subsite to increase binding affinity. Although some fragments in the secondary subsite 
are largely stabilized by crystal-lattice contacts, they still enjoy favorable interactions with the 
protein that could potentially be useful for fragment extension. By contrast, the primary subsite is 
generally free from crystal-lattice contacts. 
 To assess the effect of the bound fragments on the structure of PTP1B more globally, for 
each dataset we built an ensemble structure consisting of both the ground state and the bound 
state. Each dataset was modeled with an innovative PDB format as a multiconformer structure 
that represents both a heterogeneous apo state and a heterogeneous holo state. Due to limitations 
in the PDB model format and in the ability of conventional refinement programs to interpret and 
create reasonable restraints for this model type, either one conformation or four alternative 
conformations were used to describe each residue, often when only two were necessary. Due to 
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this forced degeneracy, refinement of coordinates, occupancy, and B-factors must be highly 
restrained. We interpret the resulting occupancies as a good approximation of the fraction of unit 
cells that have a ligand present. Refining these ensemble structures using restraints that avoid 
overfitting allowed for some structural differences between the two states to emerge. In 
principle, these structural differences could give some prediction of the functional effects one 
might expect upon developing a higher affinity version of the molecule. The refined ensemble 
structures were of high quality. However, generally speaking, the structural differences were 
subtle: the global backbone RMSD (N, Cα, C atoms) between the ground state and bound state 
ranged from 0.7 to 1.7 Å. Cases with larger RMSD (>1.25 Å) generally involved either active-
site fragments that directly shift the WPD loop, or fortuitous oxidation of the active-site Cys215 
(van Montfort et al., 2003). Thus, fragment binding did not dramatically shift PTP1B from the 
open to the closed state in many of these structures. Many of these fragments are certainly 
benign binders that bind to non-allosteric sites. However, the strong preference for the open state 
even with fragments that bind to allosteric sites is likely due to the absence of glycerol, which is 
present in our multitemperature structures (see Materials and methods). It is likely that weak 
fragments do not overcome this energetic preference, and instead elicit conformational changes 
primarily in their immediate vicinity. Including glycerol to place the protein in a regime in which 
the open vs. closed states are more nearly isoenergetic during fragment soaks could potentially 
interfere with fragment binding to the 197 site, since ordered glycerols also fortuitously bind 
there (Figure 4.22). 
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Validating a functional allosteric linkage with covalent tethering 
 The small-molecule fragments described above were identified by a naive screen and are 
not optimized for high-affinity binding to the 197 site or L16 site of PTP1B. Nevertheless, we 
selected 20 fragments that were deemed to bind in either site during early rounds of iterative 
PanDDA analysis (see Materials and methods) and tested whether they have allosteric effects 
using enzyme activity assays. Unsurprisingly, we did not observe inhibition of enzyme activity 
by the fragments up to the maximum concentrations we were able to assay due to solubility of 
the fragments. It is important to note that this is not surprising due to the fragments’ small sizes, 
relatively simple chemical structures, and low affinities (soaking with fragments at 30–150 mM 
concentrations resulted in observed occupancies of only 10–30% in the crystal structures). 
However, looking ahead, the dozens of cocrystal structures with small-molecule fragments 
bound at these promising allosteric sites (and at the previously explored BB2 site) that we have 
reported here offer a foothold for future medicinal chemistry efforts to design allosteric 
inhibitors for PTP1B. 
 Instead, here we focus on an alternative strategy to validate the concept of allosteric 
inhibition at the 197 site: covalent binding to enhance ligand occupancy. Specifically, we used 
‘Tethering’ (Erlanson et al., 2000; Erlanson et al., 2004), in which a residue near the site of 
interest is mutated to cysteine, then the mutant is mixed with disulfide fragments under partially 
reducing conditions. Affinity of the fragments for the site of interest drives the formation of a 
disulfide bond between the fragment and the adjacent cysteine. The extent of cysteine labeling 
can be measured using whole-protein mass spectrometry, and serves as a metric to rank the 
affinity of fragments for a given site. One major advantage of Tethering over other fragment-
based approaches is that it can leverage low-affinity binding events into quantitatively labeled 
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protein species, whose enzymatic activity can then be assayed. Here, we used Tethering to 
successfully identify a covalent allosteric inhibitor at the 197 site of PTP1B (Figure 4.8). 
 
Figure 4.8. Characterization of a functional covalent allosteric inhibitor. (A) The chemical 
structure of our covalent disulfide fragment 2. (B) Tethering and Inhibition of K197C at varying 
concentrations of 2. The tethering EC50 observed was 7.8 ± 1.1 µM and the Ki for pNPP activity 
was 7.1 ± 1.1 µM with a maximum inhibition of ~60%. Tethering data represents all tethering 
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events combined. (C) Tethering and Inhibition of WT* at varying concentrations of 2. The 
tethering EC50 and the Ki for pNPP activity were both >50 µM. Tethering data represents all 
tethering events combined. Data represent the mean of three independent assays ± the standard 
error of the mean. All assays were performed in the presence of 100 µM of β-mercaptoethanol. 
 For the allosteric 197 site in PTP1B, we chose to tether to a K197C mutant for several 
reasons. First, K197 is on the α3 helix, which is a key allosteric element in PTP1B (Choy et al., 
2017). We predicted that small-molecule tethering to our site could could perturb the helix via 
K197C, perhaps mimicking the effects of a free molecule binding to the WT protein and altering 
the K197 conformational distribution. Second, K197 and E200 are the two residues on α3 whose 
Cα-Cβ vectors point in roughly the correct direction toward the allosteric 197 site we describe; 
however, E200 engages in crystal-lattice contacts which would interfere with tethering in our 
P3121 space group, so we focused on K197C instead. 
 To efficiently explore the chemical space of covalent small molecules for the 197 site, we 
used a library of 1600 disulfide-capped fragments designed for covalent tethering experiments 
(Kathman et al., 2014; Burlingame et al., 2011a). From our initial screen, we identified 50 
fragments that tethered to K197C > 3 standard deviations above the average percent tethering for 
all 1600 compounds (Figure 4.23 panel A). We next measured the ability of these top fragments 
to modulate PTP1B’s phosphatase activity (Figure 4.23 panel B). Formation of the tethered 
complex followed by a pNPP assay identified only one fragment, 1 (Figure 4.23 panel C), that 
appeared to inhibit PTP1B at a percentage comparable to the percentage of tethered complex 
(Figure 4.23 panel B), suggesting a direct relationship between labeling and inhibition. 
While 1 thus showed the behavior we desired, the percent labeling and inhibition were relatively 
low. We hypothesized that altering the linker between the fragment core and the disulfide bond 
may lead to improved interactions between the protein and small molecule. For this reason, we 
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designed and synthesized 2 (Figure 4.8 panel A), which has the orientation of the amide bond 
reversed, allowing for one less carbon in the disulfide linker (Figure 4.23 panel C). 
 When assayed, 2 showed improved tethering and inhibition of K197C relative 
to 1. 2 exhibited dose-dependent tethering and partial noncompetitive allosteric inhibition of 
K197C with a tethering EC50 of 7.8 ± 1.1 µM and a Ki for pNPP activity of 7.1 ± 1.1 µM 
(maximum inhibition of ~60%) (Figure 4.8. panel B and Figure 4.24 panel A). 
Importantly, 2 appeared to show little to no tethering of WT* and minimal inhibition, supporting 
that 2’s activity is specific to the 197 site and not due to tethering of the active-site cysteine 
found in both K197C and WT/WT* (Figure 4.8 panel C and Figure 4.24 panel B). In fact, the 
inhibition that is observed for WT* does not correlate with tethering, suggesting the inhibition 
may be from nonspecific factors, such as aggregation, at higher concentrations of 2 (≥50 µM). 
Michaelis-Menten kinetic analysis of K197C in the presence of 2 (50 µM) showed a statistically 
significant ~50% reduction in Vmax relative to DMSO treatment, but no significant effect on 
KM for the pNPP substrate (Figure 4.24 panels C,E,F). This supports a noncompetitive allosteric 
mechanism of inhibition. The effect on WT* kinetics was similar to the nonspecific inhibition 
observed in the dose titration experiment (Figure 4.24 panel D), once again supporting that the 
activity of 2 is specific for the K197 site on PTP1B. To further profile the inhibitory effect of 
tethering of 2on K197C, we assayed the ability of the tethered complex to dephosphorylate the 
alternative substrate DiFMUP (Welte et al., 2005). As with pNPP, the tethered complex was 
inhibited, with kinetic analysis showing a dramatic reduction in Vmax, but no significant effect on 
KM (Figure 4.25). These results once again support a partial noncompetitive allosteric 
mechanism of inhibition. 
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 To further validate that 2 acts specifically through the K197 site and to explore the 
mechanism of inhibition by 2, we solved a high-resolution (1.95 Å, Table 1) crystal structure of 
K197C tethered with 2. The structure confirms that 2 tethers to K197C rather than to the active-
site catalytic Cys215, and also that tethered 2resides in the 197 site (Figure 4.9 panel A) rather 
than in the relatively nearby BB site, which is also theoretically within reach of the tethering 
linker on the other side of the α3 helix. We modeled 2 as partially populated and, indeed, the 
83% refined occupancy in the crystal structure was very similar to the ~85% conjugation 
measured after tethering in solution prior to crystallization. 2 adopts a conformation in which the 
two rings are nearly coplanar. This interpretation is further validated by a ‘polder map’, in which 
both the ligand and bulk solvent are omitted (Liebschner et al., 2017) (Figure 4.26). While 
coplanar biphenyl rings are typically believed to be disfavored due to steric clashes, it is possible 
that hydrogen bonding of D148 with the phenol combined with the electronegativity of the para-
fluoro leads to delocalization of the rings’ electrons and promotes a coplanar conformation. 
Additionally, 2 packs against the hydrophobic floor, centered on Leu172, of the relatively 
shallow binding pocket in the 197 site. Trapping of coplanar biphenyl rings covalently attached 
to a protein has previously been reported (Pearson et al., 2015). 
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Figure 4.9. A functional small-molecule inhibitor tethered to the allosteric 197 site. (A) The 
tethered inhibitor 2 is highly ordered (~85% occupancy) in the 197 site, as seen by 2Fo-Fc 
electron density for our 1.90 Å structure contoured at 0.75 σ (cyan volume) and at 1.5 σ (blue 
mesh) that is continuous to the K197C sidechain. A few waters (transparent red spheres) which 
appear to be mutually exclusive with the molecule are likely displaced by binding. (B) Many 
fragments from WT* cocrystal structures (transparent orange) overlay well with 2 in the K197C 
cocrystal structure (green). One fragment in particular (solid orange) has a ring substructure that 
overlays very closely with a ring substructure of 2. (C) The K197C 2-tethered structure (green) is 
similar to the K197C apo structure (gray), but upon tethering there are several conformational 
changes (arrows and asterisk) in the α3 helix: the whole backbone shifts up in this view slightly 
leading back into the WPD loop (top), N193 switches rotamers, and the sidechains of F196 and 
E200 move within rotameric wells. The end of the α6 helix, including E276 and F280, appears to 
respond in concert. (D) Several of these changes mirror changes from open-to-closed apo PTP1B 
(arrows and asterisk) as seen in the two conformations of our 278 K model (red/orange). (E) 
Overview as in Figure 4.2 panel E for context. The viewing orientation in (A) is as in Figure 4.1 
panel B (‘back side’ of PTP1B), except zoomed in on the 197 site (labeled in Figure 4.1 panel 
B). The viewing orientation in (C–E) is as in Figure 4.1 panel B. 
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 To elucidate confomational changes induced by 2, we also solved a high-resolution (1.95 
Å, Table 1) crystal structure of apo K197C in the same crystal form for comparison. As 
mentioned previously, PTP1B remains in the open state without glycerol; glycerol was absent 
from the tethered K197C structure (to avoid competition for binding in the 197 site) and from the 
K197C apo structure (for consistency), so we are unable to see any dramatic shifts in the global 
open-closed equilibrium that 2 may induce. Tyr153 shifts its position slightly and Tyr152 
responds by shifting fully to its up rotamer, but this is likely due to the loss of interactions with 
the WT K197 upon mutation. Beyond these mutation-induced effects, we see some 
conformational changes associated with tethering of 2. The key residue Asn193 (Choy et al., 
2017) changes rotamers, the sidechain of Phe196 on α3 ‘slides’ to change its aromatic stacking 
arrangement with Phe280 on α6 (Figure 4.9 panel C), and Glu276 -- which contacts the wedge 
residue Leu192 (Choy et al., 2017) -- rotates sidechain dihedral angles. These sidechain 
movements appear to couple to subtle, more distributed backbone shifts (Deis et al., 2014) of the 
α3 helix, several residues of which move up toward the WPD loop by ~0.5 Å (Figure 4.9 panel 
C). Interestingly, these sidechain and particularly backbone movements are somewhat similar to 
those between the two macrostates of apo PTP1B at high temperature (Figure 4.9 panel D). Thus, 
although the mechanistic details remain unclear, allosteric inhibition by 2 may involve 
conformational changes, especially of α3, that are similar to those that occur during the global 
transition from the open to the closed state (Choy et al., 2017). This interpretation is consistent 
with a recent report that mutations (Y153A, M282A) in what we here recognize as the 197 site 
and L16 site alter the equilibrium between the WPD loop’s open and closed states (Cui et al., 
2017). We note that the non-competitive allosteric mechanism observed suggests that 
tethering 2 to K197C may shift the protein’s energy landscape in such a way as to alter the 
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kinetics of WPD loop motions. Future work to explore this issue would nicely complement the 
crystallographic and functional analysis we provide here. 
 Interestingly, several of the other noncovalent fragments bound to WT* overlay well with 
the aromatic rings of 2 tethered to K197C (Figure 4.9 panel B). This structural convergence 
suggests promising new avenues for future medicinal chemistry efforts. First, more 
conservatively, portions of specific fragments could be added to 2 to yield improved covalent 
allosteric inhibitors for K197C PTP1B. Second, perhaps more promisingly, portions of 2 could 
be combined with (portions of) specific fragments to create potent new non-covalent allosteric 
inhibitors for WT PTP1B. 
 
Discussion 
 Our analysis of PTP1B paints a portrait of an inherently allosteric system. Allostery is 
fundamentally tied to protein functions such as catalysis via the theme of conformational 
motions (Goodey and Benkovic, 2008). Here, we have harnessed new approaches in X-ray 
crystallography to map coordinated conformational redistributions that underlie allostery in the 
dynamic enzyme PTP1B. Metaphorically, we were able to use this map of PTP1B’s 
‘intramolecular nervous system’ to reveal allosteric ‘pressure points’ that enable long-range 
modulation of its function. 
 Proteins sample many conformations from a complex energy landscape (Frauenfelder et 
al., 1991), many of which are accessible and represented among the millions to trillions of 
molecules in a protein crystal. However, an X-ray crystallographic dataset provides only 
ensemble-averaged information -- so it is difficult to decipher individual minor conformations 
from a single dataset. A key to our work was harnessing the power of en masse structural 
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analysis, which let us reveal minor conformations and the shifts between them that allow a 
dynamic protein to function. We exploited families of structures in two different ways. First, we 
contrasted structures at several different temperatures (Keedy et al., 2015b) for PTP1B to track 
coordinated conformational shifts which underlie allosteric communication. Second, we used 
hundreds of structures of PTP1B with different small-molecule fragments to calculate a 
statistical ‘background’ electron density map representing the unbound state, which we could 
subtract to reveal fragment-bound conformations (Pearce et al., 2017) for many allosteric sites. 
This requires using the PDB format of alternative locations to encode both compositional and 
conformational heterogeneity within a single model. Our multi-structure equilibrium X-ray 
approaches complement other methods for breaking the degeneracy of ensemble-averaged data 
to resolve multiple conformations of macromolecules. For example, 3D classification algorithms 
in cryo-electron microscopy enable in silico purification of different compositional and 
conformational states (Scheres, 2016). Time-resolved X-ray experiments, for example with free-
electron lasers, offer great promise for mapping conformational changes with both spatial and 
temporal resolution, although general experimental strategies are still forthcoming for the vast 
majority of proteins that are non-photoactivatable (Hekstra et al., 2016). More generally, 
integrative modeling algorithms can synthesize data from disparate sources at different 
resolutions, including solution NMR or small-angle X-ray scattering, to build ensembles of 
structures that are consistent with all the experimental data (van den Bedem and Fraser, 
2015; Russel et al., 2012). 
 By exploiting a new multitemperature multiconformer X-ray approach, we have 
identified a collective allosteric network that is contiguous on the ‘back side’ of the protein, 
centered around the quasi-ordered α7 helix (Figure 4.2 panel E, Figure 4.9 panel E). This 
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network includes the BB site, which was previously targeted with a small-molecule allosteric 
inhibitor (Wiesmann et al., 2004). It also includes adjacent sites (the 197 site and the L16 site) in 
either direction from the BB site, which have not been targeted previously with small-molecule 
inhibitors. Several residues in these additional sites were implicated as being part of putative 
allosteric sites by recent work using mutagenesis and NMR chemical shift and dynamics 
information (Choy et al., 2017; Cui et al., 2017). Our work agrees with those studies in 
identifying the 197 site and L16 site as potentially important players in PTP1B’s collective 
allosteric network. We additionally complement them by revealing, in atomic detail, alternative 
conformations that these sites natively populate. Our work suggests that allosteric perturbations 
do not necessarily induce conformational changes in PTP1B -- instead, the alternative 
conformations are already latently sampled by the apo protein and are simply stabilized by the 
allosteric perturbations. Portions of the allosteric network we observe here in PTP1B -- in 
particular the series of aromatic and hydrophobic residues linking the allosteric BB site to the 
active site (Figure 4.3) and the cluster of aromatic residues behind and beneath the WPD loop 
(Figure 4.20) -- are analogous to the dynamic hydrophobic spines that play central roles in 
allosteric activation of protein kinases (Taylor and Kornev, 2011; Kim et al., 2017). Our analysis 
suggests that allostery in PTP1B is characterized by interdependent conformational changes 
spanning length scales: helical order-disorder transitions, hydrophobic shifts, local sidechain 
rotamer changes, subtle helical twists, and large discrete active-site loop motions. 
 Our work reveals new opportunities for long-range control of PTP1B function by 
impinging upon tendrils of this expanded allosteric network with small molecules. Specifically, 
we have used two different small-molecule techniques with complementary strengths to reveal 
new footholds for developing allosteric inhibitors for PTP1B in the future. First, we used a new 
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high-throughput method with small-molecule fragments to map the ligandability of the entire 
surface of PTP1B with high structural resolution. Although individually these fragments have 
low affinity, collectively the 110 protein:fragment structures we report reveal overlapping poses 
with a multitude of precise binding interactions at specific sites in PTP1B (Figure 4.7 panels 
A,B,C). Many of the 11 binding sites outside the active site are likely to be benign. Importantly, 
our multitemperature X-ray analysis of the apo protein provides a way to predict which binding 
sites are instead likely to be allosterically coupled to function. Based on the result that the same 
small number of sites are both (a) implicated as allosteric by multitemperature X-ray analysis of 
conformational changes in apo PTP1B and (b) the most ligandable sites from the fragment screen 
across the entire surface, we conclude that conformational changes may be important for 
allosteric ligand binding in this protein. Second, we used covalent tethering to probe the 
functional effects of a high-occupancy ligand at one promising allosteric site. Our work takes 
advantage of a synergy between fragments and tethering. Fragments bind weakly, but allow for 
the visualization of hundreds of chemical entities bound to distinct sites in a protein. By contrast, 
tethering does not provide high-throughput structural information, but allows for targeted 
perturbations to functionally probe a specific site, and additionally can provide lower-throughput 
structural information about chemical matter that allosterically inhibits a protein variant. 
Importantly, the structural and functional information from these techniques can be combined to 
open doors for future structure-based drug design efforts (Figure 4.9 panel B). Together, our 
results illuminate a promising new region of chemical space that may be fruitfully explored by 
future medicinal chemistry efforts to develop potent non-covalent allosteric inhibitors for WT 
PTP1B. 
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 Although our work helps set the stage for such efforts, generating potent and selective 
ligands based on linking of fragment-screening hits is a difficult and time-consuming process 
that is beyond the scope of this current study. While none of the fragments identified to bind at 
the 197 site in our work have the potency or selectivity for proper assaying of their effect on 
enzyme activity, let alone for use as a cell-active ligand, their identification supports the 
ligandability of the 197 site, and motivates future efforts to identify potent ligands at this site. 
Our use of covalent tethering at the 197 site allowed us to drive occupancy of fragment 2 at this 
site and functionally validates the allosteric effect of ligand binding at this site on PTP1B 
phosphatase activity. The percent tethering observed for 2 is correlated with the percent 
inhibition observed (Figure 4.8 panel B), indicating that the tethered compound drives inhibition. 
However, the maximum inhibition is only ~60% (Figure 4.8 panel B and Figure 4.25 panel A), 
which is consistent with a partial noncompetitive allosteric mechanism of inhibition. This 
mechanism is supported by our kinetic analysis of 2-bound K197C (Figure 4.24 panel  
C and Figure 4.25 panel B) where the reduction in enzyme rate is driven by a reduction in Vmax, 
not a change in KM (Figure 4.24 panels E,F and Figure 4.25 panels C,D). Partial inhibition is a 
common paradigm in noncompetitive allosteric inhibition, where ligand occupancy does not 
perfectly correlate with inhibition (Ramsay and Tipton, 2017; Whiteley, 2000). 
 The ‘druggability’ of the 197 site in WT PTP1B is further supported by recent work 
using structure-based simulations and virtual screening, which found that the 197 site bound 
several diverse molecules in silico, and was the most responsive to allosteric perturbations 
among several potential allosteric pockets identified in PTP1B (Kumar et al., 2018). Together 
with our findings, these data imply that while the development of potent non-covalent allosteric 
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inhibitors targeting the 197 site may be arduous, a concerted effort toward this goal may 
ultimately be fruitful. 
 Future efforts to develop potent non-covalent allosteric inhibitors for PTP1B can explore 
an additional feature of the allosteric 197 site that may enhance its druggability. As stated above, 
the quasi-disordered α7 helix is capable of reordering into different conformations, some of 
which cover the α3-α6 region including the 197 site. We observe several reordered α7 
conformations under different conditions: with BB3 at 273 K, with BB1 at 100 K, in the S295F 
(α7) mutant, in the L192A (α3) mutant with an active-site inhibitor (Figure 4.15 panel C), and 
with a fragment in the BB site (Figure 4.7 panel A). Similarly, the disordered C-terminus, 
including α7, accommodates a recently reported allosteric inhibitor (Krishnan et al., 2014). For 
the BB site, the malleability of α7 is likely a double-edged sword. On one hand, reordered 
conformations of α7 may contribute binding energy to allosteric inhibitors by forming a ‘lid’ 
over what is partially a ‘cryptic site’ (Cimermancic et al., 2016). On the other hand, they may 
also accommodate different small-molecule variants equally well, such that it is difficult to 
improve upon inhibition -- that is, the structure-activity relationship (SAR) is flat. However, the 
197 site is structurally distinct from the BB site, and is accessible to different, more C-terminal 
portions of α7. Future work will test the hypothesis that the 197 site can yield improved allosteric 
inhibitors that take advantage of these unique structural features. Notably, it is possible that the 
flat SAR observed at the BB site is due to an inhibition mechanism that is unrelated to the 
particular binding site, which is not uncommon in PTP1B drug discovery efforts -- if this is the 
case, targeting the 197 site may face similar hurdles. 
 Our work motivates specific future efforts to allosterically inhibit PTP1B activity for 
therapeutic purposes. However, the allosteric network illuminated here by probing PTP1B with 
 
 
117 
non-biological perturbations (temperature and small molecules) in vitro may also be relevant to 
how the enzyme is regulated in vivo, in at least three ways. First, in addition to directing 
subcellular localization (Frangioni et al., 1992), the quasi-disordered C-terminal region of 
PTP1B reorders to interact with the ‘back side’ of the catalytic domain in different ways, is 
phosphorylated at disordered serine residues in vivo to regulate function (Brautigan and Pinault, 
1993), and mediates allosteric inhibition by natural product molecules (Krishnan et al., 2014). 
Moreover, removing α7 reduces activity in PTP1B (Choy et al., 2017), and removing the 
disordered C-terminus in the related phosphatase TCPTP reduces activity even more 
dramatically (Hao et al., 1997). Second, Tyr152 (Figure 4.5) is phosphorylated in vivo, which 
contributes to binding to the insulin receptor kinase (IRK) (Bandyopadhyay et al., 1997; Rhee et 
al., 2001) and is required for binding to N-cadherin (Bandyopadhyay et al., 1997; Rhee et al., 
2001). Tyr152 phosphorylation is sterically compatible only with the ‘up’ rotamer, which is 
correlated with the global open state of PTP1B; it is therefore possible that Tyr152 
phosphorylation and/or subsequent IRK or cadherin binding events directly affect PTP1B 
activity via the allosteric network we report here. Third, in several other protein tyrosine 
phosphatases (PTPs), protein-protein interactions occur on the ‘back side’ of the catalytic 
domain -- coinciding with where we observe three major allosteric sites in PTP1B. For example, 
in RPTPγ and RPTPε, the non-catalytic D2 domain binds to the catalytic D1 domain at an 
interface coinciding with the allosteric network we report on the back of PTP1B (Barr et al., 
2009). Additionally, the N-terminus of PTPL1 wraps around the area coinciding with the L16 
site in PTP1B, and docks in the area coinciding with the ɑ7 helix in PTP1B (Villa et al., 2005). 
Together, these observations suggest that the allosteric network we establish here within the 
catalytic domain of PTP1B may function as a ‘receiver’ for allosteric inputs from the C-terminus 
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in cells. If so, this strategy operates in parallel with other mechanisms such as active-site 
oxidation (van Montfort et al., 2003) and phosphorylation of other sites in the catalytic domain 
(Ravichandran et al., 2001) as part of a complex, multifaceted regulatory scheme. 
 Finally, it is interesting to note that different protein tyrosine phosphatases (PTPs) share a 
structurally conserved catalytic domain with PTP1B -- but have different variants of the α7 helix 
or even entirely different N- or C-terminal domains (Alonso et al., 2004) that can be trapped in 
inhibitory conformations for allosteric inhibition, as recently realized for SHP2 (Chen et al., 
2016). Similarly, regulatory domains or subdomains were recently targeted for allosteric 
inhibition of the serine/threonine phosphatases Wip1 (Gilmartin et al., 2014) and PP1 (Carrara et 
al., 2017). It will be exciting to dissect the mechanisms by which different PTPs are allosterically 
controlled by their specific regulatory domains -- both to unravel these proteins’ unique cellular 
roles, and to reveal new opportunities to correct their dysregulation in disease. 
 
Materials and methods 
Cloning, expression, and purification 
 For all ‘wild-type’ PTP1B experiments here, we used what we refer to as the WT* 
construct: residues 1–321, with the C32S/C92V double mutation (Erlanson et al., 2003) to 
prevent off-target tethering reactions, in a pET24b vector with a kanamycin resistance gene. 
K197C, K197A, Y152G, and Y153A were created using site-directed mutagenesis from the 
WT* construct. 
 Protein was expressed and purified as previously reported (Pedersen et al., 2004), with 
some minor variations. For expression, we transformed BL21 E. colicells with plasmid, grew 
cells on LB + kanamycin plates overnight at 37°C, inoculated 5 mL starter cultures of 
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LB + kanamycin with individual colonies, grew shaking overnight at 37°C, inoculated larger 1 L 
cultures of LB + kanamycin, grew shaking at 37°C until optical density at 600 nm was 
approximately 0.6–0.8, induced with 100 mM IPTG, and grew shaking either for 4 hr at 37°C or 
overnight at 18°C. Cell pellets (‘cellets’) were harvested by centrifugation and stored at −80°C in 
50 mL conical tubes. 
 For purification, we first performed cation exchange with an SP FF 16/10 cation 
exchange column (GE Healthcare Life Sciences) in lysis buffer (100 mM MES pH 6.5, 1 mM 
EDTA, 1 mM DTT) with a multi-stage 0–1 M NaCl gradient (shallow at first for elution of 
PTP1B, then steeper); PTP1B eluted around 200 mM NaCl. We then performed size exclusion 
with a Superdex 75 size exclusion column (GE Healthcare Life Sciences) in size exclusion buffer 
(100 mM MES pH 6.5, 1 mM EDTA, 1 mM DTT, 200 mM NaCl). PTP1B appeared highly pure 
in SDS-PAGE gels. 
 
Crystallization 
 WT* PTP1B was dialyzed into crystallization buffer (10 mM Tris pH 7.5, 0.2 mM 
EDTA, 25 mM NaCl, 3 mM DTT) with at least a 200x volume ratio overnight at 4°C. We were 
unable to grow apo WT* PTP1B crystals initially, so we synthesized the active-site inhibitors 
OBA and OTP as in (Andersen et al., 2002) (OBA = compound 3a, OTP = compound 12h). We 
were unable to solubilize OTP as used in (Pedersen et al., 2004). Instead, we co-crystallized 
PTP1B with OBA (Andersen et al., 2000). We first solubilized OBA to 250 mM in DMSO, then 
created a 10:1 molar ratio of PTP1B:OBA. Crystallization drops were set in 96-well sitting- or 
hanging-drop format at 4°C with 10–15 mg/mL protein with 1 μL of protein solution + 1 μL of 
well solution (0.2–0.4 M magnesium acetate, 0.1 M HEPES pH 7.3–7.6, 12–17% PEG 8000), 
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then trays were incubated at 4°C. Crystals several hundred μm long grew within a few days, and 
often continued to grow bigger for several more days. We created seed stocks from these crystals 
by pipetting the entire drop into 50 μL of well solution, iterating between vortexing for 30 s and 
sitting on ice for 30 s several times, and performing serial 10-fold dilutions in well solution. Apo 
crystals were grown by introducing seed stock (0x, 10x, or 100x diluted) into freshly set drops, 
either by streaking with a cat whisker or pipetting a small amount (e.g. 0.1 μL into a 2 μL drop). 
Serial seeding using new apo crystals successively improved crystal quality. We also added 
ethanol to the well solution based on an additive screen (Hampton Research), and added glycerol 
to mimic the previously published apo structure protocol (Pedersen et al., 2004), resulting in the 
following final WT* PTP1B crystallization well solution: 0.3 M magnesium acetate, 0.1 M 
HEPES pH 7.5, 0.1% β-mercaptoethanol, 16% PEG 8000, 2% ethanol, 10% glycerol. The 
resulting crystals were used for our WT* PTP1B multitemperature analysis. 
 We also crystallized WT* PTP1B in MRC SwissCi 3-well sitting-drop trays. Protein was 
at 30–50 mg/mL protein in the same crystallization buffer. The well solution was very similar 
except for having a slightly lower precipitant concentration (13–14% PEG 8000) and no 
glycerol. Drops were set at room temperature with 135 nL protein solution + 135 nL well 
solution + 30 nL seed stock, then trays were incubated at 4°C. Crystals appeared within a few 
days. The best seed stocks had been diluted 10-100x. These crystals were used for the BB3-
soaking and fragment-soaking experiments. 
 We crystallized apo K197C in the microbatch format with Al’s oil covering all wells. 
Protein was at 5–30 mg/mL in the same crystallization buffer as WT* but without DTT. The well 
solution was 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% β-mercaptoethanol, 10–26% 
PEG 8000, 2% ethanol. Drops were set on ice with 1 μL protein solution + 1 μL well solution, 
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then trays were incubated at 4°C. Crystals appeared within a few days. We also grew apo K197C 
crystals in a few other similar conditions. 
 We crystallized K197C tethered to 2 in the 96-well hanging-drop format. Protein was at 
15 mg/mL in the same crystallization buffer as WT* but without DTT. The well solution was 0.2 
M magnesium acetate tetrahydrate, 20% PEG 3350. Drops were set at room temperature with 
100 nL protein solution + 100 nL well solution, then trays were incubated at 4°C. Crystals 
appeared within a few days. 
 
X-ray data collection 
 We used PDB ID 1sug for the apo WT 100 K dataset. The apo WT* 278 K dataset was 
collected at Stanford Synchrotron Radiation Lightsource (SSRL) beamline 12–2. All fragment-
soaked datasets were collected at Diamond Light Source beamline I04-1. All other datasets were 
collected at Advanced Light Source (ALS) beamline 8.3.1. 
 For apo WT* 180, 240, and 278 K, crystals had been grown in 2 μL drops with 10% 
glycerol in the mother liquor, then 1.5 μL of 50% glycerol was added several hours before data 
collection, resulting in a final concentration of ~27% glycerol. Some crystals were also dabbed 
into more 50% glycerol just before mounting. 
 For BB3-complexed WT*, crystals were soaked with 125 nL of 10 mM BB3 (in DMSO). 
No glycerol was present in these crystals. 
 For apo WT* and BB3-complexed WT*, crystals were looped and placed in a plastic 
capillary with ~70% mother liquor,~30% water to prevent dehydration during data collection, 
regardless of temperature; datasets were obtained at different temperatures simply by adjusting 
the cryojet temperature before placing the crystal on the goniometer. Helical data collection 
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(translation along the crystal coupled to goniometer rotations) was used to expose fresh regions 
with each shot, to minimize radiation damage. 
 For apo and 2-tethered K197C, crystals were simply looped and directly mounted on the 
goniometer in front of the cryojet. For apo K197C, a small amount of ice was likely present on 
the crystal. 
 For fragment-soaked PTP1B, WT* PTP1B crystals in MRC SwissCi 3-well sitting-drop 
trays were soaked with small-molecule fragments using acoustic droplet ejection technology and 
a database mapping individual fragments to individual crystals as described (Collins et al., 2017). 
PTP1B crystals were quite tolerant to DMSO, so we were able to achieve high fragment 
concentrations and long incubation times: we soaked overnight for >8 hr at final concentrations 
of 30% DMSO and 30–150 mM fragment (depending on the concentration of the fragments in 
the source library). Additionally we collected X-ray data for 48 ‘apo’ datasets (soaked with 
DMSO), 42 of which gave high-resolution datasets, to better establish the unbound background 
electron density for PanDDA analysis. Despite the high DMSO concentrations, we did not 
observe difference electron density consistent with any ordered DMSO molecules bound to 
PTP1B. Some fragments were soaked into additional crystals if good datasets were not obtained 
from the initial soak; however, only 2 of the 110 fragment-bound datasets contain the same 
fragment. We also collected a relatively small number of trial datasets (28) near room 
temperature instead of cryogenic temperature, but they were generally low-resolution, and none 
revealed bound fragments. 
 Most crystals stuck to the bottoms of wells regardless of construct and tray format, but it 
was often possible to gently dislodge them, or to physically break them off then expose the 
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unperturbed portion of the crystal to the X-ray beam. Each dataset in this study was collected 
from a single crystal. 
 
X-ray data processing 
 To process the multitemperature and tethered datasets, we used XDS (Kabsch, 2010). In 
each case we chose a resolution cutoff for which CC1/2 (Karplus and Diederichs, 2012) was 
statistically significant at the 0.1% level (above 0.4). We created a new set of Rfree flags for the 
278 K WT* apo dataset, then transferred them to the MTZ file of every other dataset with the 
reflection file editor in PHENIX (Adams et al., 2010) (for PDB ID 1sug, we first deleted the 
existing Rfreeflags). We solved each structure by molecular replacement with Phaser (McCoy et 
al., 2007). One solution was obtained for each dataset. For WT*, we used PDB ID 1c83 with all 
waters and the WPD loop removed. For K197C, we used a refined WT* PTP1B model for 
molecular replacement. 
 For fragment-soaked datasets, we used XDS and a custom script [80; copy archived at 
https://github.com/elifesciences-publications/xds_iter] to automatically determine resolution 
cutoffs for all datasets. The resolution cutoff was initialized at 1.4 Å and incremented until the 
following criteria were met for the highest-resolution bin: at least 1.0 I/σ(I), at least 50% CC1/2 
(Karplus and Diederichs, 2012), and at least 90% completeness. Rfree flags were created for the 
highest-resolution dataset by transferring and extending the flags from the 278 K WT* apo 
dataset using the PHENIX reflection file editor. These Rfree flags were then transferred from that 
highest-resolution dataset to every other dataset in the fragment-soaking experiment. For 
PanDDA to accept the MTZ files as inputs, it was necessary to modify each file so that all 
columns (H, K, L, structure factors, map coefficients, and R-free flags) had the same number of 
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indices; no observations were omitted in this step. We then phased each dataset with Phaser 
using a reference model that was created by interpreting a high-resolution DMSO-soaked apo 
dataset. Next, we refined each initial model from Phaser using phenix.refine with the following 
flags to prevent excessive coordinate drift: ‘reference_coordinate_restraints.enabled=True 
‘reference_coordinate_restraints.sigma=0.1’. Structure factors were then dropped from MTZ 
files, leaving map coefficients as inputs to PanDDA. Filled map coefficients (from PHENIX) 
were used to avoid Fourier series truncation effects in PanDDA maps. The resulting models were 
used as input to PanDDA (see below). 
 
Structure modeling 
 For Figure 4.10, we re-refined the following 36 structures of PTP1B from the PDB either 
as-is, or with a dual-conformation WPD loop: 1bzj 1kak 1oem 1oeo 1sug 1t48 1t49 1t4j 2azr 
2b07 2bgd 2f6f 2f6t 2f6v 2f6w 2f6y 2f6z 2f70 2f71 2h4k 2hb1 2qbp 2qbq 2qbr 2qbs 2zmm 2zn7 
3cwe 3d9c 3eax 3eb1 3eu0 3i7z 3i80 3sme 4i8n. For the dual-conformation refinements, we 
constrained occupancies of the open + closed conformations of the WPD loop to 1. 
 For multitemperature WT/WT*, we refined the initial model using phenix.refine for 10 
macrocycles with automated water picking turned off. Next, we inserted preliminary open and 
closed alternative conformations for the WPD loop, and refined for another 10 macrocycles with 
automated water picking turned on. Finally, we performed several rounds of manual rebuilding, 
including manual addition and deletion of protein, solvent, and glycerol conformations and 
refinement with automated water picking turned off. Anisotropic B-factors were not used in 
refinement. The α7 helix was modeled as alternative conformation A only, with the unmodeled B 
conformation presumed to correspond to the disordered state; this allowed the occupancy of the 
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ordered state to be refined. It was necessary to provide explicit occupancy parameter files to 
phenix.refine in some cases. For many residues, conformations obtained from PDB ID 1sug or 
1t49 or another of our datasets (usually higher temperatures) were useful for ‘filling in’ missing 
density. Often the missing conformations would not have been obvious based on the map alone, 
but once inserted and refined they seemed to fit well. This cross-dataset conformational-
sampling approach also had the effect of emphasizing differences between models from different 
temperatures while minimizing differences due to chance or arbitrary modeling choices. 
Nevertheless, we encourage future users of these datasets to compare across different 
temperatures based at least in part on the electron density, and not just our models. The building 
process was guided by all-atom structure validation with MolProbity (Chen et al., 2010). The 
100 K WT model (1sug) is truly WT, whereas our new WT* datasets are all C32S/C92V, as 
noted above; however, both cysteine-scrubbing mutations are structurally conservative, distal to 
the active site, and apparently uncoupled from the WPD loop and all allosteric regions. 
 Glycerol (~20% final) was present in WT* crystals during each multitemperature data 
collection to maintain consistency with the 100 K WT structure (PDB ID 1sug), in which 
glycerol was used as a cryoprotectant. Several ordered glycerol molecules, including those in 
contact with the closed WPD loop and at the allosteric 197 site, were evident from electron 
density at all temperatures. However, in some cases, it was difficult to differentiate between 
ordered waters, glycerols, or simply noise in the map. For example, the electron density was 
uncertain at some of the elevated temperatures for some glycerols originally modeled in PDB ID 
1sug. When glycerol was omitted from crystals, the WPD loop was entirely in the open 
conformation regardless of temperature, from cryogenic temperature to near room temperature 
(data not shown). Our interpretation is that ordered glycerols in the active site, which are evident 
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from the electron density at all temperatures, make weak contacts with the WPD loop’s closed 
conformation, and thus shift the protein’s energy landscape to a regime in which the open vs. 
closed conformations are near enough to isoenergetic that temperature can modulate their 
populations. This interpretation is strengthened by the fact that these glycerol molecules align 
well with a bound mimic of the pTyr substrate (PDB ID 1pty), which causes the loop to close 
during the catalytic cycle. 
 For K197C, we used a similar refinement procedure, including many manual tweaks of 
alternative conformations for protein and water atoms. For the 2-tethered K197C structure, we 
omitted 2 for many rounds of refinement, allowing the electron density for the missing molecule 
to become extremely convincing before we finally added it to the model. The distance between 
the sulfur atoms in K197C and the ligand was restrained to 2.15 Å with a σ of 0.1 Å for 
refinement. 
 For fragment-soaked datasets, we used the PanDDA approach (Pearce et al., 2017) in a 
few stages. First, using PanDDA version 0.1, we ran pandda.analyse, and interpreted and 
modeled events. Next, using the new PanDDA version 0.2, we ran pandda.analyse again. During 
this second run, datasets which were events in the first run were excluded from background 
density calculation, and datasets that had substantial map artifacts or very noisy/low-quality 
maps in the first run were excluded entirely. 
 Some events for which we modeled bound fragments in the earlier PanDDA version 0.1 
runs were not detected as events in the final PanDDA version 0.2 run. In these cases, we 
manually created event maps based on the 1-BDC background subtraction values from the earlier 
PanDDA runs. In most cases, visual inspection confirmed that these early events likely 
correspond to bound fragments. 
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 Many PanDDA ‘events’ in the active site corresponded not to ligand binding, but rather 
to protein conformational changes of the WPD loop, P-loop, and Y46 loop that are caused by 
oxidation of the catalytic Cys215, a natural PTP1B regulatory mechanism (van Montfort et al., 
2003). Some other active-site events were difficult to interpret, perhaps due to active-site 
dynamics or differences in the appropriate background model for the open vs. closed state of the 
protein; future methodological improvements may clarify modeling in such cases. 
 We built a generic unbound-state model by interpreting both an average map for the 
highest-resolution bin and one of the best individual apo datasets. The WPD loop was modeled 
as open, Tyr152 was modeled with two alternative sidechain conformations on the loop 11 
backbone that is compatible with the open WPD loop, and the N-terminus (start of α1) and C-
terminus (end of α6, since α7 was disordered) were fit as well as possible. Ordered waters were 
also manually positioned. This generic unbound-state model was superposed onto each PanDDA 
input model in the correct reference frame, then refined, to create an unbound-state model for 
each dataset. 
 For each fragment-bound state, we inspected the fragment binding site, plus the several 
interesting regions of the protein mentioned above, in detail interactively. Waters were copied 
over from the unbound-state model, then moved or deleted where they conflicted with the bound 
fragment and/or the PanDDA event map. For a small number of planar fragments, several copies 
of the fragment bind in a parallel stack bridging the 197 site and a symmetry-related copy of the 
WPD-loop residue Phe182 via a crystal-lattice contact. Some areas such as Tyr152 were 
modeled with alternative conformations in the bound state only when they were well justified in 
the event map; otherwise we generally adhered to the unbound-state model. The correct 
modeling choice for the termini was uncertain in some cases. 
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 To refine structures for the 110 datasets with one or more modeled fragments, first we 
created restraints files for the ligands with eLBOW (Moriarty et al., 2009). For a small number 
of ligands, we additionally used AceDRG (Long et al., 2017) and found that AceDRG generated 
more realistic restraints. Next, the pandda.export method in PanDDA version 0.2 was used to 
create an ‘ensemble structure’ containing both the unbound state (including alternative 
conformations) and the bound state (including alternative conformations) in one multiconformer 
model. In pandda.export, the parameter ‘options.prune_duplicates_rms = 0.2’ was used to merge 
alternative conformations that were highly similar, and the parameter 
‘duplicates.rmsd_cutoff = 0.4’ was used to restrain the coordinates of somewhat similar 
alternative conformations to be identical. These parameter values were chosen to effectively 
merge residues with very similar coordinates, while still allowing residues we evaluated as 
having genuine alternative conformations to remain separate and unrestrained. The resulting 
geometry restraint files from pandda.export are necessary to minimize overfitting or coordinate 
drift during refinement of this model type. 
 For refinement of the ensembles representing multiconformer models of the apo and 
bound states, we first refined each ensemble structure with phenix.refine to obtain water 
positions. The first stage of PHENIX refinement was 10 macrocycles with no removal or 
addition of waters (‘ordered_solvent = False’) to let the existing waters relax into local minima. 
The second stage of PHENIX refinement was another 10 macrocycles with automated removal 
and addition of waters (‘ordered_solvent = True’) to remove waters that were unable to reach 
local minima and add waters that were clearly missing. Adding and removing waters, when 
compared to only removing them, generally had negligible effect on MolProbity scores, but 
improved Rwork and Rfree. During this first PHENIX refinement stage to obtain water positions, 
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occupancies were fixed to the original PanDDA BDC value for the ground state and 1-BDC for 
the bound state; occupancy was distributed evenly between substates when the ground state or 
the bound state had alternative conformations for some residues. We observed coordinate drift 
and unstable B-factors for the protein with PHENIX refinement. Therefore, we copied the water 
positions obtained from PHENIX into the initial ensemble models, and refined with Refmac 
(Murshudov et al., 2011). To do so, we first set all B-factors to 40 Å2, set bound-state 
occupancies to 2*(1-BDC) and unbound-state occupancies to 1–2*(1-BDC) (with occupancy 
evenly distributed across alternative conformations within each state), and generated new 
restraints files that included the water molecules by running the PanDDA utility 
giant.make_restraints with the same RMSD parameter as with giant.merge_conformations: 
‘duplicates.rmsd_cutoff = 0.4’. Then, each ensemble model was refined with Refmac using 
giant.quick_refine with the ligand CIF and custom giant.make_restraints restraint parameter files 
using the protocol herein. First, each model was refined for the default 10 cycles, with the extra 
arguments to Refmac ‘MAKE HOUT Yes’, to preserve hydrogens, and ‘HOLD 0.001 100 100’ 
to restrain XYZ coordinates but still allow for some geometry regularization and encourage B-
factor and occupancy convergence. Next, the output from that refinement was fed into a loop of 
Refmac refinement with the default 10 cycles per run, and the ‘HOLD 0.0001 100 100’ 
argument, essentially fixing the XYZ coordinates, while letting occupancies and B-factors refine. 
Our output was the result of the 4th round (1 round + 3 rounds) of refinement in Refmac. 
However, the occupancies refined with these refinements did not converge to the correct 
occupancy (as seen by huge difference peaks describing the ligand). We then refined these 
structures with PHENIX, fixing the XYZ coordinates and manually scanning across possible 
occupancies while refining B-factors with the following settings: 
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refinement.refine.strategy = individual_adp, 
hydrogens.optimize_scattering_contribution = False, main.number_of_macro_cycles = 10, 
optimize_mask = True, optimize_adp_weight = True. While in principle one could interpret the 
difference density to pick an optimal refined occupancy, no other statistics calculated provided a 
clear choice of occupancy. We ultimately chose to deposit occupancies of the bound state at 2.2 
times the event map occupancy (1-BDC). This occupancy choice was motivated by the trend 
previously found by Pearce et al. (2017). In cases where the total bound occupancy was 50% or 
higher, the models were manually inspected, and a few dropped to low occupancies that 
minimized difference features of the ligand. The resulting final ensemble structures of the 
unbound state plus the fragment-bound state were converted from PDB to mmCIF format and 
deposited in the PDB using the new multimodel submission procedure. 
 
Visualization 
 Coot (Emsley et al., 2010) was instrumental to visualizing and interactively modeling all 
structures. PyMOL (Schrödinger, 2016) was used for all molecular graphics after initial 
modeling. We frequently used the volume rendering feature for low-contour electron density 
alongside the traditional mesh for higher-contour electron density. 
 
Synthesis of tethered compounds: Synthesis of 3-amino-2',4'-difluoro-[1,1'-biphenyl]−4-ol 
 A solution of 2,4-difluorophenyl boronic acid (188 mg, 1 mmol, 1.0 equiv), 2-amino-4-
bromophenol (7.2 mg, 0.62 mmol, 1.2 equiv), Pd(PPh3)4 (57.8 mg, 0.05 mmol, 0.05 equiv), and 
Na2CO3 (318 mg, 3 mmol, three equiv) in THF (8 mL) was stirred at 90 ˚C overnight. The 
reaction was allowed to cool, taken up in water, and then extracted 3x with EtoAC. Organic 
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layers were combined, washed with brine, dried over Na2SO4, concentrated in vacuo and purified 
using flash chromatography (MeOH/DCM) to obtain 22.1 mg of product (10% yield). Calcd for 
C12H10F2NO (M+H+): 222.07; Found 222.8. 
 
Synthesis of tethered compounds: Synthesis of 2 
 To a mixture of 3-amino-2',4'-difluoro-[1,1'-biphenyl]−4-ol (22.1 mg, 0.1 mmol, one 
equiv), dithiodiglycolic acid (9.1 mg, 0.05 mmol, 0.5 equiv), HOBt·H2O (19.9 mg, 0.13 mmol, 
1.3 equiv), and DIPEA (0.226 µL, 1.3 mmol, 1.3 equiv) in THF (300 µL), EDCI·HCl (25 mg, 
0.13 mmol, 1.3 equiv) was added. The reaction was stirred at room temperature overnight. To 
this was added a solution of bis[2-(N,N-dimethylamino)ethyl]disulfide dihydrochloride (70.3 
mg, 0.25 mmol, 2.5 equiv) and TCEP (2.5 mg, 0.01 mmol, 0.01 equiv) in THF/H2O (8:3, 275 
µL). The reaction was stirred at room temperature overnight. The reaction was taken up in 
EtoAC/H2O, and extracted three times with EtOAc. Organic layers were combined, washed with 
brine, dried over Na2SO4, concentrated in vacuo and purified using flash chromatography 
(DCM/MeOH) followed by preparative HPLC (C18 column (50 × 19 mm), Methanol/Water–
0.05% formic acid gradient: 10:90 to 100:0 over 12 min; 20 mL/min; 254 nm detection for 18 
min.) to obtain 9.1 mg of 2 (23% yield). 1H NMR (400 MHz, Acetone-d6) δ 9.55 (s, 1H), 8.17 (s, 
1H), 8.06–8.04 (m, 1H), 7.54–7.45 (m, 1H), 7.22–7.19 (m, 1H), 7.12–7.00 (m, 3H), 3.94–3.78 
(m, 2H), 3.15–2.99 (m, 4H), 2.54–2.52 (m, 6H). Calcd for C18H21F2N2O2S2 (M+H+): 399.1; 
Found 398.93. 
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Tethering 
 We screened K197C against a previously synthesized library of 1600 disulfide fragments 
made available by the UCSF Small Molecule Discovery Center (SMDC) (Kathman et al., 
2014; Burlingame et al., 2011b). 
 For the screen, tethering reactions were performed using the following conditions: 1x 
tethering buffer (25 mM Tris pH 7.5, 100 mM NaCl), with 500 nM of K197C, 1 mM β-
mercaptoethanol, and 100 µM of fragment (0.2% DMSO), 1 hr at rt. Unless otherwise noted, 
tethering reactions for follow-up experiments and activity assays were performed using the 
following conditions: 1x tethering buffer, 1 µM of K197C, 0.1 mM β-mercaptoethanol, and 50 
µM of fragment (2% DMSO), 1 hr at rt. For DiFMUP assays 100 µM of fragment (0.2% DMSO) 
was used during tethering. For crystallography, tethering reactions were performed using the 
following conditions: 1x tethering buffer, 0.76 mg/mL of K197C, 0.1 mM β-mercaptoethanol, 
500 µM of TCS401, and 250 µM of fragment (2% DMSO), 2 hr at rt. A total reaction size of 3.5 
mL was used for preparation of crystallography samples. Following labeling, the reaction was 
dialyzed into crystallization buffer overnight to remove TCS401 and unbound fragment. In all 
cases, the percent of tethering was measured using a Waters Xevo G2-XS Mass Spectrometer, 
and calculated by comparing the relative peak heights of the unmodified and modified protein. 
Tethering EC50 values were calculated using nonlinear fitting in Prism 7 (Graphpad), n = 3. 
 
Activity assays 
 For activity assays of WT* PTP1B vs. allosteric mutants (Figure 4.19), protein was 
diluted to 269 nM (WT*) or 200 nM (mutants) in a variant of pNPP activity assay buffer (50 mM 
HEPES pH 7, 100 mM NaCl, 1 mM EDTA, and 1 mM DTT). WT* assays were performed at 
 
 
133 
269 nM protein and mutant assays were performed at 200 nM, so WT* data is normalized to 200 
nM in both panels in Figure 4.19. Enzyme activity assays were performed across 10 p-
nitrophenyl phosphate (pNPP) concentrations obtained by serial two-fold dilutions starting from 
20 mM. A no-enzyme well was also assayed. Absorbance at 405 nm for each reaction was 
monitored every 30 s for 5 min using a Tecan Infinite M200 Pro. The rate (mAU/min) of each 
reaction was calculated over the 5 min. Michaelis-Menten parameters were then calculated using 
Prism 7 (Graphpad). kcat values were calculated using an pNPP extinction coefficient of 18,000 
M−1 cm−1 and a path length of 0.29 cm. These parameters for WT* PTP1B were similar to those 
reported previously for WT (Choy et al., 2017); small discrepancies may be due in part to 
differences in the length of the protein construct being used. 
 For activity inhibition assays of WT* PTP1B with small-molecule fragments, 20 
fragments were chosen early in the iterative PanDDA analysis process (see ‘Structure 
modeling’). Protein was diluted to 200 nM in a variant of pNPP activity assay buffer (50 mM 
HEPES pH 7, 100 mM NaCl, 1 mM EDTA, 0.05% Tween-20, and 100 mM β-mercaptoethanol). 
Enzyme activity assays were performed with 0.15 or 1 mM fragment in 2% DMSO (final) or 
with 2% DMSO without fragment as a control, with 5 mM pNPP. A no-enzyme well was also 
assayed. Absorbance at 405 nm for each reaction was monitored every 30 s for 5 min. The rate 
(mAU/s) of each reaction was calculated over the 5 min. These rates were compared with 
fragment vs. with DMSO. 
 For single-point assays of tethered K197C, completed tethering reactions (post 1 hr 
incubation) were diluted to a final concentration of 200 nM K197C with a variant of pNPP 
activity assay buffer (50 mM HEPES pH 7, 100 mM NaCl, 1 mM EDTA, 0.05% Tween-20, and 
100 mM β-mercaptoethanol) and pNPP (5 mM final). A no-enzyme well and a DMSO-only well 
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were also assayed. Absorbance at 405 for each reaction was monitored every 30 s for 5 min 
using a Tecan Infinite M200 Pro. Percent inhibition was calculated using the following equation: 
100(1- ((RateFragment-RateNo Enzyme)/(RateDMSO-RateNo Enzyme))). 
 For 2 titration assays of tethered K197C and WT*, tethering reactions were performed at 
nine different concentrations of 2 obtained by serial three-fold dilutions starting at 50 µM. After 
1 hr incubation, the reactions were diluted to a final concentration of 100 nM K197C and WT* 
with a variant of pNPP activity assay buffer (50 mM HEPES pH 7, 100 mM NaCl, 1 mM EDTA, 
0.05% Tween-20, and 100 mM β-mercaptoethanol), the same concentration of 2 as used during 
tethering, and pNPP (5 mM final). A no-enzyme well and a DMSO-only well were also assayed. 
Absorbance at 405 nm for each reaction was monitored every 30 s for 5 min using a Tecan 
Infinite M200 Pro. The rate (mAU/s) of each reaction was calculated over the 5 min. Percent 
inhibition was calculated using the following equation: 100(1- ((RateFragment-RateNo 
Enzyme)/(RateDMSO-RateNo Enzyme))). Ki values were calculated using nonlinear fitting in Prism 7 
(Graphpad), n = 3. 
 For pNPP kinetics experiments with tethered complexes, completed K197C and WT* 
tethering reactions (post 1 hr incubation) were diluted to a final concentration of 200 nM K197C 
and WT* with a variant of pNPP activity assay buffer (50 mM HEPES pH 7, 100 mM NaCl, 1 
mM EDTA, 0.05% Tween-20, and 100 mM β-mercaptoethanol), 2 (50 µM), and 12 pNPP 
concentrations obtained by serial two-fold dilutions starting from 20 mM. Absorbance at 405 nm 
for each reaction was monitored every 30 s for 5 min using a Tecan Infinite M200 Pro. The rate 
(mAU/min) of each reaction was calculated over the 5 min. Data was plotted and fit using Prism 
7 (Graphpad), n = 3. Vmax and KM values were calculated using the Michaelis-Menten nonlinear 
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fit in Prism 7 (Graphpad). All p-values and significances were calculated using a FDR-Approach 
Multiple t-test in Prism 7 (Graphpad). 
 For DiFMUP inhibition experiments with tethered complexes, completed K197C and 
WT* tethering reactions (post 1 hr incubation) were diluted to a final concentration of 2 nM 
K197C and WT* with a variant of DiFMUP activity assay buffer (50 mM HEPES pH 7, 100 mM 
NaCl, 1 mM EDTA, 0.05% Tween-20), and 9.4 µM of DiFMUP. Fluorescence at 450 nm with 
358 nm excitation for each reaction was monitored every 30 s for 3 min using a Tecan Infinite 
M200 Pro. The rate (ΔF/min) of each reaction was calculated over the 3 min. Percent inhibition 
was calculated using the following equation: 100(1- ((RateFragment-RateNo Enzyme)/(RateDMSO-
RateNo Enzyme))), n = 3. 
 For DiFMUP kinetics experiments with tethered complexes, completed K197C tethering 
reactions (post 1 hr incubation) were diluted to a final concentration of 2 nM K197C with a 
variant of DiFMUP activity assay buffer (50 mM HEPES pH 7, 100 mM NaCl, 1 mM EDTA, 
0.05% Tween-20), and 11 DiFMUP concentrations obtained by serial two-fold dilutions starting 
from 300 µM. Fluorescence at 450 nm with 358 nm excitation for each reaction was monitored 
every 30 s for 3 min using a Tecan Infinite M200 Pro. The rate (ΔF/min) of each reaction was 
calculated over the 3 min. Data was plotted and fit using Prism 7 (Graphpad), n = 3. Vmax and 
KM values were calculated using the Michaelis-Menten nonlinear fit in Prism 7 (Graphpad). All 
p-values and significances were calculated using a FDR-Approach Multiple t-test in Prism 7 
(Graphpad). 
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Data availability 
 Multiconformer models and structure factors for the multitemperature WT and WT* 
(6B90, 6B8E, 6B8T, 6B8X), BB3-bound (6B8Z), K197C apo (6BAI) and tethered (6B95) 
datasets have been deposited in the Protein Data Bank (Berman et al., 2000). 
 We have made publicly available several files that document our PanDDA analysis of all 
WT* fragment-soaked datasets. For each dataset, we provide a model of the unbound state, 
structure factors, an average map for the corresponding resolution bin, a PanDDA Z-map, and 
one or more PanDDA event map(s) as applicable. For fragment-bound datasets, we also provide 
the refined ground state model and the bound state model (before they were merged into an 
ensemble and refined) as separate PDB files, along with PHENIX, Refmac, and ligand restraint 
files used in the ensemble refinement. Additionally, we provide an overall PanDDA log file. 
These files are hosted at Zenodo at the following DOI: 10.5281/zenodo.1044103. Finally, using a 
new deposition procedure, refined ensemble structures for the 110 WT* fragment-bound datasets 
have been deposited to the PDB (5QDE, 5QDF, 5QDG, 5QDH, 5QDI, 5QDJ, 5QDK, 5QDL, 
5QDM, 5QDN, 5QDO, 5QDP, 5QDQ, 5QDR, 5QDS, 5QDT, 5QDU, 5QDV, 5QDW, 5QDX, 
5QDY, 5QDZ, 5QE0, 5QE1, 5QE2, 5QE3, 5QE4, 5QE5, 5QE6, 5QE7, 5QE8, 5QE9, 5QEA, 
5QEB, 5QEC, 5QED, 5QEE, 5QEF, 5QEG, 5QEH, 5QEI, 5QEJ, 5QEK, 5QEL, 5QEM, 5QEN, 
5QEO, 5QEP, 5QEQ, 5QER, 5QES, 5QET, 5QEU, 5QEV, 5QEW, 5QEX, 5QEY, 5QEZ, 5QF0, 
5QF1, 5QF2, 5QF3, 5QF4, 5QF5, 5QF6, 5QF7, 5QF8, 5QF9, 5QFA, 5QFB, 5QFC, 5QFD, 
5QFE, 5QFF, 5QFG, 5QFH, 5QFI, 5QFJ, 5QFK, 5QFL, 5QFM, 5QFN, 5QFO, 5QFP, 5QFQ, 
5QFR, 5QFS, 5QFT, 5QFU, 5QFV, 5QFW, 5QFX, 5QFY, 5QFZ, 5QG0, 5QG1, 5QG2, 5QG3, 
5QG4, 5QG5, 5QG6, 5QG7, 5QG8, 5QG9, 5QGA, 5QGB, 5QGC, 5QGD, 5QGE, 5QGF). 
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Supplemental Figures 
 
Figure 4.10. The WPD loop adopts multiple conformations only in the absence of inhibitors. 
This figure is a supplement related to Figure 4.2. 36 structures from the PDB in the same space 
group as our datasets (P3121), originally modeled as only-open or only-closed, were naively re-
refined with open and closed WPD loops modeled as alternative conformations with occupancies 
constrained to sum to 1. Almost all models have an active-site inhibitor bound. In P3121 the loop 
is free from any crystal contacts. (A-C) Representative examples of structures with the WPD 
loop originally modeled as closed or open (left, blue or red), and our re-refined dual-
conformation models (right, purple). 1.0 σ 2Fo-Fc (cyan) and ±3.0 σ Fo-Fc electron density 
(green/red) are shown. (A) PDB ID 1sug: apo PTP1B; originally closed. 2Fo-Fc electron density 
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supports the dual-conformation model; residual Fo-Fc density reflects partial-occupancy waters 
(Figure 4.11). (B) PDB ID 2f70: PTP1B in complex with an active-site inhibitor; originally 
closed. Fo-Fc electron density suggests the dual-conformation model is a poor fit. (C) PDB ID 
2f6f: PTP1B in complex with another active-site inhibitor; originally open. Fo-Fc electron 
density suggests the dual-conformation model is a poor fit. (D) Loop occupancies for the re-
refined dual-conformation models are bimodal: either ~fully open (left) or ~fully closed (right). 
The curve is a fit to the histogram using kernel density estimation, and is shown to emphasize the 
bimodal nature of the distribution. The only exception is the one published apo structure in this 
space group (1sug), which can be successfully refined with partial open and closed occupancies. 
The viewing orientation in (A-C) is as in Figure 4.1 panel A (‘front side’ of PTP1B), except 
zoomed in on the active site (labeled in Figure 4.1 panel A). 
 
 
Figure 4.11. Mutually exclusive partial-occupancy protein and solvent atoms complicate model 
building. This figure is a supplement related to Figure 4.2. (A) Although both closed and open 
WPD loop states are supported by 0.8 σ 2Fo-Fc electron density (cyan volume) in the 100 K apo 
PTP1B structure, several +3.2 σ Fo-Fc electron density (green mesh) remain unexplained 
(arrows). (B) Partial-occupancy waters (red spheres) with the opposite ‘altloc’ alternative 
conformation label as the closest protein atoms (‘A’ vs. ‘B’) dramatically reduce the difference 
density and better explain the data. See (Pedersen et al., 2004). The waters modeled here 
resemble water networks from either the closed-only (2f70) or the open-only (2f6f) structures. 
The viewing orientation in A–C) is as in Figure 4.1 panel A (‘front side’ of PTP1B), except 
zoomed in on the active site (labeled in Figure 4.1 panel A). 
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Figure 4.12. Radiation damage is minimal across all datasets. This figure is a supplement 
related to Figure 4.2. Plots of Rd (Diederichs, 2006) versus frame-number difference for each 
dataset reveal little evidence for radiation damage. Statistics for WT apo at 100 K, which is from 
PDB ID 1sug, are not shown. 
 
 
Figure 4.13. Alternative conformations in apo PTP1B recapitulate a reported conformational 
switching mechanism in the active site during WPD loop closing. This figure is a supplement 
related to Figure 4.3. Alternative conformations in our 278 K apo structure corresponding to the 
open state (red) vs. closed state (dark blue) recapitulate conformational changes for several 
residues (labeled) in the active site that undergo a CH/π-mediated switch between the open state 
(pink, 5k9v) and TCS401-inhibitor-bound closed state (light blue, 5k9w) (Choy et al., 2017). The 
viewing orientation is as in Figure 4.1 panel A (‘front side’ of PTP1B), except zoomed in on the 
active site (labeled in Figure 4.1 panel A). 
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Figure 4.14. Allosteric inhibitor binding quenches conformational heterogeneity regardless of 
temperature. This figure is a supplement related to Figure 4.3. (A) The pose of BB3 in our new 
1.80 Å 273 K structure (red) is well-justified by 2Fo-Fc electron density contoured at 0.75 σ 
(cyan volume) and at 1.5 σ (blue mesh). The pose is also essentially identical to the poses in 
previously published 100 K structures with BB3 (1t4j, magenta) and BB2 (1t49, pale green), 
which is very similar in structure and inhibition to BB3 (Wiesmann et al., 2004). (B) 2Fo-Fc 
electron density contoured at 0.75 σ (cyan) supports only a single conformation along the 
previously characterized allosteric pathway, rather than the multiple conformations seen at 278 K 
from our multitemperature apo PTP1B series (Figure 4.3); a 100 K structure in the closed state 
(1sug, blue) is shown for comparison. This confirms that inhibitor binding quenches 
conformational heterogeneity essentially completely, locking the protein in the open state. The 
viewing orientation in A) is as in Figure 4.1 panel B (‘back side’ of PTP1B), except zoomed in 
on the BB site (labeled in Figure 4.1 panel B). The viewing orientation in B is as in Figure 4.1 
panel A (‘front side’ of PTP1B), except slightly zoomed in. 
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Figure 4.15. Allosteric-inhibitor-bound PTP1B has some low-occupancy conformations only at 
273 K. This figure is a supplement related to Figure 4.3. (A) At 273 K, despite a good fit to 2Fo-
Fc electron density, shown contoured at 0.75 σ (cyan volume), the allosteric inhibitor BB3 
cannot be sufficiently modeled with a single conformer, as evidenced by +3.5 σ (green mesh) 
and −3.5 σ (red mesh) Fo-Fc difference electron density. These features are absent from the 100 
K structure with BB3 (1t4j). (B) These unexplained difference features disappear when a second 
alternate conformer is added with a translation at the ‘bottom’ of the molecule (from this viewing 
angle) and dihedral-angle changes at the ‘top right’. (C) The disordered α7 helix is reordered 
above the BB binding site in various structures: 273 K with BB3 (pink; BB3 molecule in green), 
100 K with BB1 (pale blue, PDB ID 1t48), 100 K with the S295F mutation (orange, PDB ID 
2f6f), and 100 K with the L192A mutation and the TCS-401 active-site inhibitor (yellow, PDB 
ID 5ka9). The normal ordered α7 conformation (blue, PDB ID 1sug) is shown for reference. 
See Figure 4.7 panel A for another example of a reordered α7 conformation. (D–G) Evidence for 
some of the conformations in C. (D) At 273 K, 2Fo-Fc electron density contoured at 1.0 σ (cyan 
volume) and Fo-Fc difference electron density contoured at +3.5 σ (green mesh) and −3.5 σ (red 
mesh) suggest something remains unmodeled above the bound BB3 molecule. (E) Modeling a 
reordered portion of the disordered α7 helix, including Trp291 (pink), fits the 2Fo-Fc density, 
removes the positive Fo-Fc peaks, and has reasonable interactions with nearby sidechains on α3 
(left). (F–G) At 100 K, the electron density (shown at the same contour levels) suggests a 
different reordered conformation of α7 above BB1 (PDB ID 1t48). Both reordered α7 
conformations (D–E) vs. (F–G) place residues 290–292, including Trp291, in the same place. 
However, the C-terminal portion of the reordered conformation with BB1 at 100 K, including 
His296 (right), is sterically incompatible with the N-terminal portion of the α6-α7 junction with 
BB3 at 278 K, including Ser286. Neither conformation is compatible with the electron density 
for the other, suggesting that differences in temperature and/or inhibitor dictate different α7 
conformations. The viewing orientation in C–G) is as in Figure 4.1 panel B (‘back side’ of 
PTP1B), except zoomed in on the BB site (labeled in Figure 4.1 panel B). 
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Figure 4.16. The conformational distribution of the α7-coupled loop 16 titrates with 
temperature. This figure is a supplement related to Figure 4.4. The loop consisting of residues 
237–243 (bottom right) is single-conformer at low temperatures including (A) 100 K and (B) 180 
K, as evidenced by 2Fo-Fc electron density contoured at 1.0 σ (cyan volume) and at 1.0 σ (blue 
mesh). By contrast, it adopts multiple conformations at higher temperatures including (C) 240 K 
and (D) 278 K. The viewing orientation is as in Figure 4.4. 
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Figure 4.17. Alternative conformations in apo PTP1B recapitulate and expand upon reported 
coupling between loop 11 and α3. This figure is a supplement related to Figure 4.5 (A) 
Structures of the apo open state (yellow, 5k9v) and the closed state with the active-site inhibitor 
TCS401 (pink, 5k9w) (Choy et al., 2017) feature coupled movements of the loop 11 backbone, 
including Tyr152, and Asn193 within α7. (B–D) In our 278 K apo structure, we also observe 
coupling between these residues. However, Tyr152 is best fit with a ‘down’ plus an ‘up’ rotamer 
as alternative conformations for the open-state backbone, and only a down rotamer for the 
closed-state backbone. This is borne out by 2Fo-Fc electron density contoured at 0.3 σ (cyan 
volume) and Fo-Fc electron density contoured at +2.8 σ (green mesh) and −2.8 σ (red mesh) 
after refinement with either the down rotamer (C) or the up rotamer (D) omitted. A partial-
occupancy water that is mutually exclusive with the up rotamer is also present (transparent red 
sphere). Note: Asn193 may also adopt another low-occupancy rotamer. (E) The down Tyr152 
rotamer in the WPD-closed-compatible L11 backbone conformation (red) would sterically clash 
(pink pillows) with Thr178 in the open state of the WPD loop (orange). Both Tyr152 rotamers in 
the WPD-open state (orange) would sterically clash with the ordered conformation of the α7 
helix (red). The viewing orientation in all panels is as in Figure 4.1 panel B (‘back side’ of 
PTP1B), except zoomed in on loop 11, the α3 helix, and the α7 helix (labeled in Figure 4.1 panel 
B). 
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Figure 4.18. The allosteric 197 site has local sequence differences in related PTPs. This figure 
is a supplement related to Figure 4.5. Several amino acids in the allosteric 197 site in PTP1B 
(gray) are different at the equivalent positions in the closest homolog, TCPTP (orange). The 
viewing orientation is as in Figure 4.1 panel B (‘back side’ of PTP1B), except zoomed in on the 
197 site (labeled in Figure 4.1 panel B). 
 
 
Figure 4.19. Mutations along the 197 site’s allosteric pathway reduce enzyme activity. This 
figure is a supplement related to Figure 4.5. (A) Point mutations to several residues along the 
allosteric pathway from the allosteric 197 site to the active site reduce activity to varying 
degrees. Data represent the mean of four independent assays ± standard deviation. (B) Michaelis-
Menten kinetics for WT* vs. allosteric point mutants ± the standard error of the mean. See 
Materials and methods for details. 
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Figure 4.20. Flexible aromatic residues complete an allosteric circuit. This figure is a 
supplement related to Figure 4.5. Conformational heterogeneity for Tyr176 links Tyr152 in the 
allosteric 197 site to Phe191 in the previously reported allosteric pathway (Wiesmann et al., 
2004) and Trp179 in the WPD loop, thus completing an allosteric circuit. (A-D) In apo PTP1B, 
2Fo-Fc electron density contoured at 0.8 σ (cyan volume) and at 0.8 σ (blue mesh) generally 
justifies a single conformation these aromatic residues at low temperatures, but multiple 
conformations at high temperatures -- especially for Tyr176 and Tyr152. (E) These individual 
conformations are evident in the previously published 100 K apo (blue, 1sug) or BB2-bound 
(green, 1t49) structures, respectively. The viewing orientation in all panels is as in Figure 4.1 
panel B (‘back side’ of PTP1B), except looking down from the top of that image into the core of 
the protein. 
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Figure 4.21. Fragments overlap with the BB allosteric inhibitor scaffold and suggest possible 
improvements. This figure is a supplement related to Figure 4.7. Out of the 24 fragments that 
bind in the same site as BB2 (PDB ID 1t49, orange), two example fragments (green) are shown 
that overlap parts of BB2’s pose (asterisks), but also have chemical extensions that may be 
fruitfully added to the BB scaffold (arrows). (A) The first fragment has aromatic rings in roughly 
the same positions as does BB2 and a carbon matching a methyl extension in BB2, but in the 
fragment that carbon is part of two additional protruding rings. (B) The second fragment places 
two oxygens and a methyl in the same position as the equivalent atom types in BB2, but has a 
unique ethyl extension. 
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Figure 4.22. Fragments in the 197 site overlay with glycerols from multitemperature structures. 
This figure is a supplement related to Figure 4.7. Fifteen fragments (green) in the primary subsite 
of the 197 site occupy a similar region of space as ordered glycerols (red) from our 278 K apo 
structure. The viewing orientation is as in Figure 4.1 panel B (‘back side’ of PTP1B), except 
zoomed in on the 197 site (labeled in Figure 4.1 panel B). See also Figure 4.6 panel E (right) for 
orientation. 
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Figure 4.23. Identification of a functional covalent allosteric inhibitor. This figure is a 
supplement related to Figure 4.8. (A) 1600 disulfide fragments were screened for their ability to 
covalently label K197C. The location of 1 in the data is highlighted. Data represents a single 
experiment. The % Tethering data reported is for the 1:1 (2:K197C) adduct only. (B) Follow up 
tethering and pNPP inhibition assays of the top 50 fragments from the initial screen. 1, showed 
the second best inhibition of pNPP activity and correlated well with percent tethering. This 
suggested the activity was specific through K197C. Other fragment tested showed either poor, or 
non-specific inhibition of pNPP activity. Percent tethering represents a single experiment. The % 
Tethering data reported is for the 1:1 (2:K197C) adduct only. Percent inhibition represents the 
average of three independent assays ± the standard error of the mean. Both assays were 
performed in the presence of 50 µM of 1 and 100 µM of β-mercaptoethanol. (C) Structure 
of 1 as well as the closely related analog 2. Molecular differences between 1 and 2 are 
highlighted in red. 
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Figure 4.24. 2 tethers to only a single cysteine in K197C and inhibits through a reduction in 
Vmax. This figure is a supplement related to Figure 4.8. (A) Percent tethering of K197C at varying 
concentrations of 2. The vast majority of labeled K197C appears to have only a single tethering 
event of 2, supporting specific labeling of K197C. Observation of more than one tethering event 
suggests nonspecific labeling of native cysteines in PTP1B. (B) Percent tethering of WT* at 
varying concentrations of 2. Very little tethering of WT* is observed (<10%) with the total 
coming from a combination of different adducts, supporting nonspecific labeling. (C) Michaelis–
Menten kinetic analysis of K197C in the presence and absence of 2 (50 µM). Compound 
2 causes a ~ 54% reduction in Vmax relative to DMSO but almost no change in KM, supporting a 
non-competitive allosteric mechanism of inhibition. (D) Michaelis–Menten kinetic analysis of 
WT* in the presence and absence of 2 (50 µM). Compound 2 causes only a ~ 20% reduction in 
Vmax relative to DMSO but almost no change in KM. This background inhibition does not 
correlate with labeling and may be caused by nonspecific factors, such as aggregation of 2 at 
higher concentrations (≥50 µM). (E) Tethering of compound 2 to K197C reduces the 
Vmax observed for dephosphorylation of pNPP. Values are derived from the data shown in (C). 
Vmax was calculated using the Michaelis-Menten nonlinear fit in Graphpad Prism 7. (F) 
Tethering of compound 2to K197C shows no effect on the KM observed for dephosphorylation of 
pNPP. Values are derived from data shown in (C). KM was calculated using the Michaelis-
Menten nonlinear fit in Graphpad Prism 7. Data represent the mean of three independent 
assays ± the standard error of the mean. All p-values and significance was calculated using a 
FDR-Approach Multiple t-test in Graphpad Prism 7. All assays were performed in the presence 
of 100 µM of β-mercaptoethanol. 
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Figure 4.25. 2 inhibits K197C catalysis of DiFMUP through a reduction in Vmax. This figure is a 
supplement related to Figure 4.8.  
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Figure 4.26. Polder omit map of K197C tethered structure. This figure is a supplement related to 
Figure 4.9. 
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Room temperature fragment screen of PTP1B 
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Keedy 
 
Introduction  
 Many protein systems are regulated by the binding of small molecules. The ability to 
identify new small molecules that bind to new protein targets is a critical step toward the 
development of new biophysical assays, and drug discovery. In systems where targeting the 
active site of the enzyme is not tractable, finding an allosteric pocket in which to target can be a 
challenge. In addition, many possible binding sites are hidden in the apo-state of the protein and 
only open upon ligand binding (cryptic sites); identifying these sites and then subsequently 
finding suitable binders for those sites only further complicates this search.  
The concept of fragment-based ligand screening, the screening of small molecules of less 
than ~300 Da, has been gaining traction as a method of early hit-identification (Patel et al., 
2014). Fragments being less complex than traditional initial hits for ligand optimization, allows 
for a wider screening of chemical space in a similar screen, and provides a more striped down 
starting point from which to expand upon with further optimization. Also, with less molecular 
weight, molecules have the advantage of being less specific and therefore facilitating a higher hit 
rate during screening, and also allow the facile screening of multiple sites on the protein surface 
(Hadjuk et al, 2007; Hersterkamp and Whittaker, 2008; Erlanson et al., 2004). The drawback is 
 
 
166 
often that with the reduced number of atoms comes at the cost of binding affinity, which can 
significantly hinder the ability to detect binding events, and limits orthogonal screening methods 
and measurement of functional effects that result from ligand binding. Based on recent 
advancements in crystal soaking (Collins et al., 2017) and apo-state background subtraction 
(Pearce et al., 2017), screening fragments using crystallography now provides superior 
sensitivity. Also, with the additional information of the pose of fragment in the binding site 
environment, further optimization of screens can be rationally expanded. 
Most fragment screening efforts via crystallography have been conducted at cryogenic 
temperatures, which reduces the impact of radiation damage on data collection strategy, and to 
increase throughput. However, collecting crystallography data at room temperature can reveal 
states that would otherwise be quenched during the freezing process (Fraser et al., 2011). These 
masked states could provide valuable insight into the allosteric regulation of the system, and the 
states of the protein that are most relevant for further ligand optimization. Interestingly, it has 
been shown that in addition to the quenching of protein conformational states, in some cases 
ligand binding can only be observed at room temperature (Fischer et al., 2015).  
Based on the thermodynamics of ligand binding it is expected that the equilibrium 
occupancy of ligands to also be altered by temperature. In Fischer et al., they calculate that the 
expected occupancy of a ligand at 33 mM concentration with a 26 mM Kd, would be 99.9% at 
100 K, and only 56% at 293 K (Fischer et al., 2015). However, these calculations are for a linear 
equilibrium relation with temperature, and the freezing process is not fully at equilibrium. While 
the freezing rate clearly does allow for some conformational rearrangement, it is unclear at 
which point the system gets locked by the freezing of the solvent, and whether that represents an 
effective equilibrium at that freezing phase transition temperature or a ‘hotter’ system still 
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relaxing towards the shifted equilibrium. Clearly, much remains to be discovered about the role 
of temperature in the screening fragments via crystallography. 
In a previous study (Keedy et al., 2018), we completed a large-scale fragment screen of 
about 1,400 ligands on the system of protein tyrosine phosphatase, PTP1B (also known as 
PTPN1). Despite its label as an ‘undruggable’ target, due to the failed efforts to develop active-
site inhibitors of PTP1B, PTP1B remains an important therapeutic target for diabetes, cancer and 
Rett syndrome (Elchebly et al., 1999; Krishnan et al, 2014, Krishnan et al., 2015). Like many 
enzymes, PTP1B is a dynamic protein whose exchange between states is critical for function. 
While, our fragment screen of PTP1B at cryogenic temperature revealed 110 modeled ligand hits 
on many sites on the protein, the cryo ground state for PTP1B at only samples some of the 
conformations seen at higher temperatures. Room temperature data collection for crystallography 
on this system enables the capture of these multiple ground state conformations in a single 
dataset. Here, we combine the approaches of fragment screening and room temperature 
crystallography to recreate a smaller-scale fragment screen on PTP1B, to compare the insights 
from screening at multiple temperatures.  
 
Results and methods 
Selection of fragments for fragment screen 
 The fragments used in this study were selected from the Maybridge 1000 fragment 
library, the Edelris Keymical fragment library, and the Diamond Light Source in-house library 
(DSPL) (Cox et al., 2016), and were all a subset of the previously published cryo-temperature 
experiment (Chapter IV). Of the available compounds that were used in the previous screening 
study, we aimed to soak approximately 1/3 of compounds that were positive hits in the cryo-
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experiment. The remaining 2/3 of compounds were not hits in the previous study and were split 
between fragments that were as similar as possible and as dissimilar to the fragment hits from the 
previous study as determined by a Tanamoto similarity score. While, all fragments were soaked 
into crystal trays using the above criteria, we were not able to collect datasets of every soaked 
well within our allotted beamtime. In total, we collected 269 datasets with 111 unique fragments. 
After data processing, this left us with 81 unique fragments. Of those, 37 fragments were hits 
from the previous screen, and 44 were not detected hits from the prior screen.  
 
Data and quality control for data processing 
 Most datasets were collected with a strategy to 180º degrees of rotation over 1800 images 
with 0.1º wedges. Some datasets near the end of the data collection shift were lowered to collect 
only 120º of crystal rotation, as smaller crystals sometimes did not appear to survive the full 180º 
dose. The frames that were used to process the datasets were manually chosen to exclude frames 
where the number of detected spots dipped below around 20, commonly due to the crystal 
rotating out of the beam, the crystal reaching the end of its lifetime, or when the diffraction 
quality dropped as a result of the dimensions of the crystal. In cases where multiple datasets were 
collected from the same crystal, the datasets were then merged, but when multiple crystals were 
shot from the same well, these datasets were not merged together. Resolution cutoffs were 
chosen to ensure the following statistics in the highest resolution bin: an I/sigma of 1.0 or higher, 
a completeness of 90% or higher, and a CC1/2 of at least 50%. The resolutions of individual 
datasets were not held to be the identical, and the cutoff for each dataset was chosen to be the 
point at which the reflections from the highest resolution bin made the statistics of the that bin 
better, or kept the same for I/sigma, CC1/2 and completeness. Datasets shared a common set of 
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R-free flags and a common reference dataset to ensure consistent data indexing due to the space 
group of the crystal form, P 31 21 1. Of the 112 fragment and apo conditions collected from the 
experiment, 89 conditions successfully processed and were then prepared for PanDDA analysis. 
Over 80% of the datasets processed were better than 2.5 Å resolution. The highest resolution that 
the data were analyzed for PanDDA analyses was 2.0 Å. 
  
Comparison of hits between screening efforts 
 For the 37 fragments datasets that were hits in the cryogenic screen and had complete 
datasets fed into PanDDA analysis, interestingly, we were able to only able to identify density 
corresponding to these ligands in 14 cases (Figure 5.1). Individual custom PanDDA event maps 
were created for each of these 37 datasets by using the occupancy of the ligand from the cryo 
dataset. As seen in Figure 5.2, while the density is unambiguous in most cases from the cryo 
screen, the room temperature screen does not show any sign of density corresponding to a ligand 
in the subsequent room temperature screen. For the 14 cases where previous hits showed density 
corresponding to the ligand (Figure 5.2), several datasets reveal density suggesting alternative 
poses of the ligand from that of the cryogenic screen. Of the other molecules screened, there are 
three datasets that show significant density in the event maps possibly corresponding to a new 
ligand hit from the room temperature screen (Figure 5.3).  
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Figure 5.1. Fragment hits from the cryogenic temperature fragment screen that also show strong 
density in the room temperature screen. The model in green represents the solved structure from 
the cryo temperature data collect, while the yellow model represents the ground state structure of 
the room temperature screen. In dark blue, is the density from the event map for the cryo screen, 
and in cyan is the density from the room temperature screen. 
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Figure 5.2. Fragment hits from the cryogenic temperature fragment screen that did not show 
density in the room temperature screen. The model in green represents the solved structure from 
the cryo temperature data collect, while the yellow model represents the ground state structure of 
the room temperature screen. In dark blue, is the density from the event map for the cryo screen, 
and in cyan is the density from the room temperature screen. 
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Figure 5.3. Signal for possible fragment hits uniquely detected in the room temperature screen. 
Here is shown model and density for the possible three events detected where there is strong 
density. The cyan map represents the PanDDA background corrected event map at the 
occupancy (background density correction factor) as detected by the pandda.analyse run. Ligand 
models are placed in the two strongest cases (left and middle), but the ligand is not placed in the 
right panel. Further optimization of the ground state phases, or the scanning of possible 
occupancies is still necessary to properly determine the pose of this ligand into this density. 
 
Conformational changes detected 
 The ground state of the room temperature structure captured in this screen differs in 
several ways from the ground state used in the cryo structure screen. There is an increased 
amount of heterogeneity in the room temperature structure, such as the loop near the L16 site as 
referenced in Chapter IV (Figure 5.4). Additionaly, to the multiple states observed at 
equilibrium, the PanDDA algorithm detects any datasets that deviate significantly at some 
fractional population away from the distribution of datasets used to calculate the average density 
of the ground state. Interestingly, in addition to the binding of some of the screened fragments, 
the PanDDA analysis also detected other minor conformations or states of the protein crystal. 
One site in particular, the catalytic cysteine 215, appears to undergo an oxidation event in a 
fraction of the datasets (Figure 5.5 panel a). This oxidation signal can be seen in datasets at both 
data collection temperatures. The oxidation of this residue corresponds with large structural 
rearrangements of the protein. This residue, sitting in the active site of the enzyme, is a natural 
method of regulation for PTP1B in vivo (van Montfort et al., 2003). Interestingly, in one case, 
the oxidation event also occurs in the same dataset as a fragment hit. In many cases these 
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oxidation events, even with the accompanying large structural shift in the protein’s 
conformation, are undetectable in the traditional 2mFo-DFc electron density maps (Figure 5.5 
panel b). In other cases, density in detected by PanDDA for this residue that takes a different 
signal and is not accompanied by the same structural change seen in the case of the oxidation 
event (Figure 5.5 panel c). This leads us to hypothesize that this may not been a different 
oxidation event, but rather a form of radiation damage, or some other phenomenon. In other 
cases, we detect unexpected ordering of the C-terminal tail of protein (Figure 5.6), normally 
accompanying the closing of the primary WPD-loop. Interestingly we see examples where the C-
terminus is ordered and the WPD is either stable in only the open or closed conformation (Figure 
5.6).  
 
Figure 5.4. Loop at L16 site is mobile in the apo-state in only the room-temperature structure. 
On the left, is the 2Fo-Fc map for an apo dataset for the cryo-temperature screen. On the right, is 
the 2Fo-Fc map for an apo dataset for the room temperature screen. The residues shown are a 
loop in the L16 site, with the yellow model in both panels corresponding to the room-
temperature apo-structure, and the green model corresponding to the cryo-temperature apo-
structure. 
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Figure 5.5. Detection of different signals at catalytic cysteine 215. (a) Cysteine 215 showing 
density corresponding to a single oxidation of the thiol to sulfenic acid. In cyan, the PanDDA 
event map showing the density unique to the event (the oxidation). In purple, is the standard 2Fo-
Fc map for this structure. The difference density corresponds to the Z-map indicating statistically 
significant signal for this conformation of the cysteine residue. (b) Cysteine 215 showing density 
for the non-oxidized structure. Again, cyan and purple represent the PanDDA event map and 
2Fo-Fc maps respectfully, and the difference map is the Z-map. The model is shifted 
dramatically relative to the model in panel a. Although shown from similar relative perspectives, 
the model has rotated approximately 180º about the backbone and shifted slightly relative to the 
other panel. The major green peak in panel b below the backbone of Cys215, corresponds to the 
sulfur as seen in panel a. (c) Density showing the final abnormal signal type seen in several 
datasets across both cryo and room-temperature datasets. In cyan is the PanDDA event map, and 
the difference map is the PanDDA Z-map. Significant density is shown blurred abour the sulfur 
atom. 
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Figure 5.6. Unexpected decoupling of the ordering of C-terminus with the state of the WPD-
loop. In the top panels, the dataset PTP1B-z055 is shown, with the yellow model corresponding 
to the ground state of the protein, and the green state corresponding the deposited PanDDA 
multistate model from the cryo-screen. In cyan, the event density for the room-temperature 
dataset and in blue the event density for the cryo-dataset. The C-terminal region is shown on the 
left panel, and the WPD-loop region is shown on the right panel. While the ground state of this 
crystal shows significant density for the open state of the WPD loop, the event density shows 
closure of the WPD-loop along with the C-terminal ordering. In most structures, the backbone is 
no longer modeled after residue 283, while the Trp291 is clearly visible in the center of the right 
panel. In the bottom panels is the dataset PTP1B-z068, with the orange model representing the 
deposited multistate structure from the cryo-temperature screen, and the green model showing 
only the ground state of the room temperature screen. Here, the PanDDA event map for the room 
temperature dataset is shown in blue. In this dataset the WPD-loop remains open in the event 
density, even with the ordering of the C-terminus as in the PTP1B-z055 dataset. 
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Discussion 
 Crystallography experiments conducted at multiple temperatures (both cryogenic and 
room temperature) reveal differences in protein structure as a result of how thermodynamics 
affects the relative energies of different alternative conformations. In the same way, it is to be 
expected that temperature could play a large role in the ability to detect and bind fragments. In 
addition, there is synergy between these effects, in that the proteins states that are stabilized can 
also alter the binding affinity and/or pose of the ligand. Therefore, it is possible that certain 
ligands may only bind at room temperature despite the thermodynamic advantage at colder 
temperatures due the binding competent conformation only being populated at higher 
temperatures. Additionally, some protein conformations are only present after freezing as a result 
of the change of the water packing upon freezing, as seen in cyclophilin A (Keedy et al., 2015). 
While the thermodynamic shift of ligand binding at equilibrium can be mapped given knowledge 
of the concentration and binding affinity, the crystal once frozen is no-longer free to exchange 
with the solution. The freezing rate of crystals clearly allows for the conformational exchange of 
some protein motions, it is also unclear to what extent the relative occupancy of ligands can be 
altered during the fast freezing process. Finally, differences seen between screens can also be 
limited by the differences in data collection strategy, or limitations in reproducibility of the 
manual steps of the soaking experiments, such as crystal to crystal variability, effective soaking 
rates, amount of osmotic shock when dispensing the fragment to the crystal drop, etc. 
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